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CA-SP1, by the viral protease. Large deletions in stem-loop 1 (SL1) in the 5’ untranslated region (UTR) 
of HIV-1 genomic RNA (gRNA) delay CA-SP1 processing. SL1 harbours the dimerisation initiation site 
(DIS) palindrome suggesting that efficient Gag processing may be linked to gRNA dimerization as shown 
in HIV-2. However, a dimerisation mutant with normal Gag processing was identified. Gag processing 
defects are hallmarks of late domain mutants, and SL1 mutation was found to result in reduced virus 
release. HIV-1 hijacks the host’s endosomal complexes required for transport (ESCRT) pathway to 
enable budding. An ESCRT-associated protein, ALIX, is known to be capable of binding to the 
nucleocapsid (NC) domain of Gag using lipids or RNA as a ‘bridge’ in vitro. It was hypothesised that SL1 
mutation disrupts an RNA-dependent interaction that occurs during virus assembly. Consistent with 
this, an intact SL1 was found to be required for efficient ALIX function. Increasing the abundance of 
gRNA in the cell by expressing it in trans accelerated CA-SP1 processing in a manner that required 
ALIX’s binding motif in p6. Gag processing could also be accelerated by introducing previously 
identified compensatory mutations into the SP1 and NC domains of Gag, in a manner reminiscent of 
the actions of maturation inhibitor resistance mutations. The effects of the compensatory mutations 
were also dependent on intact late domain motifs. These data suggest that gRNA is involved in 
regulating virus budding and maturation through interaction with ALIX. A model is proposed whereby 
the packaging signal (psi) region of gRNA acts as a bridge between Gag and ALIX, acting as a checkpoint 
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Human immunodeficiency virus type 1 (HIV-1) is a human retrovirus of the lentivirus genus and the 
causative agent of acquired immune deficiency syndrome (AIDS) (Barre-Sinoussi et al., 1983; Gallo et 
al., 1984; Popovic et al., 1984). AIDS can also less frequently be caused by HIV-2, although the viruses 
share little sequence homology (Guyader et al., 1987).  
HIV-1 and HIV-2 are derived from distantly related simian immunodeficiency virus (SIV) strains which 
infect chimpanzees (SIVcpz) (Huet et al., 1990) and sooty mangabeys (SIVsmm) (Hirsch et al., 1989) 
respectively. SIVs are generally asymptomatic in their natural hosts, indicating that the viruses and 
their hosts have co-evolved for a long period, a finding supported by phylogenetic analysis (Worobey 
et al., 2010). SIVcpz has however been shown to be associated with premature death in wild 
chimpanzees (Keele et al., 2009).  
HIV-1 is a recent introduction into the human population. Molecular clock analysis estimates that the 
most recent common ancestor of all HIV-1 group M subtypes emerged between 1910 and 1930 in 
Kinshasa in the present-day Democratic Republic of Congo. Indeed Kinshasa is where the earliest 
known HIV-1 sequences were found, and today the city has the highest diversity of HIV-1 strains in the 
world (Faria et al., 2014; Korber et al., 2000). 
HIV-1 quickly spread through high-risk groups in the population to create a pandemic that has infected 
an estimated 78 million people, of whom 35 million have died and 36.7 million are currently infected, 
with 2.1 million new infections occurring per year (UNAIDS, 2016). In the early days of the pandemic 
HIV infection was a death sentence due to lack of treatments, and patients died within years of 
becoming infected. Thanks to significant investment in research into antiretrovirals (ARVs) and the 
used of highly active antiretroviral therapy (HAART), in which combinations of ARVs are used to 
increase the barriers to resistance, people infected with the virus are now able to live healthy and long 
lives. Unfortunately, they must take these drugs for the rest of their lives to keep the virus under 
control, as cessation of treatment causes a rebound in viral load.  
Efforts are intensifying to find a cure, although at present this still seems some way off. Furthermore, 
out of the 36.7 million people currently infected, only 18.2 million are accessing antiretroviral therapy 
(UNAIDS, 2016). Development of an effective vaccine is difficult because the most conserved epitopes 
on the virus’s envelope (Env) glycoprotein are shielded by glycosylation and are embedded within a 
structure which undergoes conformational changes during binding to host cells (Barouch, 2009). 
There are four lineages (termed “groups”) of HIV-1 that arose from separate cross-species transmission 
events in West central Africa, likely through hunting and the bushmeat trade. HIV-1 group M is by far 
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the most successful, with a global geographical spread. Population bottlenecks have led to the 
establishment of nine subtypes, labelled A-D, F-H, J and K. Group M is responsible for most infections 
and deaths, whilst group O is responsible for less than 1% of infections, and groups N and P account 
for just a handful of documented cases restricted to Cameroon and the surrounding countries. Group 
M and N viruses are closely related to SIV found in chimpanzees, whilst group P and O viruses are most 
closely related to SIV found in gorillas (D’arc et al., 2015; Sharp and Hahn, 2011). 
HIV is spread predominantly through heterosexual sexual intercourse, which accounts for 70% of 
transmission events. The remainder occurs through sexual intercourse between men who have sex 
with men, mother to child transmission (during pregnancy or at birth), intravenous drug use or, rarely 
now, blood and blood product transfusion (Shaw and Hunter, 2012).  
Socioeconomic factors mean that the challenges posed by HIV-1 vary between world regions. In the 
developed world – where ARVs are more readily available – the focus is on preventing transmission by 
ensuring that infected individuals adhere to treatment, thus reducing the risk of transmission to their 
partners. An additional measure is pre-exposure prophylaxis, whereby ARVs are prescribed to 
individuals who are uninfected but are at high-risk of being infected, to prevent the establishment of 
infection if they are exposed to HIV. Post-exposure prophylaxis is administered following high-risk 
activity, and ARVs are also given to babies born to HIV-positive mothers. In developing countries, lack 
of education, access to diagnostic facilities and the availability of drugs are the major barriers to 
controlling transmission. 
A cure for HIV infection remains elusive because although ARVs suppress the viral load, they cannot 
eliminate the reservoir of viruses that establish latency. Research is intensifying into approaches which 
will force the virus out of latency to enable it to become a target for pharmacological agents or 
immunotherapy – the so-called ‘kick and kill’ strategy (Archin and Margolis, 2014). 
1.2. Clinical presentation of HIV infection 
Clinically, HIV infection can be categorised into three stages (illustrated in Figure 1): the acute stage; 
the latent stage – not to be confused with viral latency; and AIDS. Acute HIV infection occurs during 
the peak of viremia in the first few weeks post-exposure, and is associated with a self-limiting flu-like 
set of symptoms termed acute retroviral syndrome (ARS) (Henn et al., 2017). These include fever, 
headache, malaise, cough and lymphadenopathy (Robb et al., 2016), meaning that ARS is 
symptomatically indistinguishable from a range of other infections.  
The latent stage of infection is associated with few (if any) symptoms, and low levels of virus replication 
due to a robust immune response. In the absence of effective treatment with ARVs, replication in and 
killing of CD4+ T-helper cells results in a progressive decline in CD4+ cell levels, and consequently a 
decline in the ability of the immune system to control virus replication (Alizon and Magnus, 2012). This 
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stage of infection can last several years, but once CD4+ levels are sufficiently low the clinical signs of 
AIDS become apparent.  
A weakened immune system enables establishment of infection and presentation of symptoms 
associated with opportunistic pathogens or malignancies that are normally cleared or controlled by 
healthy individuals. Opportunistic bacterial, fungal and viral pathogens associated with AIDS include 
Mycobacterium tuberculosis, Streptococcus pneumoniae, Cryptococcus neoformans, Candida sp., 
Toxoplasma gondii, and cytomegalovirus (CMV) (Holmes et al., 2003). Cancers commonly associated 
with AIDS include Kaposi’s sarcoma and non-Hodgkin’s lymphoma (Cheung, 2005). The inability of the 
immune system to combat these diseases results in rapid deterioration of health and short life 
expectancy for patients with AIDS (Morgan et al., 2002). 
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Figure 1 – Viral load and CD4+ T-cell count over the course of an untreated infection 
 
Illustration of the changes in CD4+ T-cell counts and viral load (measured by HIV RNA copies/ml) 
throughout the course of an infection in the absence of treatment. The infection can be divided into 
three stages. The initial acute phase lasts a matter of weeks and is associated with a rapid burst of viral 
replication accompanied by a decline in the CD4+ count, while patients may experience flu-like 
symptoms. A robust immune response brings the viral load under control and ushers in the latent stage 
of infection, which is generally asymptomatic. Over several years there is a gradual decline in the CD4+ 
cell count, which leads to AIDS, in which opportunistic pathogens and neoplasms cause a rapid decline 
in health, leading to death. 
Source: https://commons.wikimedia.org/wiki/File:HIV-timecourse_simple.svg  
1.3. HIV-1 genome organisation and structure 
HIV-1 encodes 9 genes producing 3 structural, 2 regulatory and 4 accessory gene products. The 
structural proteins are group-specific antigen (Gag), polymerase (Pol) and Env. Gag and GagPol are 
multi-domain proteins that are processed into mature proteins in the late stages of viral assembly by 
the viral protease (PR). The domains of Gag and their functions in virus replication are shown in Figure 
2. 
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Figure 2 – Structure and function of Gag domains 
 
Box diagram illustrating domains of Gag (to scale), with crystal structures and the key functions of 
each domain described below. Gag is formed of four major domains (MA – Matrix, CA – Capsid, NC – 
Nucleocapsid, and p6) joined by two linker regions (SP1 and SP2). The specific functions encoded in 
Gag’s domains coordinate key stages throughout the virus lifecycle, including Gag assembly, genome 
packaging and recruitment of ESCRT proteins to allow virions to bud from the host cell.  
Source: Modified from (Freed, 2015). 
Env is expressed as a single gp160 protein that is cleaved into its active gp120 and gp41 subunits by 
host proteases. The regulatory proteins are trans-activator of transcription (Tat) and regulator of 
expression of virion proteins (Rev), and the accessory proteins are viral protein U (Vpu), viral protein R 
(Vpr), virion infectivity factor (Vif) and negative factor (Nef). 
In addition to these, key steps of the virus replication cycle are regulated by ribonucleic acid (RNA) 
structures in the genomic and subgenomic viral RNA (vRNA) species. A number of these are found at 
the 5’ and 3’ UTRs. The 5’UTR is composed of a repeat (R) region, a unique 5’ region (U5) and a series 
of helix loop RNA structures termed stem-loops that perform critical functions in viral replication 
(Figure 3). 
R is present at both the 5’ and 3’ ends of the genome and includes the trans-activation response 
element (TAR) and the poly(A) hairpin, although the former acts at the 5’ end and the latter at the 3’ 
end. TAR is recognised by the Tat protein to promote efficient transcription (Rosen et al., 1985). The 
5’ version is dominant although the mechanism underlying this imbalance is unknown (Klaver and 
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Berkhout, 1994). Downstream of R is U5, which harbours the primer binding site (Pbs), an 18 
nucleotide sequence complementary to the 18 nucleotides at the 3’ terminus of the host transfer RNA 
(tRNA) tRNALys3 (Jiang et al., 1993).   
In between U5 and extending into the Gag open reading frame (ORF) are four stem-loops (Figure 3). 
Stem-loop 1 (SL1) is important for genome dimerisation and contains the 6-nucleotide DIS palindrome 
in its apical loop (Marquet et al., 1994; Muriaux et al., 1995; Paillart et al., 1994; Skripkin et al., 1994). 
It also contains Gag binding sites (Abd El-Wahab et al., 2014; Damgaard et al., 1998; Kenyon et al., 
2015; Wilkinson et al., 2008) making it part of the core packaging signal (psi/Ψ) with SL3 being the 
other major component (Kim et al., 1994; Lever et al., 1989; McBride and Panganiban, 1996).  
In between SL1 and SL3 is SL2, the major splice donor (Arrigo et al., 1990). As psi overlaps the splice 
donor site it is only found in full-length gRNA and not in fully- or partially-spliced vRNA. This packaging 
specificity is important as only viruses containing full-length gRNA encode all viral proteins and are 
replication competent. SL4 contains the AUG start codon for Gag. The four stem-loops are not rigid 
conformations but can adopt different structures, each of which have specific functions in the viral 
lifecycle (Berkhout and van Wamel, 2000; Kenyon et al., 2013; Lu et al., 2011). 
Functional RNA structures also exist within genes. The Gag ORF contains a frameshifting signal (Jacks 
et al., 1988) composed of a slippery site and an RNA stem-loop. Slipping of ribosomes during 
translation enables -1 frameshifting to occur at a rate of 1/20, producing the GagPol fusion protein. 
Disturbance of this frequency is detrimental to virus infectivity (Shehu-Xhilaga and Crowe, 2001). In 
the coding region of Env is the Rev-response element (RRE), a 350 nucleotide cis-acting structure to 
which Rev binds to facilitate export of unspliced and partially-spliced vRNA from the nucleus (Rosen et 
al., 1988). 
The poly(A) hairpin acts only at the 3’ end of the genome due to the presence of upstream enhancer 
sequences in the unique 3’ region (U3), where it stimulates polyadenylation of transcribed RNAs 
(Valsamakis et al., 1991).  
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Figure 3 – HIV-1 genome organisation and structures in the 5’UTR 
 
Overview of genome structure. Structural genes are highlighted in yellow, regulatory genes in blue and 
accessory genes in green. The UTRs are highlighted in red. Inset – Secondary structural depiction of the 
5’UTR with key motifs highlighted, modified from (Sleiman et al., 2012). At the 5’ end is the R region 
containing the TAR and Poly(A) hairpins. Downstream is the U5 region, containing the Pbs hairpin. This 
is followed by 4 stem-loops. SL1 contains the DIS, SL2 is the major splice donor, and SL3 is the major 
packaging signal. SL4 contains the AUG Gag start codon; in this structure, a stem-loop is not present 
and AUG is instead annealed to U5, as the 5’UTR exists in two conformations (Figure 6). 
1.4. Virion structure 
In common with all retroviruses, HIV-1’s two copies of its single-stranded ribonucleic acid (ssRNA) 
genome are packaged as a non-covalently linked dimer into the virion (Darlix et al., 1990; Paillart et 
al., 2004). Packaging a dimeric genome offers the capacity to switch template strands during reverse 
transcription. This has two clear benefits for viral replication and evolution. Firstly, given the fragile 
nature of ssRNA, the presence of two templates increases the probability of successful reverse 
transcription in the case of strand breaks (Coffin, 1979). Secondly, co-packaging of genetically distinct 
gRNAs in coinfected cells followed by template-switching in the target cell enables recombination to 
generate chimeric proviruses, a process which is a major driver of viral diversity (Burke, 1997; Hu and 
Temin, 1990). Recombination is extremely common: over 40 circulating recombinant viruses have 
been identified one of which (CRF01) was responsible for an epidemic in Thailand (Taylor et al., 2008). 
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In the mature virus particle the gRNA, coated with nucleocapsid (NC) proteins, is enclosed in a conical-
shaped core composed of 1,200-1,500 capsid (CA) protein subunits (Briggs et al., 2003) derived from 
proteolytic processing of the Gag protein (Bell and Lever, 2013).  
In addition to gRNA, the mature virion contains the viral enzymes necessary for initiating new rounds 
of infection. Reverse transcriptase (RT) has deoxyribonucleic acid (DNA) polymerase and RNase H 
activity, enabling it to catalyse production of a double-stranded DNA copy of the viral genome. 
Integrase (IN) facilitates insertion of this proviral DNA into the host cell genome to allow the virus to 
establish residency for the lifetime of the cell.  
The mature conical core of the virus is enclosed in a lipid bilayer membrane derived from the host cell 
during budding. Embedded in this membrane are matrix (MA) proteins derived from processing of Gag, 
and Env glycoproteins. Env is required for a specific interaction with receptors on target cells and 
triggering of the subsequent fusion event. It is a class I fusion protein, being predominantly α-helical, 
and is expressed on the virion surface as a trimer of heterodimers. Each heterodimer consists of a 
surface-exposed gp120 subunit and a transmembrane gp41 subunit (Weiss et al., 1990). The former 
has receptor and coreceptor binding activity, and the latter contains the fusion peptide.  
1.5. Virus entry 
HIV-1 replicates in CD4 (cluster of differentiation 4)-positive helper T-cells (Dalgleish et al., 1984; 
Klatzmann et al., 1984), as well as monocytes, macrophages and dendritic cells, which express CD4, 
the receptor utilised by Env for binding and fusion (Maddon et al., 1986; McDougal et al., 1986). The 
virus also requires one of two coreceptors, C-C chemokine receptor 5 (CCR5) or C-X-C chemokine 
receptor 4 (CXCR4), binding to which is mediated by a conformational change triggered by binding of 
gp120 to CD4 (Figure 4). Coreceptor engagement triggers membrane fusion by exposing the gp41 
subunit of Env that inserts into the host cell membrane. In this conformation, it is in a metastable 
“spring-loaded” state. The energy released by the subsequent folding back of the subunit brings the 
two membranes together to form the fusion pore (Melikyan, 2008).  
Viruses that utilise the CCR5 coreceptor are termed R5-tropic, whilst those that utilise CXCR4 are X4-
tropic. For reasons that are not entirely clear, transmitted founder viruses are almost exclusively R5-
tropic (Keele et al., 2008). Over the course of infection the viral population in a proportion of infected 
individuals may shift towards an X4-tropic phenotype, which is associated with disease progression 
(Tersmette et al., 1989).  
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Figure 4 – HIV-1 replication cycle 
 
Overview of HIV replication cycle from fusion to formation of mature virions. Virus particles fuse to the 
host cell membrane following interaction of gp120 with CD4 and a coreceptor (CCR5 or CXCR4). This 
releases the preintegration complex, containing viral RNA, reverse transcriptase, and integrase, into 
the cytoplasm. Reverse transcription leads to the formation of double-stranded viral DNA, which is 
transported across the nucleus and integrates into the host DNA, acting as a template for transcription 
of new viral RNA. Unspliced viral RNA (gRNA) serves two roles – as a template for translation of full-
length Gag and Gag-Pol, and as the genome itself to be packaged. Gag-gRNA complexes embed in the 
plasma membrane and the newly formed virions hijack the host’s ESCRT machinery to complete the 
budding process. Following budding, a series of coordinated cleavage events transform the virus from 
its immature form to an infectious mature one.  
Source: modified from NIAID. 
The predominant transmission of R5 viruses means that individuals homozygous for a CCR5 gene 
mutation termed CCR5Δ32, which prevents cell surface CCR5 expression, are resistant to HIV-1 
infection. Heterozygous individuals have a reduced risk of infection and exhibit less severe disease 
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progression (Dean et al., 1996). This is exemplified by the case of the Berlin patient – a stem cell 
transplant from a CCR5Δ32 homozygous donor eliminated the virus from the patient in what remains 
the only known case of a cure (Hutter et al., 2009). 
Aside from direct blood contact, HIV transmission between individuals occurs at the mucous 
membranes, which are heavily patrolled by macrophages and dendritic cells. Dendritic cells express 
low levels of CD4 so unlike CD4+ T cells they are not easily infected. However as antigen-presenting 
cells they can play an important role in dissemination of infection by trapping virions and transporting 
them to the lymph nodes where antigen is presented to T cells (Piguet and Steinman, 2007). 
1.6. Reverse transcription, uncoating and nuclear import 
Following entry of the viral capsid into the cytoplasm of the host cells, several key events occur. The 
single-stranded gRNA undergoes reverse transcription to produce a double-stranded DNA copy. The 
mature capsid dissociates in a process termed uncoating, which is required to enable the virus genome 
to traverse the nuclear pore complex (NPC), which is smaller in diameter (30 nm) than the capsid (50-
60 nm) (Hilditch and Towers, 2014). This ability to cross the nuclear membrane permits lentiviruses to 
infect non-dividing cells, in contrast with other retroviruses which rely on the breakdown of the nuclear 
membrane during mitosis (Katz et al., 2005). The degree of overlap between the timing of these 
processes and the mechanisms linking them are incompletely understood. 
The process of reverse transcription is illustrated in Figure 5. All retroviruses use host tRNAs as primers 
for reverse transcription (Mak and Kleiman, 1997). HIV-1 uses the tRNALys3 primer, which primes the 
initial elongation of the minus strand from the Pbs towards the 5’ end of the template gRNA. 
Meanwhile RNA in the nascent RNA:DNA duplex is degraded due to the RNase H activity of the RT 
enzyme (Step 1 and 2 in Figure 5). This ‘strong stop DNA’ is then translocated to the 3’ end (first strand 
transfer) of either the same strand or the partner strand where it binds to the complementary R region. 
Elongation continues to produce the minus strand with simultaneous degradation of the template RNA 
(Steps 3 and 4 in Figure 5). Two polypurine tracts that are resistant to degradation serve as primers for 
plus strand synthesis. This is followed by second strand transfer and completion of plus strand 
synthesis, generating a double-stranded DNA molecule that is longer than the parental gRNA with U3, 
R and U5 long terminal repeat (LTR) sequences at each end (Steps 5–7 in Figure 5)  (Hu and Hughes, 
2012). The product of reverse transcription is a preintegration complex (PIC) containing blunt-ended 
double-stranded DNA and IN (Figure 4). 
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Figure 5 – HIV reverse transcription 
 
Schematic illustrating the process of reverse transcription, described in the text above with reference 
to the steps in this diagram. Black lines represent viral RNA, and red and blue lines represent nascent 
proviral DNA strands. Dashed lines indicate degradation of RNA by RNase H activity. The host tRNA 
used to prime reverse transcription is coloured green. First and second strand transfers are highlighted 
by circled numbers.  
Inhibition of reverse transcription delays uncoating, but most reverse transcription is completed after 
the onset of uncoating, suggesting that uncoating is triggered during reverse transcription (Hulme et 
al., 2011). More recent data suggests that the trigger for uncoating is the completion of first strand 
transfer (Cosnefroy et al., 2016; Mamede et al., 2017). Imaging of virions in vitro using atomic force 
microscopy has shown that that the build-up of pressure caused by reverse transcription causes virions 
to swell and disassemble (Rankovic et al., 2017). 
Virus infectivity is sensitive to disturbances in the timing of uncoating, because the capsid is thought 
to conceal viral DNA from cytoplasmic DNA sensors, preventing stimulation of type I interferon (IFN) 
production (Manel et al., 2010; Rasaiyaah et al., 2013). The host protein cyclophilin A (CypA), which 
binds to CA (Luban et al., 1993) appears to be important for preventing premature uncoating; in vitro 
it stabilises the capsid (Shah et al., 2013). This protects the viral genome from cytoplasmic sensors, as 
inhibition of binding to CA reduces the levels of viral DNA (Braaten et al., 1996) and triggers an innate 
immune response (Rasaiyaah et al., 2013). Interestingly, Manel et al observed that when resistance to 
HIV-1 is subverted in dendritic cells (dendritic cells are normally resistant to HIV-1 infection) an 
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interaction between CypA and newly synthesised Gag triggers innate immune sensing through a cryptic 
mechanism. This highlights an evolutionary balancing act whereby CA’s interaction with CypA prevents 
premature uncoating and boosts infectivity, whilst the interaction between newly synthesised CA and 
CypA triggers innate immune sensors (Manel et al., 2010). It is unlikely that the entire capsid 
disintegrates before the genome reaches the NPC, as this would presumably trigger cytoplasmic DNA 
sensing. This is supported by the finding that CA can directly interact with the NPC protein Nup358 (Di 
Nunzio et al., 2012; Schaller et al., 2011). Furthermore, CA can be visualised in the nucleus (Chin et al., 
2015) where it appears to play a role in integration (Chen et al., 2016).  
Some have proposed that a fully intact capsid docks at the nuclear pore (Arhel et al., 2007; Matreyek 
and Engelman, 2011; Schaller et al., 2011). However, a recent study using live-cell fluorescent imaging 
revealed that uncoating takes only 30 minutes to occur following fusion and CA’s roles in later steps 
are facilitated by a partial capsid reaching the nucleus (Mamede et al., 2017). 
Another protein which binds to CA is cleavage and polyadenylation specificity factor-6 (CPSF6). 
Disruption of this interaction delays reverse transcription and uncoating (De Iaco et al., 2013; Fricke et 
al., 2013) further highlighting the link between these two processes. 
The details of nuclear localisation of the PIC have not been fully established, but short interfering RNA 
(siRNA) screens have identified roles for a transport protein, TNPO3, and NPC proteins Nup153 and 
Nup358 in infection (Brass et al., 2008; König et al., 2008). Disruption of CypA or CPSF6 binding to CA 
relieves the requirement for Nup358 and TNPO3 perhaps by directing the PIC through alternative 
nuclear import pathways (Lee et al., 2010; Schaller et al., 2011). 
It appears that CypA and CPSF6 binding to CA are important for delaying the onset of reverse 
transcription and uncoating, in addition to directing the PIC along a nuclear import pathway using 
TNPO3, Nup358 and Nup153 (Hilditch and Towers, 2014). 
1.7. Integration and latency 
Prior to the use of next generation sequencing, analysis of sites in the genome into which HIV 
integrates was limited, but the topology of the target DNA was found to be important; integration is 
favoured where DNA is bent or distorted (Pruss and Wolffe, 1994). New sequencing technologies 
allowed more thorough investigation, and it was found that integration is strongly favoured within 
genes and in particular within those which are highly actively transcribed (Schröder et al., 2002). IN 
seems to be the main determinant of integration site selection, since swapping the HIV IN enzyme for 
the murine leukemia virus (MLV) equivalent changes integration site preference to sites favoured by 
MLV (Lewinski et al., 2006). A host protein, LEDGF, was also shown to be important in target site 
selection; it binds to IN (Cherepanov et al., 2003) and knockdown of the protein reduces preferential 
targeting for active transcriptional units (Ciuffi et al., 2005). LEDGF knockdown did not block 
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integration in Ciuffi et al, however a later study using more intense knockdown and a dominant-
negative mutant demonstrated that LEDGF is in fact essential for integration (Llano et al., 2006). This 
discrepancy is due to the presence of a small but highly potent pool of chromatin-associated LEDGF 
remaining in the cell when less intense knockdown methods are used. Integration is linked to the 
preceding steps of virus replication as mutations in CA preventing CypA or CPSF6 binding alter 
integration site preference (Schaller et al., 2011). 
Once at the integration target site IN catalyses the reaction steps required for the viral DNA to be 
inserted into the host DNA. The two 3’-most nucleotides of each strand of the blunt-ended DNA are 
first removed, and the new 3’ terminal bases of the viral DNA attack the phosphodiester bonds in the 
host DNA integration site, before becoming covalently attached. Host repair enzymes then fill in the 
gaps to leave the provirus integrated (Figure 4) with a duplicated sequence at each end (Craigie and 
Bushman, 2012).  
Once integrated the proviral DNA can be used as a template for transcription by the host machinery, 
creating new virus particles (Figure 4). Alternatively, it can be silenced by epigenetic changes or by 
transcriptional interference from neighbouring transcripts, causing the virus to establish latency  
(Siliciano and Greene, 2011). 
1.8. Gene expression 
Production of new vRNA species from the integrated provirus is performed by the host’s transcription 
and splicing machinery. The viral LTR is an efficient promoter, constituting three Sp1 binding sites, a 
TATA box and an initiator sequence (Rittner et al., 1995), facilitating recruitment of transcription factor 
II D, a component of the RNA polymerase II preinitiation complex. Transcription efficiency is further 
increased by an enhancer element, composed of two NF-kB binding sites (Nabel and Baltimore, 1987), 
which is essential for reactivation of latent proviruses in CD4+ T-cells (Alcamí et al., 1995). 
However, recruitment of host factors alone is not sufficient for efficient transcription and transport of 
vRNA to the cytoplasm; two viral factors – Tat and Rev – are critical for these processes to occur 
(reviewed in Karn and Martin Stoltzfus, 2012).  
Tat, which is expressed from the central portion of the viral genome (Figure 3), is essential for viral 
transcription (Sodroski et al., 1985). Similar trans-activating factors are also found in bovine leukaemia 
virus and human T-cell lymphotropic virus (HTLV) types I and II (Sodroski et al., 1984). In the absence 
of Tat transcription initiation is unaffected, but transcription complexes stall shortly after initiation, 
demonstrating that Tat functions to promote efficient elongation of viral transcripts (Kao et al., 1987). 
It binds to a U-rich bulge near the tip of the TAR stem--loop (Dingwall et al., 1989), a in the 5’UTR 
(Figure 3), in complex with the CDK9 kinase component of the elongation factor pTEFb (Herrmann and 
Rice, 1995) and Cyclin T1 (Wei et al., 1998). Binding of Tat to CDK9 results induces a conformational 
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change in the enzyme, activating pTEFb resulting in phosphorylation of elongation factors and the C-
terminal domain of RNA polymerase II  (Isel and Karn, 1999). 
The viral genome contains multiple splice donor and splice acceptor sites giving rise to diverse vRNA 
species through alternative splicing (Purcell and Martin, 1993). Unspliced and partially-spliced RNAs 
are unable to exit the nucleus unaided because the cell has mechanisms in place to prevent intron-
containing RNA from being exported and thus translated (Cullen, 2000).  
To overcome this problem, the viral Rev protein binds to the RRE in unspliced and partially-spliced 
transcripts, facilitating their export from the nucleus to the cytoplasm (Rosen et al., 1988; Sodroski et 
al., 1986). As the RRE is in the Env coding region, it is only present in incompletely spliced RNAs. 
Rev multimers bound to the RRE interact with the transport factor Crm1 through a nuclear export 
signal (Neville et al., 1997), enabling the complex to be transported through the NPC and into the 
cytoplasm. Similar regulatory factors are also produced by HTLV I & II (Romanelli et al., 2013). By 
contrast, the genome of the simple retrovirus Mason-Pfizer monkey virus (M-PMV) contains an RNA 
structure termed a constitutive transport element that interacts directly with RNA export machinery 
(Cullen, 2003). 
Rev, Tat and Nef are described as ‘early’ genes because they are translated from fully-spliced 
transcripts and can therefore be expressed in a Rev-independent manner. Once sufficient Rev has 
accumulated unspliced and partially-spliced transcripts can exit the nucleus to enable translation of 
incompletely spliced ‘late’ genes. 
1.9. Structural switch in the 5’UTR regulating translation and packaging 
The unspliced RNA serves as both the gRNA to be packaged and as a template for Gag translation. 
These are two mutually exclusive processes. 5’UTR transcripts migrate with two distinct mobilities in 
gels suggesting the presence of two conformers (Berkhout and van Wamel, 2000). Mutational analysis 
showed that formation of the faster-migrating conformer required the poly(A) and DIS regions 
(Huthoff and Berkhout, 2001). Initial studies using RNA structure prediction tools proposed that in the 
fast migrating structure SL1 completely melts and anneals with the U5 region to form an elongated 
stem (Abbink and Berkhout, 2003; Huthoff and Berkhout, 2001). However, more recent data from 
nuclear magnetic resonance (NMR) spectroscopy and selective 2’-hydroxyl acylation analysed by 
primer extension (SHAPE) probing have refined this model. The DIS palindrome at the tip of SL1 anneals 
to residues in U5 forming a pseudoknot (Figure 6 left) (Kenyon et al., 2013; Lu et al., 2011).  
The two conformers perform different functions - packaging and translation - and the structural switch 
regulates the balance between these. In one conformation SL1 is occluded by base pairing between 
the DIS and U5, preventing dimerisation but promoting translation. In the other, SL1 is exposed to 
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enable dimerisation but translation is inhibited due to the U5-AUG interaction (Figure 6). Packaging is 
promoted in the latter conformer since this arrangement of SL1, SL3 and sequences in the 5’ sequence 
of gag form the structure recognised by the NC domain of Gag (Section 1.12) (Kenyon et al., 2015; 
Kutluay et al., 2014; Lu et al., 2011). 
Figure 6 – Structural switch in the 5’UTR 
 
The 5’UTR can adopt two conformations, promoting either translation (left), or dimerisation and 
packaging (right). SL1 contains the DIS palindrome at its tip (highlighted in red). Downstream of this 
are SL2, SL3 and SL4, which contains the Gag start codon (highlighted in green).   
Source: (Lu et al., 2011). 
Examples of structural switches controlling the balance between translation and packaging are also 
found in feline immunodeficiency virus (FIV) (Kenyon et al., 2011) and the more distantly related 
Moloney murine leukemia virus (MoMuLV) (Miyazaki et al., 2010; Mougel et al., 1993). 
In vitro, formation of the pseudoknot conformer which promotes packaging can be triggered by 
binding of the NC protein (Huthoff and Berkhout, 2001). In vivo, isolated NC protein is not available at 
this stage and gRNA is believed to be initially captured by a small number of full-length Gag molecules 
(Hendrix et al., 2015; Mailler et al., 2016). Nevertheless the unprocessed NC domain within Gag likely 
performs the same function, and this is consistent with the observation that at low concentrations Gag 
stimulates translation, whilst at a higher concentrations it is inhibitory (Anderson and Lever, 2006). 
Together, these data suggest that once sufficient Gag has accumulated for virion assembly the 5’UTR 
changes from a molecule promoting translation to one promoting dimerisation and packaging. 
Work from the Summers lab has led to an alternative hypothesis. They propose that the structural and 
therefore functional fate of each gRNA is determined at the moment of transcription, rather than a 
situation whereby each gRNA possesses the ability to switch between the two functions. 
Heterogeneity in transcription start site usage was shown to result in different numbers of G residues 
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at the 5’ end of gRNA. gRNAs with a single G residue at the 5’ end formed dimers and were 
preferentially packaged into virions, whilst those with two or three G residues formed monomers and 
were enriched on polysomes. It was proposed that the additional G residues destabilise the poly(A) 
hairpin, promoting the U5:DIS interaction (Figure 6 left) (Kharytonchyk et al., 2016). 
1.10. gRNA dimerisation 
Genome dimerisation is a unique feature of retroviruses (Paillart et al., 2004). When viewed under an 
electron microscope, RNA extracted from HIV-1 virions is seen as a dimer connected at the 5’ end of 
the genome (Höglund et al., 1997). Early studies on dimerisation of in vitro transcribed RNA suggested 
that this dimer linkage structure (DLS) was formed by contacts between polypurine tracts downstream 
of the 5’ major splice donor (Darlix et al., 1990; Marquet et al., 1991). As these sequences are found 
only in full-length gRNA this seemed a plausible mechanism for ensuring that only full-length gRNA can 
dimerise. The DLS was later found to be an artefact of using short transcripts in vitro, and is not 
important for dimerisation in vivo (Haddrick et al., 1996), however the DIS sequence upstream of the 
splice donor was found to be critical.  
The DIS is a 6-nucleotide palindrome in the apical loop of SL1. Dimerisation of gRNA is facilitated by 
intermolecular base pairing between DIS sequences (Haddrick et al., 1996; Marquet et al., 1994; 
Muriaux et al., 1995; Paillart et al., 1994; Skripkin et al., 1994). During virion maturation, the weak 
kissing-loop dimer is converted to a stronger extended dimer when the stems of SL1 melt and anneal 




Figure 7 – Maturation of the gRNA dimer 
 
The initial kissing-loop interaction formed by base pairing of DIS nucleotides is converted to a strong 
extended dimer interaction during virion maturation. NC catalyses the unwinding of SL1 and the 
establishment of extensive inter-strand base pairing.   
Source: (Russell et al., 2004). 
The importance of the DIS in initiating dimerisation explains the 100% conservation of palindromic 
sequences across all tested HIV-1 isolates (Berkhout, 1996). The palindromic nature of the DIS loop 
rather than its sequence appears to be critical for dimerisation. However some non-native palindrome 
sequences do severely impact dimerisation and virus replication, so sequence constraints do exist 
(Laughrea et al., 1999). 
Sequences involved in dimerisation and packaging overlap or are in close proximity to each other 
suggesting a link between the two processes (Abd El-Wahab et al., 2014; Clever and Parslow, 1997; 
Harrison et al., 1998; Kim et al., 1994; Laughrea et al., 1999, 1997; Lever et al., 1989; Liang et al., 1998; 
McBride and Panganiban, 1997, 1996; Paillart et al., 1996; Sakuragi et al., 2003; Shen et al., 2001, 
2000). 
There has been extensive debate about whether dimerisation precedes packaging or vice versa (Russell 
et al., 2004), but convincing evidence now exists demonstrating that formation of a dimer enables 
recognition by Gag for packaging. Duplication of the DIS in the genome results in the packaging of 
monomeric RNA. This indicates that an intra-molecular dimer can substitute for an inter-molecular one 
for recognition by Gag, showing that it is the unique structure of the dimer that is recognised for 
packaging (Nikolaitchik et al., 2013; Sakuragi et al., 2002, 2001). Furthermore, recombination between 
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subtype B (GCGCGC palindrome) and C (GUGCAC palindrome) viruses is less frequent than intra-
subtype recombination; a barrier which can be overcome by mutating their palindrome sequences to 
match (Chin et al., 2005; Moore et al., 2007). For recombination to occur heterologous RNAs must first 
be co-packaged, thus discordant palindromes, which are unable to form dimers, are less likely to be 
packaged than concordant ones. 
In recent years, it has become possible to study dimerisation taking place in cells using advanced 
microscopy techniques such as super resolution microscopy, and total internal reflection fluorescence 
microscopy (TIRFM), which allows visualisation of molecules at or near the plasma membrane. gRNA 
can be labelled by introducing sequences encoding RNA stem-loops recognised by MS2 from 
bacteriophage MS2 or BglG from Escherichia coli (E. coli) into the genome and co-expressing with a 
fluorescently labelled version of the stem-loop’s cognate binding protein. 
Chen et al developed the technique of co-expressing gRNAs labelled with two distinct fluorescent 
proteins (Chen et al., 2009). Measurement of the proportion of dual-labelled foci enables a direct 
determination of dimerisation efficiency in cells and virions. If only monomeric gRNA is present, then 
all foci would be either one colour or the other. However, if the gRNA population consists entirely of 
dimers then 50% of foci would be dual-labelled. The proportion of dual-labelled RNA in virions is close 
to 50% supporting the model whereby dimers are specifically selected for packaging (Chen et al., 2009). 
When TIRFM is used, gRNA is seen to move dynamically in and out of the membrane with a single step 
change in fluorescence, suggesting the arrival of pre-formed dimers at the membrane (Jouvenet et al., 
2009). This is supported by observation that HIV-1 gRNA colocalisation is 6-fold higher than non-viral 
RNA colocalisation in the cytoplasm (Ferrer et al., 2016). However, dimers were more enriched at the 
plasma membrane suggesting selective targeting of dimers to the plasma membrane and/or de novo 
initiation of dimerisation at the plasma membrane. This is consistent with the observation of signals 
from gRNA molecules merging on the membrane (Chen et al., 2015). 
Dimerisation is stimulated by Gag, as Gag expression increases the formation of dimers on the plasma 
membrane (Chen et al., 2015), and in the absence of Gag, dimerisation taking place in the plasma 
membrane and cytoplasm is 5-fold less efficient (Ferrer et al., 2016). Intriguingly, an NC mutant lacking 
gRNA binding was able to moderately stimulate dimerisation in the cytoplasm but not at the plasma 
membrane, suggesting that NC domain binding to gRNA is important for dimer accumulation at the 
plasma membrane (Ferrer et al., 2016). 
These results suggest that Gag acts as a chaperone to stimulate dimerisation or to stabilise newly 
formed dimers, however this does not contradict the finding that dimerisation precedes packaging. In 
agreement with biochemical and genetic data, heterodimerisation between individual gRNA molecules 
with discordant DIS sequences was severely inhibited preventing formation of heterodimer-containing 
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virions (Ferrer et al., 2016), and in the majority of cases particle assembly only occurred once a dimer 
had formed (Chen et al., 2015; Jouvenet et al., 2009).There is therefore a distinction to be made 
between Gag’s role in stimulating dimerisation and in packaging, which involves formation of whole 
virus particles around the genome.  
1.11. Spatiotemporal dynamics of Gag-gRNA interactions 
The notion of different modes of Gag binding to RNA, one involving cytoplasm-associated oligomers 
and the other membrane-associated multimers, is consistent with the finding by Kutluay et al that the 
sequences Gag associates with in the viral genome change during assembly and the formation of 
virions. Using CLIP-sequencing (CLIP-seq) they were able to probe the interactions between Gag and 
gRNA sequences in cells and virions. Cytoplasmic Gag associated with sequences around the packaging 
signal in the 5’UTR, but also with the RRE. However, in immature virions this pattern of binding was 
diminished, and instead Gag associated with numerous sequences A-rich sequences throughout the 
genome. This switch in binding appeared to be driven by Gag multimerisation, as a mutant in the 
carboxy-terminal domain of CA (CACTD) exhibited a binding profile reminiscent of cytoplasmic Gag. 
Upon virion maturation, the binding profile reverted to the one observed for cytoplasmic Gag, 
demonstrating that throughout the viral assembly process the interactions between Gag and gRNA are 
dynamic (Kutluay et al., 2014) (Figure 8).  
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Figure 8 – Changes in Gag-gRNA binding profile throughout virion assembly 
 
The interaction between Gag and gRNA is not static, changing multiple times throughout the virion 
assembly process, as illustrated in Steps 1–3 in the diagram. Early microscopy work indicated that gRNA 
doesn’t interact with Gag until it reaches the plasma membrane, but this was due to the inability to 
detect low order Gag oligomers. Instead, these oligomers are thought to interact with gRNA in the 
cytoplasm, with the 5’UTR and RRE as the main points of contact (Step 1). Upon multimerisation at the 
plasma membrane, these specific interactions are replaced by non-specific binding throughout the 
genome (Step 2). Gag-gRNA interactions in mature virions resemble that of those in the cytoplasm, 
with binding specificity returned to the 5’UTR and RRE (Step 3).  
Source: Modified from (Sundquist and Kräusslich, 2012)  
Advances in imaging techniques have provided further evidence about the dynamics of the  interaction 
between Gag and gRNA. Gag can be labelled by introducing sequences encoding fluorescent domains 
such as GFP or mCherry into its ORF and co-expressing with gRNA labelled using the methods described 
above. 
Tracing individual gRNA molecules revealed that they move in the cytoplasm in a random-walk motion 
suggestive of diffusion, both in the absence and presence of Gag, and it was concluded that Gag does 
not interact with gRNA until it reaches the plasma membrane (Chen et al., 2014). However, gRNA is a 
much larger molecule, with a molecular weight 35-fold higher than Gag, so the effect of potential Gag 
binding on the movement of gRNA is likely to be minimal (Chen et al., 2014). 
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Using TIRFM it was observed that RNA signals appear at the plasma membrane before Gag signals, 
suggesting that RNA does not interact with Gag until it reaches the plasma membrane (Jouvenet et al., 
2009). However, the sensitivity of detection in those experiments was 12 Gag molecules, so these 
results don’t exclude the possibility that gRNA arrives at the membrane in complex with a smaller 
number of Gag molecules.  
Hendrix et al overcame the Gag detection sensitivity issue by using fluorescence fluctuation 
spectroscopy, which enables inferences to be made regarding particle stoichiometry. Rather than 
looking at the effect of Gag on gRNA movement they investigated the effect of gRNA binding on Gag 
movement. Gag being a much smaller molecule makes it more likely that differences in motion will be 
observed if an interaction occurs. They found that Gag moves much more slowly in the cytoplasm than 
it should do based on its size, and that its mobility could be increased by mutating its RNA-binding NC 
domain. These data suggest that Gag and gRNA do indeed interact in the cytoplasm. NC mutation 
inhibited oligomerisation so they proposed that gRNA first interacts with Gag in the cytoplasm and 
nucleates assembly of a Gag oligomer. This is followed by anchoring in the plasma membrane where 
Gag multimerisation and particle assembly occurs (Hendrix et al., 2015). These findings are supported 
by crosslinking immunoprecipitation (CLIP) data showing that some cytoplasmic Gag dimers are 
associated with gRNA, with higher order Gag complexes only found at the plasma membrane (Kutluay 
and Bieniasz, 2010). 
1.12. Genome packaging 
HIV-1 genome packaging is remarkably efficient – over 90% of virions contain a gRNA dimer (Chen et 
al., 2009). The cis-acting determinants of packaging are found in the 5’UTR, and of particular 
importance are SL3 and SL1, as initially determined by reverse genetics experiments (Kim et al., 1994; 
Lever et al., 1989; McBride and Panganiban, 1996). Disruption of other regions also affects packaging, 
including SL4 (McBride and Panganiban, 1997) the TAR hairpin (Clever et al., 1999), poly(A) hairpin 
(Das et al., 1997) and U5-Pbs region (Russell et al., 2002). This may be due to secondary effects on the 
structure of the 5’UTR. 
The stem-loops do not function in isolation but form part of a much larger structure (Figure 3), so 
manipulation of individual stem-loops can have unpredictable effects on the overall structure of the 
region. Structural studies have helped to put these observations into context. 
A variety of structures have been predicted for the 5’UTR, reflecting the conformational flexibility of 
this region. However there is good agreement between structures derived using NMR (Lu et al., 2011), 
small-angle X-ray scattering (Jones et al., 2014) and single-molecule fluorescence resonance energy 
transfer (Stephenson et al., 2013), showing U5 bound to the start codon of Gag (Figure 3). Another 
NMR-derived structure shows the region comprising U5 and SL1 to SL4 folding into a 3-way junction 
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structure with SL2 being integral to the junction structure rather than forming a hairpin (Keane et al., 
2015).  
The trans-acting determinant of packaging interacting with the aforementioned cis-acting RNA 
structures is the NC domain of Gag (Figure 2). The key structural components of NC that enable specific 
packaging of gRNA are its two zinc finger motifs, each with the completely conserved sequence 
CX2CX4HX4C (where C = cysteine, H = histidine and X = any amino acid). In addition, NC contains basic 
residues that bind RNA non-specifically through electrostatic interactions. The spacer peptide 1 (SP1) 
domain immediately upstream of NC has also been shown to participate in packaging (Kaye and Lever, 
1998). 
In addition to reverse genetics and RNA structural probing, RNA protection and crosslinking assays 
have helped to map, at single-nucleotide resolution, the sequences and structures in the 5’UTR with 
which Gag interacts (Abd El-Wahab et al., 2014; Damgaard et al., 1998; Kenyon et al., 2015). These 
concur with data obtained using the above-mentioned techniques in that Gag binding sites map mostly 
to SL3 and SL1. 
Despite being separated in sequence space, regions identified as being important for packaging and 
Gag binding are adjacent in the three-dimensional structure (Stephenson et al., 2013) and may be 
bound by the same Gag molecule. Indeed, mapping of at least 10 potential Gag binding sequences, 
determined by crosslinking and SHAPE, onto the three-dimensional structure of psi revealed that they 
make up four major Gag binding interfaces (Kenyon et al., 2015).  
CLIP-seq data show that the region in the 5’UTR which Gag binds to in the cytoplasm comprises the 
sequences involved in the long-range interaction between U5 and AUG in addition to SL1 and SL3 
(Kutluay et al., 2014). This pattern of Gag binding is more consistent with models showing SL2 adopting 
a hairpin structure (Figure 3) (Kenyon et al., 2013; Lu et al., 2011) instead of being involved in long-
range base pairing (Keane et al., 2015). The findings of Kutluay et al also highlight another key 
determinant of successful genome packaging – the A-rich nature of the HIV-1 genome. In their CLIP-
seq experiments they showed that Gag only modestly favours binding to gRNA over host RNAs in the 
cytosol, however upon multimerisation it becomes much more selective through a preference for A-
rich regions in the gRNA over the GU-rich host RNAs (Kutluay et al., 2014). 
This process does not however exclude packaging of host RNAs and spliced vRNAs, which make up 
around half of the RNA in the virion by mass (Eckwahl et al., 2016). Their inclusion is not random as 
demonstrated by the failure to detect other host RNAs such as GAPDH (Houzet et al., 2007). As 
described earlier, HIV-1 uses the host tRNALys3 as a primer for reverse transcription through interaction 
with the Pbs, and other tRNAs interact with MA to prevent it from binding to internal membranes 
(Kutluay et al., 2014). Additionally, non-coding host RNAs such as U6 and 7SL – which are product of 
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RNA Pol III transcription – feature prominently in virus particles. Best-studied is the 7SL RNA, which is 
enriched 250-times more than actin RNA (Onafuwa-Nuga et al., 2006). One potential role for these 
non-viral RNAs is to assist in multimerisation of Gag through tethering of basic regions of NC (discussed 
further below). Another possibility is that they assist in host defence against HIV infection. There has 
been debate about the identity of the RNA that assists in packaging of the restriction factors APOBEC3G 
(Eckwahl et al., 2016) with one study finding 7SL RNA to be important for APOBEC3G incorporation 
(Wang et al., 2007). Definitive evidence is lacking at present, but it very unlikely that these host RNAs 
are enriched by chance. 
1.13. Gag multimerisation and particle assembly 
Once gRNA has reached the plasma membrane accompanied by oligomers of Gag, particle assembly 
begins (Figure 4) (Jouvenet et al., 2008; Kutluay and Bieniasz, 2010). Using microscopy, Gag-gRNA 
complexes are observed to stabilise on the membrane followed by increasing intensity of the Gag 
signal, indicating Gag multimerisation taking place (Chen et al., 2015; Jouvenet et al., 2009). As 
described above there is also a dramatic change in the binding of Gag to gRNA. Binding preference is 
switched from specific sites in the genome – psi, the RRE and 3’UTR – to less specific sites along the 
entire length of the genome (Kutluay et al., 2014). 
Most other retroviruses also assemble their capsids at the plasma membrane, however some 
preassemble immature capsids within the cytoplasm. An historical system classifying retroviruses by 
virion morphology describes different subtypes: B-type (extracellular, eccentric, spherical core), C-type 
(central, spherical core) and D-type (cylindrical core) (Fenner, 2016). C-type retroviruses assemble their 
capsids at the plasma membrane during budding (similar to HIV) and include HTLV, and Avian leukosis 
and sarcoma viruses (Weiss, 1996). B- and D- type retroviruses, on the other hand, assemble their 
capsids in the cytoplasm before budding – it is even possible to alter the morphogenesis of the D-type 
retrovirus M-PMV, by introducing a point mutation in matrix, to resemble that of a C-type retrovirus 
(Rhee and Hunter, 1990). A Gag domain (p12) in M-PMV common to B- and D- type retroviruses (but 
absent in C-types) is important for intracytoplasmic assembly at lower (physiological) levels of Gag 
expression but, is redundant for cytoplasmic assembly at higher levels of expression (Sommerfelt et 
al., 1992). 
Stabilisation and subsequent multimerisation of HIV Gag on the plasma membrane is dependent upon 
an intact MA domain (Figure 2) (Jouvenet et al., 2009; Kutluay and Bieniasz, 2010). At the N-terminus 
of MA is a myristic acid moiety, which enables it to embed into the plasma membrane (Göttlinger et 
al., 1989). This moiety is initially sequestered within a hydrophobic pocket in MA and is only exposed 
upon binding of the hydrophobic pocket to PI(4,5)P2, a phospholipid found exclusively in the plasma 
membrane (Chukkapalli and Ono, 2011; Saad et al., 2006). 
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MA is also capable of binding to nucleic acid in addition to NC. Incubation of MA with PI(4,5)P2-
containing liposomes abolishes its RNA binding activity, demonstrating that RNA and plasma 
membrane lipids compete for binding to MA (Alfadhli et al., 2009). CLIP-seq data revealed that MA 
binds almost exclusively to a particular subset of tRNAs, and this interaction inhibits internal 
membrane binding because RNase treatment of cell lysates causes Gag to redistribute to membranes 
(Kutluay et al., 2014). 
The mechanisms described above delay membrane binding and virion release, suggesting that there is 
a selective pressure for virus release to not occur too rapidly. Deletion of the globular head of MA 
enables faster and more abundant virus release, however this fails to give sufficient time for Vif to be 
expressed. Vif is a late gene which degrades the restriction factor APOBEC3G, which is packaged into 
virions where it mutates deoxycytidine residues to deoxyuridine in the nascent DNA strand during 
reverse transcription. By delaying release the virus has time to express Vif to maximise the likelihood 
of successful infection of new host cells (Holmes et al., 2015). 
The NC domain of Gag is also important for indirect Gag-Gag interactions mediated by non-specific 
RNA binding. Unlike for the initial oligomerisation event in the cytoplasm, gRNA is not required for Gag 
multimerisation, as the rate of Gag multimerisation is independent of the presence of gRNA (Jouvenet 
et al., 2009). The assembly of CA-NC complexes in vitro is stimulated by the presence of non-viral RNA 
(Campbell and Vogt, 1995), and retroviral particles produced in vivo degrade when treated with RNase 
(Muriaux et al., 2001). Furthermore, mutation of basic residues in NC reduces the ability of Gag to 
multimerise in vitro and in vivo whereas zinc finger mutations have little effect (Cimarelli et al., 2000). 
NC’s role in Gag multimerisation can be achieved by substituting it with a self-dimerising leucine zipper 
motif (Accola et al., 2000).  
Virus-like particles (VLPs) containing Gag alone can be assembled in vitro (Campbell and Rein, 1999) 
and in vivo (Gheysen et al., 1989) in the absence of gRNA, and can also be released from cells. This 
appears to contradict the observation that gRNA nucleates particle assembly.  However, gRNA may be 
important for nucleation under physiological conditions where intracellular Gag is less concentrated. 
gRNA plays an important role in virus assembly in Rous sarcoma virus (RSV). RSV Gag takes a different 
route towards the plasma membrane, briefly travelling to the nucleus assisted by nuclear localisation 
signals (NLS) in NC and MA. It is in the nucleus that Gag packages gRNA before returning to complete 
assembly at the plasma membrane. Association of the packaging signal in gRNA facilitates nuclear 
export by helping to expose a nuclear export signal in the Gag p10 domain (Parent, 2011). In HIV-1, 
mutation of the gRNA-binding motif in NC causes Gag nuclear localisation, although the implications 
of this are unclear (Grigorov et al., 2007). 
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CACTD and the SP1 domain are particularly important for the establishment of direct contacts between 
adjacent Gag molecules (von Schwedler et al., 2003). Within CACTD is the major homology region, a 
highly conserved 20 amino acid sequence common to all retroviruses (Wills and Craven, 1991). In the 
immature virion Gag molecules are arranged in a hexameric lattice, with CA-CA interactions supported 
by 6-helix bundles formed by SP1 domains (Wright et al., 2007).   
1.14. Virus budding 
Following Gag multimerisation, virus particles must bud from the cell (Figure 4). Formation of a lattice 
induces deformation of the membrane to curve away from the cytoplasmic face, but the virus does 
not encode the apparatus to sever the budding neck. Instead, like a number of enveloped viruses 
including the Ebola virus (Garrus et al., 2001; Martin-Serrano et al., 2001), it hijacks the host’s 
endosomal sorting complexes required for transport (ESCRT) machinery. 
Figure 9 – Topology of HIV budding 
 
The Gag protein alone is capable of assembling into virion structures (Step 1), but the virus lacks the 
machinery to catalyse the membrane severing event required to release the budding particle from the 
cell surface. Virus budding is topologically equivalent to the membrane remodelling events that take 
place during cytokinesis, and HIV and several other enveloped viruses take advantage of this similarity 
by hijacking the host cell’s own ESCRT machinery (Step 2). The final step of the ESCRT cascade involves 
the formation of a spiral polymer that lines the inside of the budding neck and constricts it (Step 3). 
Source: Modified from (Sundquist and Kräusslich, 2012) 
The ESCRT complexes were originally identified in budding yeast, where they are important for 
multivesicular body (MVB) formation (Babst et al., 2002b, 2002a; Katzmann et al., 2001). ESCRT 
26 
enables endosomes containing ubiquitinylated transmembrane proteins to bud into MVBs before 
lysosomal degradation. However an increasing number of roles for ESCRT is being identified, including 
cytokinesis (Carlton and Martin-Serrano, 2007; Morita et al., 2007) and a range of other functions 
which have been recently reviewed (Campsteijn et al., 2016). Enveloped viruses hijack ESCRT because 
the events required for MVB formation and virus export are topologically equivalent, with the 
membrane budding away from the cytoplasmic face. 
The ESCRT system is composed of four protein complexes (Table 1) which recruit each other in a 
sequential cascade. The membrane scission event is performed by ESCRT-III. ESCRT-III is composed of 
various charged multivesicular body proteins (CHMPs), the key components of which are CHMP2 and 
CHMP4, which form a spiral polymer to close the budding neck (Hanson et al., 2008). This is followed 
by recruitment of Vps4, an ATPase that recycles ESCRT-III components back into the cytoplasm (Lata 
et al., 2008).  
The role played by ESCRT-II in HIV budding is controversial. Early studies showed that upon knockdown 
of ESCRT-II components virus release is not affected (Langelier et al., 2006; Pincetic et al., 2008). 
However, recent evidence in knockout cell lines has demonstrated that it may be required for optimal 
virus budding. A two-fold reduction in the virus release ratio was observed using siRNA knockdown of 
ESCRT-II and by CRISPR/Cas9 EAP45 knockout, however knockdown using shRNA left the release ratio 
unaffected despite reduced amounts of intracellular and extracellular Gag, which were attributed to 
an effect on transcription (Meng et al., 2015).   
An in vitro study using purified proteins and giant unilamellar vesicles showed that recruitment of 
ESCRT-III to Gag complexes was dependent on the presence of ESCRT-II (Carlson and Hurley, 2012), 
however this is a simplified artificial system so interpretation of results must be performed with 
caution. Further work is needed to confirm the importance of ESCRT-II in HIV budding. 
Table 1 – components of the ESCRT complexes in humans 
Complex name Components 
ESCRT-0 HGS; STAM1, 2 
ESCRT-I TSG101; VPS28; VPS37A, B, C, D; MVBB; UBAP1 
ESCRT-II EAP20; EAP30; EAP45 
ESCRT-III CHMP1A, B; CHMP2A, B; CHMP3; CHMP4A, B, C; CHMP5; CHMP6; CHMP7; 
IS1 
 
ESCRT proteins are recruited through motifs in the p6 domain at the C-terminus of Gag (Figure 2). 
Deletion of p6 results in a severe reduction in particle release with virions remaining tethered to the 
plasma membrane (Göttlinger et al., 1991; Huang et al., 1995). The p6 domain is also called the “late 
domain” since mutation affects a late step in virus assembly. 
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The first motif to be identified as important for budding was the PTAP motif (Göttlinger et al., 1991; 
Huang et al., 1995; Martin-Serrano et al., 2001), which recruits tumour susceptibility gene 101 
(TSG101), a component of ESCRT-I (Garrus et al., 2001; Martin-Serrano et al., 2001; VerPlank et al., 
2001). In its prototypic role, TSG101 binds to ubiquitinylated transmembrane proteins and recruits 
downstream ESCRT complexes enabling endosomes to bud into MVBs (Katzmann et al., 2001). In the 
context of virus budding it is hijacked by Gag to recruit ESCRT to the plasma membrane (Garrus et al., 
2001; VerPlank et al., 2001).  
A second motif, YPXnL, exists towards the C-terminus of p6 and recruits the host protein ALG-2 
interacting protein X (ALIX) (Strack et al., 2003; Von Schwedler et al., 2003). ALIX is not a member of 
the ESCRT machinery but is termed an ESCRT-associated protein, and it also participates in MVB 
formation (Fujii et al., 2007). It has three major domains – the N-terminal Bro1 domain interacts with 
CHMP4 (Kim et al., 2005) and NC (Popov et al., 2008); the central V domain interacts with the YPXnL 
motif in p6; and the proline-rich region interacts with TSG101 (Figure 10) (Fisher et al., 2007). 
Figure 10 – Domains and crystal structure of ALIX 
 
A) Domain organisation of ALIX with domain names labelled above and interaction partners labelled 
below. B) Crystal structure of ALIX. Colours of helices correspond with those regions indicated in A. 
Residues highlighted yellow and red are those involved in binding to CHMP4 (an ESCRT-III protein), and 
the YPXnL domain of Gag, respectively. A short hydrophobic linker connect the Bro1 domain with Arm 
1 of the V domain.  
Modified from (Fisher et al., 2007). 
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The ultimate outcome of both the TSG101 and ALIX pathways is to transiently recruit ESCRT-III 
components and Vps4 to the inside of the budding neck (Figure 11) (Prescher et al., 2015) at the end 
of Gag assembly (Jouvenet et al., 2011), enabling fission of budding necks and recycling of ESCRT 
components back into the cytoplasm. 
The PTAP-TSG101 pathway is generally considered to be dominant, as disruption results in more severe 
defects in virus release in widely used cell lines (Fisher et al., 2007; Göttlinger et al., 1991; Huang et 
al., 1995). In 293T and HeLa cells, using full-length virus, disruption of the PTAP motif results in a 20-
100-fold reduction in virus release (Fisher et al., 2007; Huang et al., 1995) whereas disruption of the 
YPXnL motif results in a 2-3-fold reduction (293T) (Fisher et al., 2007), or in no reduction (HeLa) 
(Demirov et al., 2002).  
However, in a minimal Gag construct lacking the globular domain of MA and the C-terminus of CA, 
YPXnL mutation results in a 10-fold reduction in release from HeLa cells, suggesting that other factors 
compensate for YPXnL mutation in the context of a full-length virus (Strack et al., 2003).  
Whilst being useful investigational tools, 293T and HeLa cells may not accurately replicate the 
physiological conditions encountered by the virus in natural infection. Fujii et al introduced mutations 
into the YPXnL motif and evaluated the effect on virus release in a HeLa cells in addition to 
physiologically relevant primary T cells and macrophages. As observed before and by others, in HeLa 
cells ALIX binding site mutations had no effect on virus release (except for a 5-fold reduction in the 
Y36A mutant), whilst PTAP- mutation resulted in a 10-fold reduction. In the Jurkat T-cell line and in 
monocyte-derived macrophages (MDMs), the Y36A mutation resulted in greater (Jurkat) or equivalent 
(MDMs) release defects than the PTAP- mutant.  
In a virus replication assay, ALIX binding site mutations resulted in more severe defects in replication 
kinetics than PTAP- mutation, whilst the reverse was true in MDMs. The authors hypothesised that the 
relative importance of the TSG101 and ALIX pathways may be due to differences in expression levels 
between cell types, however the Jurkat cell line expresses higher levels of TSG101 but appears to be 
more dependent on the ALIX pathway (Fujii et al., 2009). The block in virus release caused by 
interference with the PTAP-TSG101 pathway can be rescued by overexpressing ALIX (Fisher et al., 2007; 
Usami et al., 2007), providing that the YPXnL motif and CHMP4 binding site are intact. Therefore, ALIX 
can compensate for a defective TSG101 pathway by providing an alternative link to ESCRT-III. ALIX 
therefore appears to play a vital role in circumstances of low TSG101 availability or disruption of Gag-
TSG101 binding (Usami et al., 2007). 
Microscopy studies initially showed that GFP-tagged ALIX is recruited progressively to Gag assembly 
sites (Jouvenet et al., 2011). A later study found that the GFP tag disrupts ALIX function, but that 
introduction of a linker corrects this defect. These wild type-like ALIX molecules were recruited to the 
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budding neck transiently at the end of assembly (Ku et al., 2014). In contrast TSG101 appears to 
accumulate progressively with Gag assembly (Bleck et al., 2014). ALIX and TSG101, despite binding in 
very similar positions in p6, are positioned distinctively in assembling virions – ALIX is positioned more 
peripherally than TSG101, which is more central (Bleck et al., 2014). 
Figure 11 – Role of ESCRT system in HIV-1 release  
 
The PTAP and YPXnL motifs in the p6 domain of Gag recruit TSG101, a member of ESCRT-I, and ALIX, 
an ESCRT-associated protein, respectively. Both pathways converge on recruitment of ESCRT-III, 
components of which forms spiral filaments that constrict and sever the budding neck, before recycling 
back into the cytoplasm by VPS4.   
Source: (Meng and Lever, 2013). 
The practice of usurping the ESCRT pathway by hijacking TSG101 and ALIX is not limited to HIV or even 
to retroviruses. ESCRT is the only well characterised cellular pathway which facilitates budding away 
from the cytoplasmic face, and as such it is hijacked by a plethora of viruses. The TSG101-binding 
P(T/S)AP motif first identified in HIV-1 can be found in the structural proteins of filoviruses, 
arenaviruses, rhabdoviruses and reoviruses. 
The ALIX-binding YPXL motif first identified in Equine Infectious Anemia Virus has since been found in 
paramyxoviruses, arenaviruses, flaviviruses, hepadnaviruses, herpesviruses and tombusviruses 
(Votteler and Sundquist, 2013). ALIX is also important for Ebola virus release – the VP40 matrix protein 
of the virus possesses a YPXL/I consensus motif that interacts with ALIX. siRNA knockdown of ALIX 
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reduced virus release, and overexpression of ALIX rescued production of the budding deficient 
PTAP/PPEY L-domain deletion mutant (Han et al., 2015). 
1.15. Virus maturation 
During and after budding, PR cleaves Gag and GagPol at highly conserved recognition sites (Figure 12) 
(Kaplan et al., 1994; Lee et al., 2012; Mattei et al., 2016), each with a consensus shape recognised by 
PR despite differences in sequence (Prabu-Jeyabalan et al., 2002). Cleavage at each site occurs at a 
different rate (Pettit et al., 2005) so processing takes place in a particular order (Figure 12) which if 
disturbed by cleavage site mutations or pharmacological agents is extremely detrimental to virus 
infectivity (Li et al., 2003; Nowicka-Sans et al., 2016; Wiegers et al., 1998). Gag is cleaved into MA, CA, 
SP1, NC, SP2 and p6 (Figure 12), whilst Pol is cleaved into PR, RT and IN.  
Gag processing triggers a structural rearrangement of the viral core termed maturation, which is 
essential for the virus to become infectious (Göttlinger et al., 1989; Kohl et al., 1988; Peng et al., 1989). 
The electron dense outer shell is replaced by a conical inner core (Figure 4 and Figure 12). Gag 
processing also triggers dimer maturation (Figure 7) because the mature NC protein acts as a 
chaperone facilitating formation of the extended dimer (Darlix et al., 1990; Muriaux et al., 1996). 
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Figure 12 – Gag processing and virion maturation 
 
Illustration of the stages of Gag processing and the accompanying changes in virion morphology. Red 
lightning strikes represent cleavage events, which appear on the page in the order they occur in the 
virion. This ordered processing occurs because the 5 cleavage sites between the 6 domains of Gag are 
cleaved by PR at different rates. Gag processing causes the viral core to undergo structural 
rearrangement, with the final CA-SP1 cleavage being particularly important for the formation of a 
conical core. To aid interpretation of the figure the domains of Gag are not drawn to scale. 
The PR enzyme is a homodimer, with each monomer contributing an aspartic acid residue critical for 
formation of the active site (Wlodawer and Gustchina, 2000). As PR is initially embedded as a domain 
within GagPol this necessitates the formation of a GagPol dimer to commence Gag processing. The PR 
domains in the GagPol dimer self-excise through an intramolecular cleavage (Pettit et al., 2004) to 
become a much more stable molecule with greater enzymatic activity (Lee et al., 2012). 
The mechanism underpinning the non-infectious nature of immature virions remained unknown for 
some time, but several investigators have found that blocking Gag processing prevents virions from 
fusing with target cells (Chojnacki et al., 2012; Murakami et al., 2004; Wyma et al., 2004). Two 
mechanisms have been described that explain this phenomenon, although the two are not mutually 
exclusive and are likely to both be required for efficient (Chojnacki et al., 2017). Studies by the Rousso 
group found that maturation of the core reduced virion stiffness and increased fusogenicity, likely due 
to the dramatic structural reorganisation of Gag that takes place. Curiously the increased stiffness of 
immature particles was abolished by removal of the cytoplasmic tail of Env, suggesting that Env may 
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help to stabilise the immature Gag shell in addition to its primary role of facilitating fusion. The authors 
proposed that this stiffness switch acts to prevent the entry of aberrantly formed virions (Kol et al., 
2007; Pang et al., 2013). 
Chojnacki et al also observed a role for the cytoplasmic tail of Env in fusion, however in their study 
they were using stimulated emission depletion microscopy to study the effect of maturation on the 
localisation of Env trimers on the viral membrane. In mature particles Env trimers clustered together 
into a single focus, whereas in immature particles several foci were observed. They found that 
proteolytic processing of Gag, particularly at MA-CA, triggered clustering of the limited number (7–14) 
of Env trimers on the virion surface. Deletion of the cytoplasmic tail of Env rescued the clustering 
defect in immature virions. They proposed a model whereby the cytoplasmic tail of Env interacting 
with the immature Gag lattice traps the trimers on the virion surface. Upon maturation Env molecules 
are liberated from this trapped state to form a single focus enabling efficient interaction with CD4 
(Chojnacki et al., 2012). 
CA-SP1 processing is a particularly important step as it completes the dramatic structural 
rearrangement of the viral core (Figure 12) (Wiegers et al., 1998). CA-SP1 cleavage sites are not 
accessible to PR in the immature virion as they are folded into α-helices forming 6-helix bundles which 
support the hexameric lattice. Only upon unwinding of the helix is the cleavage site exposed, making 
CA-SP1 cleavage the slowest of all the processing steps (Bayro et al., 2016; Schur et al., 2016; Wagner 
et al., 2016). CA-SP1 processing can be specifically inhibited by a new experimental class of ARVs, 
termed the maturation inhibitors (MIs), although none have been authorised for clinical use yet. The 
prototypic MI is PA-457, otherwise known as bevirimat (Li et al., 2003). 
Gag processing and budding are tightly linked events, although the mechanism linking virus budding 
and Gag processing remains a mystery. This is mainly due to the fact they occur simultaneously and 
interfering with one process often interferes with the other - processing is disturbed by disruption of 
late domain function (Fisher et al., 2007; Huang et al., 1995) and budding is inhibited when PR is 
overexpressed (Karacostas et al., 1993) or inhibited (Kaplan et al., 1994). 
PTAP and YPXnL mutants exhibit Gag processing defects characterised by accumulation of the MA-CA-
SP1 and CA-SP1 processing intermediates (Fisher et al., 2007; Huang et al., 1995). Interference further 
down the ESCRT pathway, such as knockdown of ESCRT-II (Meng et al., 2015), ESCRT-III (Morita et al., 
2011) or over-expression of dominant-negative VPS4 protein (Garrus et al., 2001), also causes 
defective CA-SP1 processing and reduced virus release. As disruption of all stages in the pathway 
causes reduced CA-SP1 processing, this suggests that this crucial cleavage event is triggered during the 
final step of the ESCRT cascade.   
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Inhibition of PR rescues the budding defect of late domain mutants (Huang et al., 1995) by preventing 
over-processing of Gag caused by delayed release (Ott et al., 2009). On the other hand, introduction 
of PR into late domain mutant Gag-expressing cells inhibits release because Gag and GagPol are 
processed before closure of the budding neck, leading to diffusion of critical virion components back 
into the cytoplasm (Bendjennat and Saffarian, 2016). 
This highlights a race that takes place between closure of the budding neck and activation of PR. 
Interventions that disrupt the fragile balance between budding and processing result in severe 
attenuation of virus replication. 
1.16. Replication cycle summary 
In summary, the wealth of biochemical data and recent data from microscopy and 
immunoprecipitation studies suggests that the following sequence of events occurs during the late 
stages of virus assembly: 
1. Following export of gRNA from the nucleus, dimerisation occurs between complementary DIS 
sequences stimulated by Gag molecules acting as chaperones. The NC domain of Gag is bound 
to specific sequences (psi, the RRE and the 3’UTR). 
2. This results in the formation of Gag-gRNA complexes in the cytoplasm; oligomers of Gag bound 
to gRNA, which traffic to the plasma membrane by diffusion. 
3. Upon arrival at the plasma membrane Gag anchors into the membrane through the MA 
domain, stabilising the complex in the membrane. Additional dimerisation can occur on the 
plasma membrane. Gag’s binding preference switches from specific motifs to more general 
binding throughout the genome. 
4. Recruitment of monomeric Gag from the cytoplasm results in multimerisation to form an 
immature virion particle. Multimerisation is mediated by contacts between CA and NC 
although the RNA interactions required for NC-NC interactions are non-specific. 
5. Following ESCRT recruitment the virus is released from the cell and maturation occurs. The 
dramatic structural changes are accompanied by changes in the binding specificity of Gag to 
gRNA, which again binds to specific regions (psi, RRE, 3’UTR) possibly to prepare the genome 
for reverse transcription to begin. 
1.17. Observations and findings which led to this study 
The experiments performed herein were based on the observation that mutation of SL1 in the 5’UTR 
results in aberrant Gag processing and formation of immature virions (Liang et al., 1999a). An 
understanding of the mechanism linking an RNA structure in psi with Gag processing could potentially 
lead to new insights into the process of virus assembly. 
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Additionally, despite the efficacy of ARVs, the genetic flexibility of the virus means that the evolution 
of resistance mutations is a serious problem. RNA structures in the 5’UTR are some of the most highly 
conserved regions of the virus genome, so an improved understanding of the functions of these regions 
may provide insight into new mechanisms which can be targeted therapeutically (Le Grice, 2015). 
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2. Materials and methods 
2.1. Solutions 
All solutions were prepared with MilliQ water (Merck Millipore). Recipes are provided in Table 10 in 
Appendix A. 
2.2. Plasmid constructs and cloning 
 Plasmid DNA constructs obtained prior to this study 
All plasmids express ampicillin resistance genes. 
pSVC21.BH10-WT, an infectious molecular clone of HIV-1 group M subtype B (Fisher et al., 1985; Ratner 
et al., 1985) and the DIS, Stem B and Loop B mutants were gifts from Dr. Michael Laughrea (McGill 
University, Canada). All plasmid nucleotide positions mentioned hereafter refer to the reference 
sequence (accession number K03455.1). The plasmids had been made suitable for containment level 
2 work by Dr. Bo Meng by deleting a part of the coding region in Env (7042-7621) using the restriction 
enzyme BglII. The DIS mutant has the C residue at position 712 of the reference sequence substituted 
for a G, the Stem B mutant has nucleotides 697-700 deleted and the Loop B mutant has nucleotides 
725-727 deleted. These mutations affect the local structure of SL1 in the 5’UTR of the transcribed 
gRNA. These plasmids are termed pSVC21.BH10-Bgl/(mutant name). 
pCMV-VSV-G, a gift from Dr. Laurence Tiley, encodes the vesicular stomatitis virus G glycoprotein (VSV-
G) under the control of a CMV promoter. 
pBlueScript (Short et al., 1988) is a cloning vector. It was used in this study as an empty vector for 
equilibrating the amount of DNA used between different transfection conditions. 
pGEM-T Easy (Promega) is approximately a 3-kilobase (kb) linearised cloning vector. It has a 3’ terminal 
thymidine at each end, enabling ligation with PCR products generated by Taq polymerases and 
reducing the risk of vector recircularisation. 
pBJ5-ALIX-HA was a gift from Professor Heinrich Gottlinger (University of Massachusetts Medical 
School, USA) (Strack et al., 2003). It encodes full-length ALIX with an HA tag at the C-terminus, cloned 
into the mammalian expression vector pBJ5. Expression is under control of an SRα promoter (Takebe 
et al., 1988). 
pSVC21.BH10-Bgl/PTAP- was constructed by Dr. Bo Meng by mutating in the region of nucleotides 
2152-2163 (CCA ACA GCC CCA  CTA ATT CGC CTA) as described in (Huang et al., 1995). The proline-
threonine-alanine-proline (PTAP) motif in the p6 domain of Gag is changed to leucine-isoleucine-
arginine-leucine (LIRL). This prevents TSG101 binding whilst maintaining the integrity of the amino acid 
sequence of the overlapping Pol reading frame (Huang et al., 1995).  
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pSVC21.BH10-Bgl/YPXnL- was constructed by Dr. Bo Meng by mutating in the region of nucleotides 
2239-2244 (TAT CCT  TTA GTT) as described in (Dussupt et al., 2009). The tyrosine-proline-Xn-leucine 
(YPXnL – where X is any amino acid and n = 1, 2 or 3 (in the case of BH10 Xn = leucine-threonine-serine)) 
motif in p6 is altered to Leucine-Valine-Xn-Leucine (LVXnL), preventing ALIX binding whilst again 
maintaining the Pol amino acid sequence (Dussupt et al., 2009).  
pSVC21.BH10-Bgl/PTAP-/YPXnL-, containing both above-mentioned sets of mutations, was constructed 
by Dr. Bo Meng by mutating the YPXnL domain in pSVC21.BH10-Bgl/PTAP-.  
pSVC21.BH10-Bgl/F16A contains a substitution of the 16th amino acid in NC from phenylalanine to 
alanine and was constructed by Dr. Bo Meng. 
pJHIV-1-Luc and pJHIV-1 contain nucleotides 1-336 of HIV-1 HXB2 upstream of a sequence encoding 
firefly luciferase (pJHIV-1-Luc) or nucleotides 47-889 of influenza A virus segment 8 (pJHIV-1). pJHIV-1-
ΔΨ construct is identical to pJHIV-1 except that nucleotides 224-336, which form SLs 1-4, are deleted. 
Production of the pJHIV-1 and pJHIV-1-ΔΨ constructs has been previously described (Anderson and 
Lever, 2006). 
 Plasmid DNA constructs produced during this study 
The following plasmids were constructed using the cloning methods described in the rest of this 
section.  
pSVC21.BH10-Bgl/LD4 has nucleotides 718-731 deleted. It was produced by PCR site-directed 
mutagenesis (see Section 2.2.7). 
pSVC21.BH10-Bgl/MP2/MNC/(WT, DIS, Stem B, Loop B, LD4, PTAP-, YPXnL- or PTAP-/YPXnL-) contain two 
mutations in Gag. The MNC mutation substitutes a C for T at position 1989 changing the amino acid 
encoded from threonine to isoleucine in the NC domain of Gag. The MP2 mutation substitutes C for T 
at position 1913, also resulting in a change of amino acid from threonine to isoleucine in the SP1 (also 
known as p2) domain of Gag. The mutations were introduced into pGEM-T-UTR-WT subclone (see 
Section 2.2.8) before transfer back to the respective pSVC21.BH10-Bgl provirus constructs (WT, SL1 
mutants and PTAP-/YPXnL- mutants) (see Section 2.2.9). 
pSVC21.BH10-Bgl/LD4/PTAP- contains the LD4 deletion (718-731) in addition to the PTAP- mutation 
(PTAPLIRL). It was produced by digesting pSVC21.BH10-Bgl/PTAP- and pSVC21.BH10-Bgl/LD4 with 
ApaI and XcmI (see Section 2.2.5) and ligating the PTAP- insert into the LD4 vector (see Section 2.2.6). 
pSVC21.BH10-Bgl/AAG contains a mutation in the Gag start codon, which is mutated from ATG to AAG 
(TA at position 791). pSVC21.BH10-Bgl/AAG/CA contains the start codon mutation as well as a 
second mutation in the CA domain of Gag. The mutation is an insertion of 4 nucleotides (CTAG) 
between nucleotides 1511 and 1512. This introduces a stop codon and a frameshift preventing 
37 
translation from alternative start sites. The mutations were introduced into pGEM-T-UTR-WT (see 
Section 2.2.8) before transfer back to the pSVC21.BH10-Bgl provirus construct (see Section 2.2.9). 
 Agarose gel electrophoresis and extraction of DNA 
To assess the size and concentration of plasmids, PCR products and restriction digest products, samples 
were mixed with GelPilot 5X DNA Loading Dye (Qiagen) and electrophoresed in agarose gels. Gels were 
made by dissolving 0.5 g of agarose (Sigma Aldrich) in 50 ml of tris-borate-EDTA (TBE) buffer by boiling, 
allowing to cool slightly and adding 5 µl of SYBR Safe DNA Gel Stain (Thermo Fisher), and then pouring 
into a gel tank to set. When gels had set, they were immersed in 0.5X TBE running buffer and samples 
were loaded, alongside 5 µl of HyperLadder 1kb (Bioline), before running at 60 V for the time required 
to separate the relevant bands. Gels were visualised, and images captured in a gel imaging box.  
DNA was purified when required by placing the gel on a UV transilluminator, cutting out the relevant 
bands using a scalpel and processing the gel slices using the QIAquick Gel Extraction Kit (Qiagen), 
following the manufacturer’s protocol. 
 Polymerase chain reaction 
Polymerase chain reaction (PCR) mixes consisted of 1 µl of 10 ng/µl template DNA, 2 µl of 10 µM 
forward and 2 µl of 10 µM reverse primers (Table 2), 1 µl of deoxyribonucleotide triphosphate (dNTP) 
mix and 5 µl of 5X GoTaq buffer (Promega) with 0.25 µl of GoTaq G2 (Promega) or, for high fidelity 
reactions, 2.5 µl of 10X Pfu buffer (Promega) with 0.5 µl of Pfu (Promega), made up to 25 µl with 
nuclease-free water. 
Thermal cycling conditions used (unless otherwise specified) were: initial denaturation at 95 ⁰C for 2 
minutes, followed by 35 cycles of denaturation at 95 ⁰C for 30 seconds, annealing at 52 ⁰C for 30 
seconds and extension at 73 ⁰C for 2 minutes, followed by a final extension at 73 ⁰C for 5 minutes. 
To purify PCR product from the reaction mixture, the QIAquick PCR Purification Kit (Qiagen) was used, 
following the manufacturer’s protocol. Samples were taken and run on agarose gels to verify their size 
and purity, and the purified PCR products were stored at -20 ⁰C. 
Table 2 – primers used for PCR 





 Restriction digestion 
Restriction digest reactions were composed of 1 µg of DNA, 2 µl of 10X MULTI-CORE buffer (Promega) 
or 10X CutSmart buffer (New England Biolabs) and 10 units (U) of each restriction enzyme, made up to 
20 µl with nuclease-free water. 1 µl (10 U) of thermosensitive alkaline phosphatase (TSAP) (Promega) 
38 
was also added to the mixture if the digest product was to be subsequently used for ligation, to prevent 
recircularisation. Reactions were incubated for 3 hours at the required temperature (Table 3). To 
inactivate enzymes the reaction mixtures were incubated at 75 ⁰C for 15 minutes. 
Digest products were analysed using agarose gel electrophoresis and purified if required. Digestion 
with multiple enzymes was used as a diagnostic tool to check that newly produced plasmids had the 
same digest pattern as the parental plasmids from which they were derived. 
Table 3 – restriction enzymes used 
Enzyme (manufacturer) Buffer (manufacturer) Operating temperature (⁰C) 
ApaI (Roche) MULTI-CORE (Promega)/ 
CutSmart (New England 
Biolabs) 
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BssHII (New England Biolabs) MULTI-CORE 50 
XcmI (New England Biolabs) CutSmart 37 
SpeI (New England Biolabs) MULTI-CORE 37 
 Ligation 
Ligation reactions were set up with a 3:1 ratio of insert:vector. Reactions were made up of 2 µl of 10X 
Ligase buffer (Promega), 50 ng of vector, the required amount of insert and 0.5 µl of T4 DNA Ligase 
(Promega) made up to 20 µl with nuclease-free water. Control reactions were also set up which lacked 
insert, so that following bacterial transformation the number of colonies could be compared to give 
an indication of whether the ligation was successful or not. Ligation and control reactions were 
incubated for 3 hours at room temperature or overnight at 4 ⁰C and then inactivated by incubating for 
10 minutes at 70 ⁰C. 
 PCR site-directed mutagenesis 
pSVC21.BH10-Bgl/LD4 was produced using PCR site-directed mutagenesis. The primers DIS-R and Apa-
A (Liang et al., 1998) contain restriction sites for BssHII and ApaI respectively (Table 4), allowing the 
PCR product to be restriction digested and ligated into the vector. The DIS-R primer contains the LD4 
deletion (nucleotides 718-731) to be introduced into PCR products. The PCR reaction was set up using 
Pfu to minimise the risk of unwanted mutations being introduced, and modifying the annealing 
temperature to 65 ⁰C and the extension time to 75 seconds.  
Table 4 – primers used for PCR site-directed mutagenesis 
Mutagenic primer name Sequence (5’-3’) (* = restriction enzyme cut site) 
DIS-R GCTGAAG*CGCGCAGGGCGGCGACTGGTGAGTACGCC 
Apa-A CCTAGGGGCC*CTGCAATTTCTG 
The purified PCR product and pSVC21.BH10-Bgl were then digested with ApaI and BssHII in a sequential 
digest due to the different operating temperatures of the two enzymes. First an ApaI digest was 
performed, followed by inactivation, then BssHII was added. The digests were run on agarose gels and 
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purified. Ligation reactions were set up followed by transformation of 5 µl of the ligation mixture into 
bacteria (see Section 2.3.1). 
The sizes of cultured plasmids were checked by restriction digestion and agarose gel electrophoresis 
before verifying the introduction of the mutation by sequencing (GATC Biotech). 
 Production of pGEM-T-UTR subclone 
A pGEM-T Easy vector-based subclone containing nucleotides 581-2054 was produced to provide a 
construct which could be used for mutagenesis and transfer back into the pSVC21.BH10-Bgl plasmids. 
Primers 581F and 2054R (Table 2) were used to amplify this region from pSVC21.BH10-Bgl by PCR, 
followed by purification of the product before ligation of into the pGEM-T Easy vector using the 
manufacturer’s protocol. Following transformation and culture, the product size (4.5 kbp) was 
confirmed by agarose gel electrophoresis and sent for sequencing with primer 581F. The plasmid was 
termed ’pGEM-T-UTR-WT‘.  
 Subclone mutagenesis and transfer back to proviral vector 
To produce the other mutants in this study (MP2/MNC, AAG and AAG/CA mutations), whole plasmid 
site-directed mutagenesis was performed on the subclone pGEM-T-UTR-WT. The primers pairs used 
both contain the desired mutation and are complementary to each other. Unlike PCR, the reaction is 
not an amplification since only the parental plasmid can be used as a template (nicks created in newly 
formed plasmids preclude their use as a template for further amplification). 
Reaction mixtures were composed of 5 µl of 10X Pfu buffer, 1 µl each of 10 µM NC-F and NC-R primers, 
1 µl of dNTP mix, 5 µl of 10 ng/µl of pGEM-T-UTR subclone and 0.5 µl of Pfu polymerase made up to 
50 µl with nuclease-free water.  
Thermal cycling conditions used were: initial denaturation at 95 ⁰C for 1 minute, followed by 12 cycles 
of denaturation at 95 ⁰C for 30 seconds, annealing at 65 ⁰C for 1 minute and extension at 68 ⁰C for 8 
minutes. Following this 1 µl (20 U) of DpnI (New England Biolabs) was added to the reaction and 
incubated for 1 hour at 37 ⁰C to digest the wild type parental methylated plasmid. 
Plasmids were then transformed, cultured and sent for sequencing to confirm the introduction of the 
desired mutations. 
To introduce the MNC mutation into the subclone, primers NC-F and NC-R were used, and to introduce 
the MP2 mutation, primers P2-F1 and P2-R1 were used. This plasmid was termed ’pGEM-T-UTR-
MP2/MNC‘.  
To produce a construct which does not express Gag, site-directed mutagenesis was first performed on 
the subclone pGEM-T-UTR-WT using primers Gag AUGmut F and Gag AUGmut R (Table 5), changing 
the Gag start codon nucleotide sequence from ATG to AAG. An additional mutation was made using 
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primers CA Stop F1 and CA Stop R1 (Table 5), which introduced a premature stop codon and a 
frameshift in the CA domain of Gag. This plasmid was termed ’pGEM-T-UTR-AAG/CA’. 
To transfer mutated subclone sequences back into the pSVC21.BH10-Bgl provirus construct, primers 
518F and 2054R (Table 2) were used in a PCR reaction with Pfu, followed by purification. Both the PCR 
product and the pSVC21.BH10-Bgl plasmid were then digested with ApaI and SpeI, with TSAP present 
to prevent recircularisation of the vector during ligation. The digest was run on an agarose gel and the 
largest restriction fragment from the insert digest (1524 nucleotides) was gel extracted and purified. 
This was then ligated back into pSVC21.BH10-Bgl followed by transformation, culture and sequencing 
with primers 518F, 1616F or 2054R. Plasmid size and integrity was assessed by digesting with various 
restriction enzymes alongside pSVC21.BH10-Bgl plasmid to ensure that the same digest pattern was 
obtained. 
Table 5 – primers used for subclone mutagenesis 





Gag AUG mut F GGAGGCTAGAAGGAGAGAGAAGGGTGCGAGAGCG 
Gag AUG mut R CGCTCTCGCACCCTTCTCTCTCCTTCTAGCCTCC 
CA stop F1 GGAAGTGACATAGCAGGAACTACTAGCTAGTACCCTTCAGG 
CA stop R1 CCTGAAGGGTACTAGCTAGTAGTTCCTGCTATGTCACTTCC 
2.3. Bacterial expression of plasmids and sequencing 
 Bacterial transformation and culture 
For routine plasmid transformation, the laboratory stock of the DH5α strain of E. coli was used (Taylor 
et al., 1993). 5 µl of 10 ng/µl plasmid was added to a 100 µl aliquot of bacterial cells, which had been 
stored at -80 ⁰C and allowed to thaw on ice for 10 minutes. The mixture was gently flicked to mix and 
then left on ice for a further 30 minutes. Bacteria were then heat-shocked by incubating at 42 ⁰C for 
40 seconds, and on ice for 2 minutes, before adding 1 ml of Luria Bertani (LB) and incubating in a 
shaking incubator at 37 ⁰C and 220 rpm for 1 hour.  
For transformation of ligation mixtures XL10-Gold ultracompetent cells (Stratgene) were used. Cells 
which had been stored at -80 ⁰C were thawed on ice for 10 minutes. 50 µl aliquots were added to pre-
chilled round-bottom polypropylene tubes on ice, and 2 µl of 2-mercaptoethanol was added to each 
aliquot before swirling gently and incubating on ice for 10 minutes, swirling every 2 minutes. 5 µl of 
ligation mixture were added to each aliquot before swirling and incubating on ice for 30 minutes. 
Bacteria were then heat-shocked by incubating at 42 ⁰C for 30 seconds, and on ice for 2 minutes, before 
plating directly. 
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Transformation mixtures were then plated onto LB agar supplemented with 100 µg/ml ampicillin and 
incubated overnight at 37 ⁰C. The following day colonies were counted on the ligation plate and the 
control plate, where ligation was performed without addition of insert. If the number of colonies on 
the ligation plate was greater than the control plate, this indicated that the ligation had been 
successful.  
Colonies were picked using a sterile pipette tip and inoculated into 5 ml aliquots of LB medium 
supplemented with 100 µg/ml ampicillin for overnight culture in a shaking incubator at 220 rpm and 
37 ⁰C. If a larger quantity of plasmid DNA was required 1 ml of 5-ml culture was used to inoculate 400 
ml of LB medium supplemented with 100 µg/ml ampicillin. 
 
 Purification of plasmids from culture 
Plasmid DNA was purified from 5 ml and 400 ml overnight cultures using the QIAprep Spin Miniprep 
Kit (Qiagen) and the Qiagen Plasmid Maxi Kit (Qiagen) respectively, following the manufacturer’s 
protocol. To determine the concentration of purified DNA a spectrophotometer (NanoDrop) was used. 
 Producing and reviving glycerol stocks 
For long-term storage, glycerol stocks of transformed bacteria were made by mixing 500 µl of bacterial 
culture with 500 µl of 50% glycerol and storing at -80 ⁰C. Bacteria were later recovered by stabbing 
into the frozen stock with a sterile pipette tip and inoculating into 5 ml of LB medium supplemented 
with 100 µg/ml ampicillin for overnight culture. DNA was then purified as described above. 
 Plasmid DNA sequencing 
Custom sequencing primers were obtained from Sigma Aldrich as dried pellets, which were 
resuspended to 100 µM with nuclease free water and stored at -20 ⁰C.  
For sequencing reactions plasmids were diluted to 100 ng/µl and sequencing primers to 10 µM in a 
volume of 20 µl. Samples were sent to GATC Biotech for Sanger sequencing. Sequences were returned 
in FASTA format and analysed using UGENE (Unipro) software. 
Table 6 – primers used for sequencing  





2.4. Cell culture and transfection 
 Maintenance of cell lines 
293T cells (ATCC) and TZM-bl cells (NIH AIDS Reagent Program) were maintained in Dulbecco’s 
modified Eagle medium (DMEM) (Thermo Fisher). The medium was supplemented with 10% (v/v) fetal 
bovine serum (FBS) (Thermo Fisher). 
Cells were incubated in T75 flasks in 5% CO2 at 37 ⁰C, and were passaged 1:10 every 3-4 days. To 
passage cells the medium was discarded and the cells were washed gently with phosphate-buffered 
saline (PBS) before adding 1 ml of trypsin (Thermo Fisher), and incubating for 5 minutes at 37 ⁰C. 
Trypsinised cells were then resuspended to a volume of 10 ml with fresh medium. 1 ml of resuspended 
cells were transferred to a new T75 flask, and 12 ml of fresh medium was added. Cells were discarded 
and fresh stocks resuscitated before cells reached passage number 30. 
 Freezing and resuscitation of cells 
To freeze down cells for long term storage in liquid nitrogen, 4 ml of cultured cell suspension and 0.5 
ml of FBS were mixed, before adding 0.5 ml of dimethyl sulfoxide (DMSO) dropwise. 1 ml aliquots were 
added to cryovials and cooled at the recommended rate of 1 ⁰C/min using a Mr Frosty freezing 
container (Thermo Fisher) following the manufacturer’s protocol. After overnight freezing the cryovials 
were transferred to liquid nitrogen for storage. 
To thaw frozen cells, cryovials were removed from liquid nitrogen and warmed in a 37 ⁰C water bath 
with gentle shaking. The 1 ml aliquots were transferred to 15 ml conical centrifuge tubes and 5 ml of 
culture medium was added before centrifuging at 1000 rpm for 2 minutes in a benchtop centrifuge. 
The supernatant was carefully removed before resuspending the cell pellet in 5 ml of culture medium 
and transferring to a T25 tissue culture flask and incubating as described above. 
 DNA and siRNA transfection overview 
24 hours prior to transfection, 293T cells were seeded at a confluence of 40% in 6-well (≈ 2.4x106 cells 
per well) or 24-well plates (≈ 4.8x105 cells per well) to reach a confluence of 80% at transfection. For 
plasmid transfection DNA was mixed with TransIT-LT1 Transfection Reagent (Mirus Bio) (see Appendix 
B for a comparison of different transfection reagents) at a ratio of 3 µl of transfection reagent per 1 µg 
of DNA. 1µg of DNA and 3 µl of transfection reagent were used per well of a 6-well plate (unless 
otherwise specified), and 200 ng of DNA and 0.6 µl of transfection reagent were used per well of a 24-
well plate. Transfection reagent and DNA were mixed in a volume of 250 µl (for 6-well plates) or 50 µl 
(for 24-well plates) of Opti-MEM Reduced Serum Medium (Thermo Fisher). Mixtures were incubated 
at room temperature for 15-30 minutes. The transfection mixture was then added dropwise to the 
culture media, before returning the cells to the incubator. 
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For siRNA transfection 2µl of 20 µM Stealth RNAi siRNA (Thermo Fisher) was mixed with 1 µl of TransIT-
TKO Transfection Reagent (Mirus Bio) and 50 µl Opti-MEM per well of a 24-well plate, before 
incubating and adding to culture media as described above. 24 hours’ post-transfection the siRNA 
transfection was repeated.  
 In trans expression of gRNA/5’UTR 
293T cells seeded in 24-well plates were transfected with 100 ng of pSVC21.BH10-Bgl proviral DNA, 
and 100 ng of pSVC21.BH10-Bgl/AAG/CA, pJHIV-1, pHIV-1-Luc, pJHIV-1-ΔΨ or pBlueScript. 
 Knockdown of ALIX and TSG101 in the presence and absence of MP2/MNC 
compensatory mutations 
293T cells seeded in 24-well plates were transfected with 100 ng of proviral DNA (pSVC21.BH10-Bgl or 
pSVC21.BH10-Bgl/MP2/MNC) and 100 ng of pBlueScript. They were simultaneously transfected with 
siRNAs (control, siALIX, siTSG101 or siALIX and siTSG101). After 24 hours the siRNA transfections were 
repeated. 
 ALIX overexpression assay 
293T cells in 24-well plates were transfected with 30 ng of proviral DNA (pSVC21.BH10-Bgl/PTAP- or 
pSVC21.BH10-Bgl/LD4/PTAP-), with or without pBJ5-ALIX-HA, made up to 200ng with pBlueScript. 
2.5. Protein preparation and analysis 
 Harvesting transfected cell supernatants and lysates 
Cell culture supernatants were transferred to microcentrifuge tubes and clarified by centrifuging at 14 
000 rpm in a benchtop microcentrifuge for 2 minutes. The supernatant was then carefully removed 
without disturbing the cell pellet and stored at -80 ⁰C. 
Transfected cells were lysed with 1X Cell Culture Lysis Reagent (CCLR) (Promega) and then placed for 
30 minutes on a plate rocker. Lysates were then transferred to microcentrifuge tubes.  
 Purification of virions from cell culture supernatants 
Clarified supernatants were mixed with OptiPrep Density Gradient Medium (Sigma-Aldrich) in a ratio 
of 2:1 before centrifuging at 20 000 rpm in a TLA-55 rotor in an Optima MAX-E ultracentrifuge 
(Beckman Coulter). Samples were centrifuged for 90-120 minutes at 4 ⁰C before carefully discarding 
the supernatant and resuspending the virus pellet in 10 µl PBS saline, and storing at -80 ⁰C. 
 Western blotting 
Samples (cell lysates or purified virions) were mixed with an equal volume of 2X Laemmli buffer and 
boiled for 5 minutes at 95 ⁰C before centrifuging for 2 minutes at 14 000 rpm in a microcentrifuge. 
Samples were run alongside Precision Plus Dual Colour protein ladder (Bio-Rad) on 12-15% sodium 
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dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels in Western blot running buffer at 
120-140 V.  
To separate the 24 kilodalton (kDa) CA and 25 kDa CA-SP1 bands in provirus-transfected cell lysates 
15% gels were run for 4 hours or until the 25 kDa ladder marker was about 1 cm from the edge of the 
gel. Proteins were transferred from the gel to a nitrocellulose membrane (GE Healthcare) by wet 
electrotransfer in a Mini-PROTEAN Tetra Cell (BioRad). Transfer was performed in Western blot 
transfer buffer at 100 V for 90 minutes on ice or 15 V at 4 ⁰C overnight. Membranes were blocked by 
incubating at room temperature in 5% milk in PBS for 30 minutes, before incubating for 2 hours at 
room temperature or overnight at 4 ⁰C in primary antibody (Table 7) diluted in 5% milk in PBS.  
Following incubation in primary antibody, membranes were washed for 10 minutes 3 times in PBS-
0.1% tween, before incubating for 2 hours at room temperature or 4 ⁰C overnight in secondary 
antibody diluted in PBS (Table 7). This was followed by a repeat of the washing steps, before a 5-minute 
wash in PBS. Membranes were covered with 1 ml ECL (GE Healthcare) or ECL Prime (GE Healthcare) 
(for increased sensitivity) before exposure to X-Ray film and development using an automatic film 
developer. 
Table 7 – antibodies used in Western blotting 
Protein target Antibody 
type 
Species Catalogue number, 
supplier 
Concentration used 
HIV-1 CA Primary Mouse ARP313, NIBSC 1:20 000 
GAPDH Primary Rabbit ab9485, Abcam 1:2000 
HA tag Primary Rabbit 14-6756, 
eBioscience 
1:2000 
ALIX Primary Mouse 3A9, Cell Signaling 
Technology 
1:1000 
TSG101 Primary Mouse ab83, Abcam 1:2000 





Horse 7076, Cell Signaling 
Technology 
1:20 000 
Rabbit IgG Secondary 
(HRP-
conjugated) 
Donkey sc-2313, Santa Cruz 
Biotechnology 
1:20 000 
 Pulse-chase labelling 
293T cells in 6-well plates were transfected with 1 µg of pSVC21.BH10-Bgl wild type or DIS, Stem B, 
Loop B or LD4 mutant proviral DNA per well. Four identical plates were prepared in total – one for each 
time point. 24 hours post-transfection, the medium was discarded and cells were gently washed twice 
with PBS, before adding 500 µl of methionine/cysteine-free DMEM (Thermo Fisher) supplemented 
with 4mM L-Glutamine (Thermo Fisher) and 10% (v/v) FBS. Cells were incubated at 37 ⁰C in 5% CO2 for 
40-60 minutes to starve them of methionine and cysteine. 10 µl (≈ 4 MBq) of EasyTAG EXPRES35S 
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protein labelling mix (Perkin Elmer) was added directly to the medium in each of the wells, and plates 
were incubated at 37 ⁰C, 5% CO2 for 40 minutes to radioisotopically label newly synthesised protein 
with the beta radiation emitter 35S. The medium was then discarded, and the cells gently washed twice 
with PBS. 500 µl of DMEM supplemented with 2 mM methionine and 2 mM cysteine was added to 
each well. Plates for the 20, 40 and 60-minute time points were returned to the incubator, with the 
remaining plate providing the samples for the 0-minute time point. At each time point the supernatant 
was discarded and the cells were washed with 500 µl of ice-cold PBS before adding 300 µl of RIPA 
buffer and incubating for 5 minutes on ice. Lysates were pipetted up and down to break them up, and 
transferred to microcentrifuge tubes for overnight rotation at 4 ⁰C. Following overnight rotation, the 
lysates were centrifuged in a microcentrifuge at 13 000 rpm, 4 ⁰C for 15 minutes to pellet cell debris, 
and 500 µl of supernatant was harvested. 0.25 µl (3.25 µg) of ARP313 anti-p24 antibody (NIBSC) was 
added to the lysate supernatant and the samples were rotated overnight at 4 ⁰C. After overnight 
rotation 50 µl of protein G-linked sepharose beads were added to each sample and rotated at room 
temperature for 2 hours (beads were prepared by adding 50 µl of water to 50 µl of Protein G 
Sepharose, Fast Flow (Sigma Aldrich), centrifuging at 6000 rpm for 2 minutes in a microcentrifuge, 
discarding supernatant and resuspending in 50 µl water). The samples were then centrifuged at 6000 
rpm for 2 minutes in a microcentrifuge to immunoprecipitate Gag. The beads were washed by 
discarding the supernatant, resuspending in 500 µl of RIPA buffer, and repeating the centrifugation 
before again discarding the supernatant. Beads were resuspended in 50 µl of 2X Laemmli buffer and 
boiled for 5 minutes to separate the immunoprecipitated Gag from the beads. Centrifugation was 
repeated to pellet the beads and 15 µl of supernatant was loaded into a 15% SDS-PAGE gel and run at 
120 V for around 4 hours to enable maximum separation of CA-SP1 and CA bands. Gels were immersed 
in gel fixing solution for 90 minutes to allow the proteins to form insoluble aggregates in the gel to 
maximise band sharpness. The solution was then discarded, and gels were immersed in 50 ml of 
Amplify Fluorographic Reagent (GE Healthcare) for 30 minutes on a shaker. To reduce the risk of gels 
cracking during the drying process the gels were immersed in 50 ml of gel drying solution for 15 
minutes. Gels were then placed onto Whatman 3MM chromatography paper (GE Healthcare) and 
covered in cling film, before placing on a vacuum gel drier for 1 hour. Dried gels were exposed to 
Biomax MR film (Kodak) and the films developed using an automatic film developer. 
 Quantifying Gag processing and release 
Western blots of cell lysates and virions were performed and multiple exposures of blots were made 
to try to obtain images with clearly defined but not over-exposed bands. Films were scanned and 
ImageJ software (NIH) was used to quantify the density of bands. To calculate the relative efficiency of 
a processing step, the ratio of the density of products to precursors in mutants was divided by the ratio 
in the wild type.  
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Similarly, to calculate the relative release ratio the sum of the densities of Gag-associated bands in 
mutant virion blots (often only the CA band was observed in virion blots) was divided by the sum of 
Gag-associated bands in their respective lysate blots and normalised against the wild type ratio. 
 Quantifying luciferase expression 
At 48 hours post-transfection 293T cell supernatants were discarded and cells were lysed with 150 µl 
of 1X CCLR per well, before centrifuging at 14 000 rpm for 2 minutes in a benchtop microcentrifuge. 5 
µl of clarified cell lysate was added per well of a medium binding 96-well flat-bottomed polystyrene 
plate and a GloMax luminometer (Promega) was used to inject 25 µl of Luciferase assay reagent 
(Promega) into each well and to record luciferase activity. To account for background, a reading from 
the untransfected control well was also taken. 
2.6. Preparation and Northern blot analysis of viral RNA 
 Treatment to inhibit RNases 
All solutions were prepared using designated RNase-free chemicals where possible and with 
autoclaved MilliQ water. Solutions and microcentrifuge tubes were autoclaved before use. Surfaces 
(pipettes, gel tanks and worktops) were sprayed and wiped with RNaseZap (Thermo Fisher). 
 Purification of RNA from virions 
293T cells seeded in 6-well plates were transfected with 2.5 µg of pSVC21.BH10-Bgl, DIS, Stem B, Loop 
B or LD4 proviral DNA per well. At 48 hours post-transfection, the supernatants were harvested and 
processed to purify virions. 200 µl of proteinase K extraction buffer was added and samples were 
incubated at 37 ⁰C for 30 minutes to digest viral proteins. Samples were then placed on ice and RNA 
was extracted as follows: 200 µl of 5:1 phenol:chloroform (pH 4.3-4.7) (Sigma Aldrich) was added to 
each sample before briefly vortexing and then centrifuging the samples at 14 000 rpm in a benchtop 
microcentrifuge. The upper liquid phase containing RNA was transferred to a new microcentrifuge tube 
and 200 µl of 24:1 chloroform:isoamyl alcohol (Sigma Aldrich) was added, and the vortexing and 
centrifugation were repeated, before again harvesting the upper liquid phase. RNA was precipitated 
by mixing in 1/10 volumes of 3 M sodium acetate pH 5.2 and then 2.5 volumes of 100% ethanol and 
incubating on ice for 30 minutes, followed by centrifugation at 14 000 rpm in a benchtop 
microcentrifuge for 20 minutes at 4 ⁰C. The supernatant was carefully removed, and the pellet washed 
with 200 µl of ice cold 70% ethanol, before repeating the centrifugation step. The supernatant was 
discarded, and the pellet allowed to air dry for a few minutes before resuspending in 10 µl nuclease-
free water. Purified viral RNA was stored at -80 ⁰C.  
 In vitro transcription of Northern blot probe 
A DNA probe template was first produced by PCR, using primers 1878F and 2984R-T7 (Table 2). The 
reverse primer contains the promoter for bacteriophage T7 polymerase, enabling in vitro transcription 
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of an ssRNA probe which is antisense to the gRNA. Nucleotides 1878-2984 are not present in spliced 
viral RNA, thus enabling the probe to bind to full-length gRNA specifically. 
The probe was in vitro transcribed using the MAXIscript In Vitro Transcription Kit (Thermo Fisher) in 
the presence of digoxigenin (DIG)-conjugated UTP to enable later detection. The reaction mixture 
consisted of 5 µl of PCR product, 2 µl of 10X transcription buffer, 1 µl each of 10 mM ATP, CTP and GTP, 
0.6 µl of 10 mM UTP, 1.14 µl of 3.5 mM DIG-UTP (Roche), and 2 µl of T7 polymerase made up to 20 µl 
with nuclease-free water. The reaction was incubated for 3 hours at 37 ⁰C before twice treating with 
Turbo DNase by adding 1 µl to the reaction mixture and incubating for 15 minutes at 37 ⁰C. NucAway 
spin columns (Thermo Fisher) were used following the manufacturer’s protocol to purify the probe. 
The probe concentration was determined using a spectrophotometer and probes were stored at -80 
⁰C. 
 Northern blotting of virion RNA 
1 µl of 10X native gel loading solution (Thermo Fisher) was added to each 10 µl purified virion RNA 
sample. These were loaded alongside RiboRuler High Range RNA ladder (Thermo Fisher) in a non-
denaturing 1% agarose gel. Gels were run at 4 ⁰C in 0.5X TBE running buffer at 60 V for at least 4 hours 
to enable sufficient separation of dimeric and monomeric gRNA bands. Gels were visualised in a gel 
imaging box to check gel progress and RNA integrity (a 2:1 ratio of 28S:18S ribosomal RNA (rRNA) from 
the cellular RNA control indicated that RNA was not degraded in the gel). RNA was transferred from 
the gel onto a Hybond-N+ positively charged nylon membrane (GE Healthcare) by downward capillary 
transfer, using the apparatus setup described in the NorthernMax-Gly kit (Thermo Fisher), with 20X 
saline-sodium citrate (SSC) buffer. Following a 2-hour transfer at room temperature, the membrane 
was briefly washed in 0.5X TBE to remove excess salt and agarose, and crosslinked by baking at 80 ⁰C 
for 20 minutes in a hybridisation oven. The gel was visualised under UV light in a gel imaging box to 
verify that transfer had been successful. The membrane was placed into a 50 ml polypropylene 
centrifuge tube and pre-hybridised by incubating for 30 minutes at 68 ⁰C in 4 ml of UltraHyb 
Ultrasensitive Hybridisation buffer (Thermo Fisher) before addition of 1 ml of 250 ng/ml probe in 
UltraHyb to the pre-hybridisation solution, to give a final concentration of 50 ng/ml. Hybridisation was 
performed overnight at 68 ⁰C in a roller hybridisation oven with the centrifuge tube inside the glass 
hybridisation tube. This meant that less solution was required, and it was easier to work with the 
membrane. The next day the hybridisation solution was discarded, and the membrane washed for 10 
minutes at room temperature in low stringency wash buffer followed by twice washing for 15 minutes 
at 68 ⁰C in high stringency wash buffer. The DIG luminescent detection kit (Roche) was used for 
washing and binding of the alkaline phosphatase-conjugated anti-DIG antibody, following the 
manufacturers’ protocol. CDP-star (Thermo Fisher) was used as a substrate, before exposure of the 
membrane to X-ray film and development in an automatic film developer.  
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Dimer and monomer bands from northern blots were quantified by densitometry using ImageJ (NIH) 
and dimerisation efficiency was calculated by dividing the % dimer for each mutant by the % dimer for 
the wild type. 
2.7. Assessing virion infectivity and stability 
 TZM-bl infectivity assay 
293T cells seeded in a 24-well plate were transfected at 24 hours with 30 ng of pSVC21.BH10-Bgl, DIS, 
Stem B, Loop B or LD4 proviral DNA, 160 ng of pBlueScript and 10 ng of pCMV-VSV-G to produce 
pseudotyped viruses capable of a single round of infection. In addition, a well was left untransfected 
as a control. 
48 hours post-transfection 10 µl of clarified supernatant (harvested supernatant centrifuged at 14 000 
rpm for 2 minutes to pellet cells) was added to each well of a 24-well plate of 80% confluent TZM-bl 
cells to infect them. TZM-bl cells have been engineered to contain stably integrated firefly luciferase 
and E.coli β-galactosidase under control of the HIV-1 promoter (Wei et al., 2002). Upon infection, the 
HIV-1 Tat protein activates these genes enabling quantitation of infectivity. They are also engineered 
to express high levels of CD4 and CCR5 (Platt et al., 1998) for Env binding but in this context this is not 
important since the viruses have a deletion in Env and are instead pseudotyped with VSV-G, which 
uses the low-density lipoprotein receptor (LDLR) receptor for binding (Finkelshtein et al., 2013).  
At 48 hours post-infection cell supernatants were discarded and cells were lysed with 150 µl of 1X CCLR 
per well, before centrifuging at 14 000 rpm for 2 minutes in a benchtop microcentrifuge and discarding 
the pellet. Lysates were either stored at -20 ⁰C or were used immediately for analysis. Luciferase 
activity was measured as described in Section 2.5.6. Luciferase values were then divided by the input 
virus concentration as determined by enzyme-linked immunosorbent assay (ELISA) to give a measure 
of infectivity per unit virus. Finally, all values were normalised against the wild type. 
 ELISA 
ELISA was used to determine the concentration of CA in cell supernatants for normalisation of 
luciferase readings. 96-well high binding flat-bottom polystyrene plates were coated with 25 µl per 
well of ELISA coating antibody solution and left overnight. The next day 1/10 volumes of 1X CCLR was 
added to supernatants to break down viral membranes. Supernatant samples and a recombinant p24 
protein standard (Aalto Bio Reagents) were serially diluted in 0.05% Empigen in 1X Tris-buffered saline 
(TBS). Plates which had been coated overnight were incubated for 1 hour at room temperature with 
100 µl of 5% bovine serum albumin (BSA) in 1X TBS per well to block non-specific binding, before 
washing 4 times with 100 µl of 1X TBS per well. The serial dilutions of the samples and standard were 
then loaded, and the plate was put on a plate shaker for 90 minutes, followed by a repeat of the TBS 
wash. 25 µl of ELISA secondary antibody solution was added to each well before shaking for a further 
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1 hour. Wells were washed 4 times with 100 µl of PBS-0.1% Tween per well before adding 25 µl of 
Lumi-Phos Plus (Lumigen) to each well and incubating at room temperature in the dark for 30 minutes. 
A Glomax Luminometer was used to read luminescence. A standard curve was generated and used to 
interpolate CA concentrations from supernatant samples. 
 Capsid stability assay 
The capsid stability assay was based on a previously published protocol (Ohagen and Gabuzda, 2000). 
Purified virions resuspended in PBS from pSVC21.BH10-Bgl or LD4 mutant transfected cells were made 
up to 5 µl with PBS alone or with 2 µl or 4 µl of 0.05% Triton X-100 in PBS, and incubated for 10 minutes 
at room temperature. 45 µl of 50 mM Tris-HCl pH 7.4 was added and samples were incubated for 1 
hour at 37 ⁰C, before centrifuging for 1 hour at 14 000 rpm in a microcentrifuge to pellet intact 
particles. The supernatant was carefully harvested leaving 5 µl which was mixed to resuspend the 
pellet. Samples were run on an SDS-PAGE gel before Western blot detection with ARP313 anti-p24 
antibody and quantitation of the density of the pellet and supernatant bands. The proportion of p24 
pelleted out of total p24 for each Triton X-100 treatment was calculated.  
 Statistics 
A two-tailed two-sample unpaired Student’s t-test was used for statistical analysis of population 
means. This test carries several assumptions including: 
• The scale of measurement is continuous 
• The data follow a normal distribution 
• The variances of each population are approximately equal 
The t-test is ideal for the type of data generated in this project (e.g. comparing mutant and wild type 
Gag processing) as it is limited to two categories of data – it is mathematically identical to the one-way 
ANOVA with two categories – and the assumptions can be reasonably made. Even if data do not follow 
a normal distribution, the t-test is not sensitive to this providing the distributions of the two groups 
are similar (McDonald, n.d.).   
In some cases a one-sample test was used when the mean value obtained from a random sample was 
to be compared against a theoretical value.  
In both types of test, the difference between means/between the mean and expected value was 
deemed to be statistically significant if the p value was below 0.05.  
When plotting graphs with n ≥ 3 for all values, where n represents the number of independent 
experiments performed, the error bars plotted represent standard deviation. In graphs where n < 3 for 
some or all values, the error bars represent range. 
In all graphs the values plotted represent the mean of n independent experiments.  
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3. Phenotypic effects of SL1 mutations 
3.1. Introduction 
 Importance of SL1 for virus replication 
Given its importance in facilitating gRNA dimerisation and packaging, it is not surprising that SL1 
mutants are often severely attenuated (selected examples in Table 8 with further examples in Table 
11 in Appendix D). The majority of nucleotides in the stems and internal loops of SL1 are 100% 
conserved across all sequenced viral isolates (Greatorex et al., 2002), and analogues of SL1, featuring 
palindromic loops, are also found in HIV-2 and SIV (Berkhout, 1996).  
Despite being severely replication-defective, many SL1 mutants have only moderate defects in 
dimerisation and packaging (Table 8). This suggests SL1 mutation affects other steps of the virus 
replication cycle, either unrelated to or because of defective dimerisation and packaging. For example, 
the later steps of reverse transcription have been shown to be affected by large SL1 mutations (Paillart 
et al., 1996; Shen et al., 2000), likely because of a destabilising effect on the structure of the Pbs.  
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Table 8 – phenotypes of selected SL1 mutants 
Mutant name Infectivity (% 
WT) (Cell type) 
Dimerisation (% 
WT) (Cell type) 
Packaging (% WT) 
(Cell type) 
Reference 
Large deletions     
Δ248-261 < 1% (MT-4) 57% (COS7) 57% (COS7) (Laughrea et al., 
1997) 
LD3/Δ241-256 < 1% (MT-2) 53% (COS7) 20% (COS7) 
 
30% (COS7) 
(Liang et al., 
1998; Shen et al., 
2000) 
LD41 < 1% (MT-2) - 70% (COS7) (Liang et al., 
1999b, 1998) 




    
G-loop < 10% (HOS) - 83% (293T) (Clever and 
Parslow, 1997) 
S257-259 1% (SupT1) - 100% (COS7) 
 
50% (SupT1) 
(Paillart et al., 
1996) 
GGCG2 < 5% (MT-4) 59% (COS7) 60% (COS7) 
 
78% (COS7) 
(Laughrea et al., 
1999; Shen et al., 
2000) 
Stem mutants     
Δ243-247 < 0.1% (MT-4) 56% (COS7) 60% (COS7) (Laughrea et al., 
1999; Shen et al., 
2000) 
Δ248-256 < 0.1% (MT-4) 53% (COS7) 70% (COS7) (Laughrea et al., 
1999; Shen et al., 
2000) 
Δ243-2463 < 0.1% (COS-7) 59% (COS7) 25% (COS7) (Shen et al., 
2001) 
Δ274-277 < 0.1% (COS-7) 59% (COS7) 40% (COS7) (Shen et al., 
2001) 
Loop mutants     
Δ271-2734 < 1% (COS-7) 59% (COS7) 44% (COS7) (Shen et al., 
2001) 
Δ247 < 5% (COS-7) 59% (COS7) 65% (COS7) (Shen et al., 
2001) 
Numbers in superscript format indicate mutants that are equivalent to the LD4 (1), DIS (2), Stem B (3) 
and Loop B (4) mutants used in this study. Mutant names that include nucleotide positions use the 
numbering system shown in Figure 3 referring to position in the transcribed RNA, and not the system 
used in Materials and Methods which refers to position in the provirus. 
 Compensatory mutations in SL1 mutants 
Virus evolution studies can provide valuable information on the interactions taking place between 
different regions of the viral genome, to identify novel functions associated with those regions. 
Sequencing of infectious viruses that emerge from cultures of attenuated mutants can reveal 
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compensatory mutations. These are mutations that partially or fully restore a phenotype disrupted by 
a mutation without correcting the underlying mutation. 
After 18 passages of the severely defective LD3 SL1 mutant, Liang et al identified a revertant with near 
wild type infectivity and packaging. The initial deletion in SL1 remained, but two compensatory 
mutations in Gag termed MP2 and MNC appeared at the 12th residue of the SP1 domain (also known 
as p2) and the 24th residue of the NC domain respectively (Liang et al., 1998) (Figure 13). Both 
mutations involve a threonine to isoleucine substitution. The same compensatory mutations also 
appeared during culture of mutants with deletions between the Pbs and SL1 (Liang et al., 2000) and 
their introduction into the LD4 SL1 mutant also restored replication to near wild type levels (Liang et 
al., 1998). 
Figure 13 – Location of compensatory mutations in Gag 
 
Cartoon diagram of Gag showing position of the MP2 and MNC compensatory mutations in the context 
of its domains (drawn to scale). The MP2 mutation is a T I mutation at position 12 of the SP1 domain, 
and the MNC mutation is a T  I mutation at position 24 of the NC domain. 
The nearly fully infectious LD3-MP2-MNC mutant was passaged a further 11 times and two additional 
mutations which supplement the original compensatory mutations were identified in MA and CA and 
termed MA1 and CA1 (Liang et al., 1999b).  
Despite altering both gRNA and Gag amino acid sequence, the compensatory mutations act at the 
protein level because LD3-MP2-MNC gRNA could not compete for encapsidation into wild type virions 
when provided in trans. Substitution of T12 in SP1 and T24 in NC for every other amino revealed only 
that valine, leucine, and methionine, which have long hydrophobic sidechains, could functionally 
replace the isoleucine residue to restore infectivity to 5’UTR mutants (Rong et al., 2001). Wild type 
virus infectivity was greatly reduced when T12 in SP1 was replaced with either aspartic acid or glutamic 
acid, which have negatively charged side chains, or tryptophan which has a bulky hydrophobic side 
chain. This suggests that the mechanism of rescue is to restore a protein-protein or protein-RNA 
interaction. 
The residue altered by the MNC mutation is located immediately downstream of the histidine residue 
which is a critical component of the first zinc finger of NC. This mutation alone substantially restores 
packaging to 5’UTR mutants (Liang et al., 2000, 1998; Shen et al., 2000) but has no effect on wild type 
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virus packaging (Rong et al., 2001). The BH-D2 mutant, which has nucleotides in the Pbs hairpin 
deleted, can be rescued by either MNC or by a G to A substitution in U5, which would strengthen the 
U5:AUG interaction to promote formation of the packaging-competent conformer (Figure 6 right). 
These data strongly suggest that the role of MNC is to restore a defective interaction between NC and 
gRNA. 
The function of MP2 is less clear. As it is located in SP1, which must be cleaved from CA for virion 
maturation to occur (Wiegers et al., 1998), the Gag processing properties of large SL1 mutants were 
examined. Intriguingly these mutants exhibited a delay in the proteolytic cleavage of SP1 from its 
precursor CA-SP1 (Liang et al., 1999a), resulting in the production of virions with an immature 
morphology. Both compensatory mutations were required to correct this defect (Shen et al., 2000) 
suggesting that delayed CA-SP1 processing contributes to the severe attenuation of these mutants.  
Like NC, SP1 is also involved in packaging (Kaye and Lever, 1998). The MP2 mutation has been shown 
to restore packaging specificity – the ability to discriminate between gRNA and spliced vRNA – to SL1 
(Russell et al., 2003) and NC (Roy et al., 2006) mutants, although unlike MNC it does not increase 
packaging efficiency. 
The location of MP2 in SP1 suggests that its purpose is to correct the CA-SP1 processing defect that 
results from SL1 mutation. 
 Possible mechanisms for the link between SL1 mutation and delayed CA-SP1 processing 
The finding that SL1 mutation delays CA-SP1 processing raises the possibility that efficient genome 
dimerisation is required for optimal processing of Gag and production of mature, infectious viral 
particles. One potential mechanism is that GagPol molecules utilise gRNA dimers as a scaffold upon 
which to dimerise, to allow the self-excision of PR from its precursor GagPol. A prediction arising from 
this hypothesis would be that all steps of Gag processing are delayed. Alternatively, the effects of SL1 
mutation on dimerisation and CA-SP1 processing may be unrelated. MP2 and MNC cannot correct 
defective gRNA dimerisation in the LD3 mutant (Shen et al., 2000) showing that efficient Gag 
processing is possible in the absence of efficient dimerisation. Another possibility is that the effect on 
processing is due to the loss of important Gag binding sites (Abd El-Wahab et al., 2014; Damgaard et 
al., 1998; Kenyon et al., 2015; Wilkinson et al., 2008) affecting a crucial interaction. 
In HIV-2, mutation of a GGAG motif critical for gRNA dimerisation, at the base of SL1, resulted in the 
formation of virions with abnormal morphology (L’Hernault et al., 2007) caused by delayed processing 
of MA-CA-p2 (L’Hernault et al., 2012). Like in HIV-1, a point mutation (MA 70TI) arose in long-term 
culture, however unlike in HIV-1 this mutation rescued gRNA dimerisation in addition to Gag 
processing (L’Hernault et al., 2012). 
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3.2. Experimental aims 
Studies on the effect of SL1 mutation on Gag processing have only been performed using mutants 
containing large deletions in SL1. The LD3, LD4 and LD5 mutants involve 16, 14 and 30 nucleotide 
deletions respectively (Liang et al., 1999a). Such large deletions are likely to have a significant impact 
on the structure and function of neighbouring RNA motifs (Figure 3) and may also affect the balance 
between the two conformers of the 5’UTR (Figure 6). This confounds interpretation of whether the 
dimerisation and processing defects are related or are independent consequences of widespread 
disruption of the 5’ UTR. 
Therefore, for this study, 3 smaller mutants were studied to limit disruption to SL1 and minimise the 
impact on neighbouring structures. The DIS mutant contains a single nucleotide substitution in the DIS 
palindrome, the Stem B mutant a 4-nucleotide deletion in the stem of SL1 and the Loop B mutant a 3-
nucleotide deletion in the internal loop (Figure 14).  
Figure 14 – Structure of SL1 and mutations introduced 
 
A) Secondary structure prediction of SL1, with stems and loops labelled. The nucleotides deleted or 
modified in the mutant proviruses are shaded with colours corresponding to the mutant provirus. B) 
Proviral DNA sequence of SL1, from HXB2 reference sequence, accession number K03455.1, and 
modifications made in the mutant viruses. Dashes represent nucleotides that are identical to the wild 
type, blanks represent nucleotides that have been deleted and letters represent nucleotides that have 
been substituted. The colour coding used corresponds with the shading in (A). 
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To establish if a correlation exists between gRNA dimerisation and Gag processing, these phenotypes 
were assessed in each mutant using Northern blotting, pulse-chase and Western blotting experiments. 
The relative infectivity of each mutant was also assessed, and compensatory mutations were 
introduced into the wild type and mutant proviruses to assess their effect on infectivity and Gag 
processing. 
3.3. Results 
 Analysis of Gag processing 
Preliminary analysis of the effect of SL1 mutations on Gag processing was performed using pulse-chase 
metabolic labelling, to observe Gag processing over time (see Appendix C for experimental setup and 
results). Due to high levels of background and low contrast of some bands the experiment provided 
qualitative to semi-quantitative results at best and can only be regarded as supporting evidence, 
however visual inspection of the blots seemed to indicate that only the loop B and LD4 mutants possess 
a CA-SP1 processing defect (for further discussion see Appendix C). 
To corroborate the results of the pulse-chase experiments, cells transfected with provirus constructs 
were harvested 48 hours post-transfection and lysates were analysed by Western blotting (Figure 15). 
Unlike the pulse-chase experiment which shows the kinetics of processing over time, Western blotting 
provides a snapshot of the state of Gag processing in the cell at a particular time point. The lack of 
background from cellular proteins on Western blots enabled quantitation of the efficiency of each of 
the Gag processing steps (Figure 12) – Full-length Gag  MA-CA-SP1 (first cleavage), MA-CA-SP1  
CA-SP1 (second cleavage) and CA-SP1  CA (third cleavage) – by comparing the ratios of processing 
products to their precursors.  
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Figure 15 – Gag processing intermediates in SL1 mutants observed by Western blotting 
 
A) Western blot of cell lysates following transfection with the indicated proviruses. Short and long 
exposures of the blot are shown to show each Gag cleavage product. The identities of each of the Gag 
processing intermediates is indicated on the right. B) The graph shows the mean efficiency of each 
processing step relative to wild type from at least 3 independent experiments. The efficiency of each 
step was determined by calculating the ratio of products to substrates (for example, for the first step 
the ratio of MA-CA-SP1 to full-length Gag was calculated). Error bars represent standard deviation. In 
this and all other figures (unless otherwise stated) a two-tailed Student’s t-test was performed (ns = 
‘not significant’, * = ‘p<0.05’, ** = ‘p<0.01’, *** = ‘p<0.001’). 
In agreement with the pulse-chase data, both the Loop B and LD4 mutants displayed an accumulation 
of CA-SP1 relative to the wild type, whilst the DIS and Stem B mutants exhibited wild type CA-SP1 
processing (Figure 15). There were no defects in the preceding steps of processing for any of the 
mutants. However, the use of a weak detergent to lyse cells in preparation for Western blotting 
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(1XCCLR was used, which contains 1% Triton X-100) may have resulted in incomplete breakdown of 
immature virus particles at the cell membrane. This may explain the weak full-length Gag band in 
Figure 15. Whilst this could affect quantitation of the absolute rate of the first step of processing, it is 
unlikely to affect the interpretation of the results presented here as the relative rates of processing 
between the mutants and wild type are of interest in this context.  
These results show that the Gag processing defect is only caused by particular SL1 mutations and is 
specific to the final stage of cleavage, a step critical for maturation (Figure 12). 
 Effect of SL1 mutations on gRNA dimerisation 
To determine whether the efficiency of CA-SP1 processing correlates with gRNA dimerisation, 
Northern blotting was performed on gRNA isolated from virions (Figure 16). gRNA bands from wild 
type and mutant virions were quantified by densitometry to enable measurement of dimerisation and 
packaging efficiencies. Packaging efficiency was calculated by dividing the intensity of the total gRNA 
bands by the concentration of input virus, determined by ELISA to give an approximate measure of the 
amount of gRNA packaged per unit of CA (Figure 17). 
Despite disrupting the palindrome at the tip of the DIS by changing its sequence from GCGCGC  
GGGCGC, gRNA from DIS mutant virions consistently ran with the same profile as the wild type (Figure 
17A lane 2), suggesting that a perfect palindrome is not required for efficient genome dimerisation. 
On the other hand, gRNA extracted from the Stem B and Loop B mutants (Figure 17A lanes 3 & 4) was 
much more monomeric, suggesting that there is reduced formation of dimers, or formation of dimers 
with reduced stability that dissociate under the conditions used in this experiment. The finding that 
only the Loop B mutant exhibits a CA-SP1 processing defect, despite the Stem B mutant also being 
deficient in dimerisation, suggests that dimerisation is not required for efficient CA-SP1 processing. 
The weakness of the intensity of the Stem B and Loop B bands is consistent with these mutants having 
more severe packaging defects (Figure 17D) as previously shown (Shen et al., 2001). There was a good 
correlation between the ability of gRNA to form dimers and the efficiency of packaging (Figure 17) 
which is consistent with the notion that genome dimerisation is required for efficient packaging to 
occur. The DIS mutant had wild type like dimerisation and packaging, whereas the Stem B and Loop B 
mutants were defective in both phenotypes. Packaging of DIS mutant RNA in the blot presented 
appears lower than wild type but this was not observed in the other blots performed. 
58 
Figure 16 – Northern blot experimental setup 
 
Supernatants from 293T cells transfected with proviral DNA were clarified and virions were purified, 
followed by digestion of the viral proteins and purification of RNA. Dimers and monomers were 
separated by agarose gel electrophoresis, and then transferred to a membrane for hybridisation with 
a DIG-labelled antisense probe specific to full length gRNA. All procedures were carried out at 4 ⁰C to 
minimise degradation of loose dimers. The presence of DIG in the probe enabled capture of an alkaline 
phosphatase-conjugated anti-DIG antibody, followed by addition of substrate and exposure of the 
membrane to film. 
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Figure 17 – Genome dimerisation and packaging in SL1 mutants 
 
A) Northern blot of purified viral RNA hybridised with a gRNA-specific probe. The positions of the dimer 
and monomer bands are indicated. Viral RNA isolated from the cytoplasm was run in a control lane to 
verify that the lower band represents the monomeric species. B) Quantitation of dimerisation efficiency 
relative to wild type, calculated as % dimer in the mutant divided by % dimer in the wild type. The graph 
shows the mean values from at least 6 independent experiments were performed. Error bars represent 
standard deviation. C) ELISAs were performed on supernatants to determine p24 concentration. At least 
4 independent experiments were performed. D) Quantitation of packaging efficiency relative to wild 
type. The amount of gRNA in each virion prep was quantified by performing densitometry on Northern 
blot bands, before dividing by the average concentration of virus in supernatants as determined by 
ELISA. The graph shows the mean values from 4 independent experiments. Error bars represent 
standard deviation.  
 Indiscriminate acceleration of CA-SP1 processing by compensatory mutations 
Given the finding that deletion of 3 nucleotides from the Loop B motif of SL1 replicates the CA-SP1 
processing defect observed in the LD4 mutant, it was of interest to see if the compensatory mutations 
could also restore processing in the Loop B mutant. 
The MP2 and MNC mutations were introduced into the wild type and mutant provirus constructs, 
before transfection into 293T cells and Western blotting to quantify processing efficiency (Figure 18). 
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Figure 18 – Effect of MP2/MNC compensatory mutations on the stages of Gag processing 
 
A) Western blot of cell lysates following transfection with the indicated proviruses. B) Quantitation of 
the fold-change in the efficiency of Gag processing (as calculated in Figure 15) upon introduction of 
compensatory mutations. A one-sample t test was performed to compare the fold-changes against the 
null hypothesis (fold-change of 1). The graph shows the mean values from at least 3 independent 
experiments. Error bars represent standard deviation. 
The compensatory mutations rescued defective CA-SP1 processing in the Loop B mutant in addition to 
the LD4 mutant. Interestingly, CA-SP1 processing was accelerated 2 to 3-fold in all viruses, including 
the wild type (Figure 18). There were two small but statistically significant changes in the first step of 
processing – a decrease in the wild type virus and an increase in the LD4 mutant. Lanes 3 and 4 of the 
gel shown suggest an acceleration of the first step of Gag processing in the DIS mutant, however this 
was not observed in any of the other repeats of this experiment. As noted in Section 3.3.1, the full-
length Gag bands are likely to be less intense than they could be because of the weak detergent used 
to lyse cells, but this should not affect comparison of the relative rates of processing between mutants. 
The introduction of compensatory mutations had no effect on the second step of processing, and 
minor effects on the first step, as discussed above, so they therefore appear to specifically accelerate 
the final step of processing. This occurs in an indiscriminate manner regardless of the SL1 mutation 
present, i.e. their effect is the same whether SL1 is fully intact or contains a small or large deletion. 
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 Infectivity of SL1 mutants and effect of compensatory mutations 
Virus infectivity is particularly sensitive to alterations in the timing of Gag processing, so the effect of 
SL1 mutations and compensatory mutations on virus infectivity was assessed. 
Infectivity was determined using TZM-bl cells, which express luciferase under the control of a tat-
inducible promoter. They were infected with VSV-G pseudotyped viruses, and luciferase expression 
was measured. To account for variations in virus input, the luciferase reading was divided by the p24 
concentration, as determined by ELISA, to give a measurement of per-virion infectivity. The results 
are shown in Figure 19.  
Figure 19 – Effects of SL1 mutations and compensatory mutations on virus infectivity 
 
The graph shows the mean values for SL1 mutant infectivity, without and with compensatory mutations 
relative to wild type, from 4 independent experiments. Error bars represent standard deviation. Inter-
mutant (i.e. between SL1 mutant and wild type) statistical significance is indicated on top of bars, whilst 
intra-mutant (i.e. between mutant with and without compensatory mutations) is indicated on top of 
lines between bars. 
There were large differences in the infectivity of SL1 mutants (Figure 19). The DIS mutation caused a 
less than 2-fold reduction in infectivity, whereas the Stem B mutation produced a virus which 
consistently gave luciferase readings identical to negative controls, indicating a completely non-
infectious virus. The Loop B and LD4 mutants had an intermediate phenotype, as some infectivity was 
observed albeit with an efficiency of 5 to 10-fold less than wild type. 
The magnitude of the reduction in infectivity of the Stem B and Loop B mutants is greater than the 
magnitude of their respective packaging and dimerisation defects, indicating that other steps are 
affected. Likewise, the reduction in infectivity of the DIS mutant cannot be explained in terms of 
dimerisation and packaging as these were not affected by the mutation (Figure 17). 
In agreement with a previous report (Liang et al., 1998), the compensatory mutations resulted in a 
statistically significant increase of LD4 mutant infectivity to near wild type levels. The mean infectivity 
62 
of the Loop B mutant was also increased to similar levels, although greater variability meant that the 
difference was not statistically significant. The ability of the compensatory mutations to largely restore 
Loop B and LD4 mutant infectivity suggests that delayed CA-SP1 processing is the major factor 
responsible for attenuation of those mutants.  
There was also a small but statistically significant increase in Stem B mutant infectivity, turning a non-
infectious virus into one capable of replication, albeit with a 10-fold reduction in infectiousness relative 
to wild type. 
Surprisingly, despite accelerating CA-SP1 processing above its natural rate, the infectivity of the wild 
type virus was not affected, nor was the infectivity of the DIS mutant.  
3.4. Discussion 
To gain insight into the elements of SL1 required for efficient Gag processing, three SL1 mutants (DIS, 
Stem B and Loop B) that had not previously been assessed for their Gag processing capability were 
studied alongside the LD4 mutant, which served as a positive control. Gag processing efficiency, 
genome dimerisation, packaging, infectivity, and the effect of compensatory mutations was assessed. 
 Lack of correlation between gRNA dimerisation and Gag processing 
The results from the pulse-chase and Western blotting analysis show that the Gag processing defect 
caused by the 14 nucleotide LD4 deletion was recapitulated only in the Loop B mutant (Figure 15). 
Notably, CA-SP1 processing was unaffected in the Stem B dimerisation mutant (Figure 17), 
demonstrating that dimerisation is not required for efficient Gag processing (summarised in Figure 20). 
This supports the finding by Shen et al that compensatory mutations could restore Gag processing to 
the LD3 mutant without rescuing genome dimerisation (Shen et al., 2000). 
Figure 20 – Comparison of SL1 mutant phenotypes relative to wild type 
 
Values shown are mean values compiled from previous figures in this chapter for comparison purposes. 
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The effect on Gag processing was specific to the final step, CA-SP1 cleavage (Figure 15), which is 
inconsistent with the hypothesis that genome dimerisation facilitates Gag processing by providing a 
scaffold for GagPol molecules to dimerise on. If this were the case, all steps of Gag processing would 
be expected to be delayed by mutations which disrupt dimerisation.  
 Possible mechanisms for Loop B involvement in Gag processing 
In addition to its effect on Gag processing, mutation of Loop B is as detrimental to virus infectivity as 
the LD4 mutations (Figure 19). It consists of four residues – a single unpaired G on the 5’ side and an 
unpaired AGG triplet on the 3’ side – which disrupt the otherwise perfect base pairing in the main 
stem of SL1 (Figure 21 left panel).  
The loop is thermally and conformationally unstable – a single structure could not be resolved on NMR 
– and its complete conservation suggests that this flexibility is important for its function (Greatorex et 
al., 2002). The presence of an internal hinge may serve to facilitate unwinding of SL1 to enable 
maturation of the kissing loop dimer to an extended dimer (Figure 7). This hypothesis is supported by 
in vitro data; NMR analysis of a 39mer RNA corresponding to SL1 showed that Loop B had a loosening 
effect on neighbouring base pairs in the stem (Takahashi et al., 2000b). Maturation of the 39mer into 
a tight dimer in the presence of NC or following incubation at 55 ⁰C was blocked when Loop B was 
deleted (Takahashi et al., 2000a).  
RNA secondary structure calculation software predicts that the Loop B mutation (deletion of the AGG 
triplet) would result in merging of Stem B and Loop B to produce a much more thermally stable 11-
base pair stem containing a single unpaired base in place of Loop B (Figure 21). 
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Figure 21 – Predicted secondary structures of Stem B and Loop B mutants 
 
Predicted structures and free energy changes of wild type and mutant SL1 sequences, obtained using 
mfold, with no constraints on base pairing. The predicted wild type structure differs slightly from the 
structure determined by structural probing techniques, so the predictions for the mutants serve as a 
best estimate. 
The Stem B mutation on the other hand is predicted to create a larger internal loop (Figure 21). This 
would have the opposite effect to Loop B mutation on the thermal stability of SL1. The DIS mutation 
involves substitution of an unpaired residue so is unlikely to affect stability.  
One possibility therefore is that CA-SP1 processing is linked to maturation of the dimer, with Loop B 
playing a critical role by weakening the stem to allow unwinding of the kissing-loop dimer. It has been 
speculated that the large structural rearrangement of the RNA which takes place during dimer 
maturation may help to coordinate virion maturation (Takahashi et al., 2000b). The changing footprint 
of Gag/NC on the RNA during dimer maturation may trigger a structural change in the CA-SP1 cleavage 
junction, facilitating processing. 
A second related possibility is that Loop B mutation disrupts Gag binding to gRNA. RNA footprinting 
(Damgaard et al., 1998), SHAPE (Wilkinson et al., 2008) and crosslinking-SHAPE (XL-SHAPE) (Kenyon et 
al., 2015) all highlight Loop B and surrounding residues as a Gag binding site. More recently, Abd El-
Wahab et al argued that Loop B is the key motif responsible for specific packaging of gRNA into virions. 
Deletion of Loop B significantly reduced binding of full-length recombinant Gag to an in vitro 
synthesised RNA corresponding to the first 600 nucleotides of the HIV-1 genome (Abd El-Wahab et al., 
2014).  
The two features which set the Loop B mutation apart from the Stem B and DIS mutants are that it 
appears to over-stabilise SL1 and removes a potential Gag binding site. At this stage it is not possible 
65 
to conclude if either or both of these functions is important for regulating Gag processing, but as both 
processes involve binding of Gag it seems plausible that binding could trigger the structural change in 
the CA-SP1 junction to enable cleavage by PR. 
 Correlations between dimerisation, packaging and infectivity 
There was a clear correlation between dimerisation and packaging (Figure 17) consistent with the 
model of preferential packaging of dimers in virions (Russell et al., 2004).  
These phenotypes correlated with virus infectivity (summarised in Figure 20), although the reductions 
in packaging alone (3-fold for Stem B and 2-fold for Loop B) were not as severe as the reductions in 
infectivity (50-fold for Stem B and 6-fold for Loop B), further highlighting that steps other than 
packaging and dimerisation may be affected by mutation of SL1. The complete loss of infectivity from 
the Stem B mutant may be explained by the apparent 15-fold reduction in reverse transcription 
efficiency (Shen et al., 2000) together with the 3-fold reduction in packaging observed in this study.  
The above arguments assume that packaging, dimerisation and reverse transcription have additive 
effects on infectivity, but this may not be the case. Disruption to multiple stages of virus replication 
may result in synergism. In addition, the immediate effect on infectivity observed in this single-cycle 
replication assay may be different to the cumulative effect that would be observed in a multi-round 
assay, or in an infected individual.  
Despite these uncertainties, the CA-SP1 processing defect in the Loop B mutant is likely to be a key 
additional contributor to reduced infectivity, because delayed processing of CA-SP1 hinders the 
formation of mature infectious virions (Wiegers et al., 1998). 
Despite the preference for packaging gRNA dimers, monomeric gRNA bands did appear on Northern 
blots, especially in the Stem B and Loop B mutants, suggesting that monomeric RNA can be packaged. 
However, these may be the result of dimers dissociating. Despite the ambiguity associated with using 
Northern blotting to study dimerisation, the technique is still widely used and the results interpreted 
as a proxy for the efficiency of dimerisation in virions - all the dimerisation efficiency values in Table 8 
and Table 11 are derived from quantitation of Northern blots. One way to exclude the presence of 
tight dimers is to introduce an inactivating mutation in PR to prevent dimer maturation (Rong et al., 
2003) but this still does not distinguish between packaged monomers and monomers arising from 
loose dimers dissociating. Techniques to dual label gRNA and visualise individual molecules in cells 
(Chen et al., 2009; Ferrer et al., 2016) may help to answer questions about the effect of mutations on 
dimerisation without the caveats associated with Northern blotting. 
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 The effect of the DIS mutation on dimerisation and packaging – cell type dependence? 
Surprisingly, mutation of the DIS palindrome at the tip of SL1 had no effect on gRNA dimerisation or 
packaging (Figure 17) despite a 2-fold reduction in infectivity (Figure 19). This may be due to the 
palindrome playing an unappreciated role in the early stages of virus replication, which would be 
consistent with the observation that some artificial palindrome sequences are highly detrimental to 
infectivity and are never observed in nature (Laughrea et al., 1999). 
There is disagreement in the literature on the phenotypic effects of DIS palindrome mutations (Table 
9). Mutation resulted in reduced dimerisation (Shen et al., 2000) and packaging (Laughrea et al., 1999; 
Shen et al., 2000) in COS7 cells, and deletion almost completely abolished infectivity in MT-4 cells 
(Laughrea et al., 1999), however, as shown here, in 293T cells dimerisation was indistinguishable from 
wild type (Figure 17) (Hill et al., 2003; Song et al., 2007).  
Phenotypic discrepancies between cell types are also observed following more extensive SL1 mutation. 
Despite causing severe replication defects in SupT1 cells, almost-complete deletion of SL1 had no effect 
on replication in peripheral blood mononuclear cells (PBMCs) (Hill et al., 2003). The researchers 
created two SL1 mutants, by replacing the 39-nucleotide SL1 with its natural GCGCGC palindrome, or 
with an artificial ACGCGT palindrome. In SupT1 cells replication was negligible (1,000 to 10,000 times 
less infectious than WT), however in PBMCs similar replication kinetics were observed to WT, albeit 
with a slight delay. This was not due to the emergence of compensatory mutations, as sequencing 
confirmed the original deletion remained and no compensatory mutations arose in Gag. Expectedly, 
the mutants showed around a 50% reduction in packaging and a reduction in the ability to form 
discrete dimers on Northern blots, which the authors hypothesised to be due to packaging of spliced 
RNA within the virion.  
The authors suggest that a cellular factor may bind to SL1 to enhance HIV-1 replication, although 
further exploration of this is complicated by the fact that SL1 sits at the heart of a complex RNA 
structure regulating multiple aspects of the virus’s lifecycle.  
In addition, DIS mutation may disrupt the balance between the two structural conformations of the 
5’UTR (Figure 6). This may weaken the interaction between the DIS and the U5 helix, (Kenyon et al., 
2013; Lu et al., 2011), thus promoting dimerisation by allowing SL1 to be exposed for inter-strand base 
pairing. 
The effect of Stem B and Loop B mutations on dimerisation has not been assessed in 293T cells before, 
and the results (Figure 17) show that they exhibited dimerisation defects as severe as those previously 
observed in COS7 cells (Table 9) (Shen et al., 2001). As in Hill et al (Hill et al., 2003), these experiments 
suggest that the effect of particular SL1 mutations (in this instance the DIS mutation) can be cell-type 
dependent. However, the Stem B and Loop B mutants exhibited similar phenotypes to those observed 
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in COS7 cells, suggesting that these mutations play a more fundamental role in dimerisation that is not 
cell type-dependent. 
Table 9 – comparison of dimerisation and packaging data from 293T and COS7 cells 
Mutant Cell type Dimerisation 
(% wild type) 
Packaging  
(% wild type) 
Reference 




(Song et al., 2007) 
This study 




(Shen et al., 2000) 
(Laughrea et al., 1999) 
Stem B 293T 48%  34% This study 
COS7 59%  25%  (Shen et al., 2001) 
Loop B 293T 77% 52% This study 
COS7 59%  44%  (Shen et al., 2001) 
Dimerisation and packaging efficiencies from this study and others are expressed relative to wild type. 
 Effect of compensatory mutations 
Two compensatory mutations that arose during long term culture of SL1 mutants and restored 
infectivity (Liang et al., 1998) but not dimerisation (Shen et al., 2000) were introduced into each of the 
SL1 mutants and the wild type virus. CA-SP1 processing defects in the Loop B and LD4 mutants were 
corrected (Figure 18) but processing was also accelerated in the other mutants and the wild type, 
showing that they act whether SL1 is completely intact, subtly or grossly mutated. 
Correction of defective processing was associated with restoration of infectivity (Figure 19) suggesting 
that delayed processing is a major contributor to the attenuation of these mutants. No change was 
observed in the infectivity of the DIS mutant and only a small increase in the Stem B mutant, possibly 
related to the ability of the mutations to increase packaging efficiency (Liang et al., 2000, 1998; Shen 
et al., 2000).  
It is intriguing that the introduction of mutations which accelerate CA-SP1 cleavage had no effect on 
wild type virus infectivity (Figure 19) since infectivity is tightly linked to optimal Gag processing (Li et 
al., 2003; Nowicka-Sans et al., 2016; Wiegers et al., 1998). This is investigated further in the next 
chapter. 
 Parallels between SL1 compensatory mutations and maturation inhibitor resistance 
mutations 
The effect of the Loop B and LD4 mutations on CA-SP1 processing raises striking parallels with the 
effects of MIs, which attenuate virus infectivity by specifically blocking this cleavage step. Furthermore, 
the MP2 compensatory mutation that is involved in correcting defective processing maps to the same 
region of Gag as resistance mutations to the prototype MI bevirimat (Figure 22) (Adamson et al., 2006; 
Li et al., 2003; McCallister et al., 2008) and, like MP2, some of these result in specific acceleration of 
CA-SP1 processing (Adamson et al., 2006; Li et al., 2003). Resistance mutations also emerged following 
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long-term culture of infected cells with another MI, PF-46396, including one in CACTD and one in SP1 
(Waki et al., 2012). 
Figure 22 – Location of bevirimat resistance mutations and SL1 compensatory mutation MP2 
 
Sequence of CACTD and SP1, highlighting resistance mutations which emerged following in vitro culture 
(Adamson et al., 2006) and in vivo treatment (McCallister et al., 2008) with bevirimat (BVM). For 
comparison the position of the MP2 mutation (Liang et al., 1998) is indicated. 
The precise mechanism of action of bevirimat is unknown, but analysis of binding sites suggests that it 
blocks CA-SP1 processing by stabilising the CA-SP1 junction α-helix preventing exposure of the 
cleavage site (Schur et al., 2016; Wagner et al., 2016). Resistance mutations map to CA-SP1 protein 
interfaces rather than drug binding sites, and are hypothesised to act by destabilising the helix at the 
CA-SP1 junction, to cancel out the helix-stabilising effects of the drug (Schur et al., 2016). 
Given the phenotypic effects of SL1 mutation and the location of compensatory mutations, one 
attractive possibility is that the Loop B and LD4 mutations result in over-stabilisation of the CA-SP1 
helix, and that the MP2 mutation promotes destabilisation. 
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4. Effect of SL1 mutation on ESCRT function 
4.1. Introduction 
 Parallels between mutation of SL1 and late domain motifs 
CA-SP1 processing defects are regarded as hallmarks of late domain mutants, as they accompany the 
defect in particle release caused by p6 mutation (Fisher et al., 2007; Göttlinger et al., 1991; Huang et 
al., 1995). It is striking that the Loop B and LD4 mutants also exhibit this phenotype (Figure 15), which 
raises an interesting possibility that SL1 may interact with the ESCRT pathway directly or indirectly and 
be implicated in virus budding. 
 Late domain mutant-like phenotype of NC mutants 
NC mutations also give rise to a late domain mutant-like phenotype (Dussupt et al., 2011). When 
viewed under the electron microscope virus particles have an immature morphology and are observed 
tethered to the membrane indicating a failure to sever budding necks.  
There is a positive correlation between the number of basic NC residues mutated, the packaging of 
gRNA and the severity of Gag processing defects (Cimarelli et al., 2000). Replacement of single residues 
in NC with alanine causes delayed processing of MA-CA-SP1 and CA-SP1, as well as a modest two-fold 
reduction in virus release (Dorfman et al., 1993). Replacing the distal cysteine residues of both zinc 
fingers results in a 10-fold reduction in release from HeLa cells (Dorfman et al., 1993) although the 
effect is more modest in 293T cells (Popov et al., 2008). Replacement of all basic residues with alanine 
in the zinc fingers of NC results in a 13-fold reduction in virus release from 293T and HeLa cells. In 
Jurkat and CEM T cells NC mutant virus release was completely blocked (Dussupt et al., 2011). Given 
that NC’s main role is in RNA binding it is tempting to speculate that this function is important for 
ESCRT recruitment. 
These observations are interesting in the context of this study as SL1 is an integral part of the structure 
recognised by NC for packaging (Section 1.12) (Kim et al., 1994; Sakaguchi et al., 1993). Thus, it appears 
that mutation of cis- or trans- acting packaging signals can disturb Gag processing. 
 NC interacts with ALIX and TSG101 
NC appears to be involved in recruitment of ALIX and TSG101 by Gag, as both ALIX (Popov et al., 2008) 
and TSG101 (Chamontin et al., 2015) physically interact with NC in in vitro pulldown assays. Little is 
known about the latter interaction, but the ALIX-NC interaction is becoming increasingly well 
understood. 
ALIX is incorporated into YPXnL- mutant virions, providing the zinc finger motifs are intact, 
demonstrating that ALIX interacts with Gag through the NC domain in addition to the YPXnL motif  
(Dussupt et al., 2009). When both the PTAP and YPXnL motifs are mutated, budding can be restored by 
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expressing the Bro1 domain of ALIX alone, providing NC is intact, as Bro1 contains a binding site for 
the ESCRT-III protein CHMP4 (Dussupt et al., 2009). 
Although both TSG101 and ALIX may interact with NC, the NC-ALIX interaction appears to be stronger 
than that of NC-TSG101. This is because mutation of the YPXnL motif while maintaining NC only 
moderately reduces the amount of ALIX incorporated into virions, whereas mutation of the PTAP motif 
almost completely abolishes TSG101 incorporation (Bendjennat and Saffarian, 2016). However 
deletion of the second zinc finger of NC severely reduced colocalization of Gag and TSG101 at the 
plasma membrane (Chamontin et al., 2015). 
 Possible role of RNA in ALIX/TSG101-Gag interaction 
The interaction between ALIX and NC was initially thought to be direct because it was not abolished 
by nuclease treatment (Popov et al., 2008). However, solvent accessible surface analysis combined 
with mutagenesis revealed 5 residues important for NC binding forming a positively charged patch in 
the N-terminal domain of Bro1. As the NC residues responsible for the interaction are also positively 
charged, it seemed plausible that a negatively charged intermediate such as nucleic acid could bridge 
these two proteins. Indeed, in contrast with the previous study RNase treatment was found to disrupt 
the interaction (Sette et al., 2012).  
This discrepancy was clarified later when it was found that the NC-Bro1 interaction can be mediated 
by RNA or lipids (Sette et al., 2016). In the first study (Popov et al., 2008) lipids were present in the 
sample preparation rendering the interaction insensitive to RNase treatment, whereas in the second 
study (Sette et al., 2012) lipids were excluded by detergent treatment. Nuclease treatment enhanced 
binding of NC to membrane lipids (Sette et al., 2016), in a manner analogous to the negative regulation 
of MA binding to internal membranes by tRNA binding (Chukkapalli et al., 2010; Kutluay et al., 2014). 
Using a yeast two-hybrid screen Sette et al found that ALIX’s natural binding partner is Syntenin, which 
NC appears to mimic (Sette et al., 2016). Syntenin is involved in cell extension, interacting through its 
tandem PDZ motifs, analogous to the zinc fingers of NC (Figure 23), with the Bro1 domain of ALIX in 
the plasma membrane.  
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Figure 23 – Comparison of nucleocapsid and Syntenin 
 
Cartoon representation of nucleocapsid and Syntenin with domains involved in the Bro1 interaction 
coloured. Nucleocapsid and Syntenin both contain tandem interaction domains. Nucleocapsid interacts 
with Bro1 through its zinc finger motifs, while Syntenin uses PDZ domains. 
The authors proposed a model whereby a subset of Gag molecules in the assembled immature virion 
switch binding preference from RNA to plasma membrane lipids at the budding neck, enabling 
recruitment of ALIX and subsequent binding of ESCRT-III proteins to facilitate scission (Figure 24). 
However, this model does not account for the finding that RNA has been shown to act as a bridge 
between ALIX and NC in vitro. We propose that RNA binding may maintain NC in a conformation which 
is suitable for Bro1 binding, before exchange of an RNA bridge for a lipid one in the budding neck.  
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Figure 24 – Model of ALIX function in HIV-1 budding proposed by the Bouamr lab 
 
1) In the cytoplasm, Gag assembly complexes associate with RNA, stimulating Gag nucleation and 
preventing premature association with internal membranes. 2) When Gag reaches the plasma 
membrane, it becomes enriched in PI(4,5)P2 domains. 3) Once sufficient Gag has accumulated to form 
a spherical particle, a subset of NC domains find themselves in close proximity to the budding neck, 
where they dynamically trade RNA for lipids at the plasma membrane. NC and the Bro1 domain of ALIX 
co-insert in these cholesterol rich domains, stimulating ESCRT-III recruitment and membrane scission. 
Image modified from (Sette et al., 2016). 
4.2. Experimental aims 
Taken together, the studies discussed above show that RNA can bridge the ALIX-NC interaction in vitro, 
and raise the possibility that RNA is involved in enabling Gag to recruit ALIX in vivo. The CA-SP1 
processing defect observed in the Loop B and LD4 mutants (Figure 15) is reminiscent of that observed 
in late domain and NC mutants, so it was of interest to investigate specifically if SL1 mutation affects 
virus release and the function of ALIX. To assess the effect of SL1 mutation on virus release, Western 
blotting was performed. The Gag processing phenotypes of SL1, NC and late domain mutants were 
compared, and the effect of combining the LD4 mutation with a PTAP late domain mutation on Gag 
processing was also studied to determine if SL1 and late domain mutations disrupt the same pathway. 
An ALIX overexpression assay was used to determine the importance of SL1 in ALIX-mediated virus 
release and enhancement of CA-SP1 processing. Finally, the compensatory mutations were introduced 
in the context of mutated late domains and knocked-down ESCRT proteins to assess the requirement 
of ESCRT for their ability to rescue SL1 mutant phenotypes. 
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4.3. Results 
 The LD4 mutation reduces virus release 
For these experiments the LD4 mutant was used as it exhibited the greatest defect in CA-SP1 
processing (Figure 15). Densitometry was performed to quantify the release ratio – the amount of 
extracellular Gag relative to intracellular Gag – from Western blots of cell and virion-associated Gag 
(Figure 25). 
The release ratio of the LD4 mutant was found to be about 4-fold lower than wild type (Figure 25). 
However, the reduction in extracellular pelletable CA may be due to reduced virion stability, as 
observed for some NC mutants (Wang and Aldovini, 2002). To exclude this possibility an assay based 
on a previously published protocol was used (Ohagen and Gabuzda, 2000). Briefly, purified virions were 
treated with detergent to break down membranes, followed by centrifugation to pellet intact cores, 
leaving CA from degraded virions in the supernatant. Virion stability was assessed by calculating the 
proportion of total pelleted CA (Figure 26). 
Figure 25 – The LD4 mutation in SL1 reduces virus release from 293T cells 
 
A) Western blot of cell lysates and purified virions following transfection with the indicated proviruses. 
B) Quantitation of release ratios. Densitometry was performed on all Gag associated bands and release 
ratios were normalised to wild type. The graph shows the mean values from 5 independent 
experiments. Error bars represent standard deviation.  
Virions were not degraded in the absence of detergent treatment, in agreement with previous studies 
(Ohagen and Gabuzda, 2000; Willey et al., 1994). Detergent treatment caused appearance of CA in the 
supernatants, indicating dissociation of viral cores following membrane disruption. On average wild 
type virus preparations pelleted two-fold more CA than the LD4 mutant. This difference was not 
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statistically significant, however with further repeats of the experiment this may not be the case. Taken 
together, results from Figure 25 and Figure 26 suggest that the reduction in CA pelleted by the LD4 
mutant is likely to be due to a genuine reduction in virus release rather than reduced virion stability, 
although a small effect on capsid stability cannot be excluded given the trends observed in the data.  
SL1 mutation therefore gives rise to defects in Gag processing and a reduction in virus release that are 
both typically associated with late domain mutations. 
Figure 26 – Stability of wild type and LD4 capsids and release into supernatants 
 
A) Western blot showing pellet and supernatant-associated CA bands for each mutant following 
treatment with the indicated concentrations of detergent. B) Quantitation of the proportion of CA 
pelleted for each mutant under each condition. The graph shows the mean values from 3 independent 
experiments. Error bars represent standard deviation. 
 SL1 and late domain mutation effects are non-additive 
It was noted previously that combining NC and PTAP mutations did not have an additive effect on the 
defect in processing, indicating that NC and p6 domain mutations disrupt the same pathway (Popov et 
al., 2008). To investigate if the same is true for SL1 and NC mutations, CA-SP1 processing efficiency was 
calculated for an LD4/PTAP- double mutant (Figure 27). 
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Figure 27 – Non-additive effect of LD4 and PTAP- mutations on CA-SP1 processing 
 
A) Western blot of cell lysates following transfection with the indicated proviruses. B) Quantitation of 
CA-SP1 processing efficiency normalised to wild type. The graph shows the mean values from 9 
independent experiments. Error bars represent standard deviations.  
When combined, the processing defect of the double mutant was almost identical to the one observed 
for the PTAP- mutation alone (Figure 27). 
 Mutation of SL1 reduces ALIX-dependent virus release 
As ALIX has been shown to bind to NC in an RNA-dependent manner (Sette et al., 2012), it was 
hypothesised that an intact SL1 is required for efficient ALIX binding to NC.  
To test this hypothesis, an ALIX overexpression assay was used. Mutation of the PTAP motif blocks the 
TSG101 pathway making the virus dependent on overexpression of ALIX for otherwise inefficient virus 
release. By combining a PTAP- mutation with other mutations it is possible to identify sequences 
required for efficient ALIX function. This approach was previously used to discover that NC contains an 
ALIX binding site (Popov et al., 2008). 
First, the assay was optimised by transfecting increasing amounts of HA-tagged ALIX-expressing 
plasmid alongside wild type and PTAP- provirus plasmids (Figure 28).  
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Figure 28 – Optimising rescue of release by ALIX overexpression 
 
Western blot of cell lysates and purified supernatants, following transfection with the indicated 
proviruses and increasing amounts of ALIX-HA plasmid. 
ALIX overexpression had no effect on wild type virus release, however at transfection amounts greater 
than 60 ng there was an inhibitory effect as previously reported (Dussupt et al., 2009). PTAP- mutant 
release was most efficient when 40-60 ng of ALIX-HA was transfected, so for the overexpression assay 
40 ng of ALIX-HA plasmid was used. 
Despite rescuing virus release (Figure 28), overexpression of ALIX appeared to have no effect on virus 
infectivity (Figure 29), however there was a great deal of variation particularly for the WT virus without 
ALIX overexpression (bar 1 in Figure 29). 
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Figure 29 – Effect of ALIX overexpression on virus infectivity 
 
Infectivity of the wild type virus and PTAP- mutant produced by transfection of 293Ts with provirus 
alone (bars 1 and 3) or cotransfected with 40 ng ALIX plasmid (bars 2 and 4). The graph shows the mean 
values from 3 independent experiment (2 experiments for bar 4). Error bars represent standard 
deviation.  
The ability of overexpressed ALIX to rescue release of PTAP- and LD4/PTAP- mutants was then assessed. 
The fold change in release ratio upon ALIX overexpression was calculated and normalised to the PTAP- 
control (Figure 30).  
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Figure 30 – Mutation of SL1 reduces the ability of ALIX to rescue release of the PTAP- mutant 
 
A) Western blot of cell lysates and purified supernatants following transfection with the indicated 
proviruses, with or without ALIX overexpression. B) Quantitation of the efficiency of rescue by ALIX. 
Densitometry was performed on all p24-associated bands from lysates and virions. The graph shows 
the mean values from 9 independent experiments. Error bars represent standard deviation.  
Introduction of the LD4 mutation did not block ALIX’s ability to rescue release, however, there was a 
modest but significant reduction in the efficiency of rescue (Figure 30). The band with a molecular 
weight equivalent to that of MA-CA-SP1 on the lower virion blot is unusual, as virion preparations 
normally only contain fully processed Gag in the form of CA. It is possible that it is a cellular artefact 
but given its similarity in size to MA-CA-SP1 it has been retained in the figure. Nevertheless, this band 
does not affect the interpretation that the ability of ALIX to rescue virus release is weaker in the 
presence of the LD4 mutation. 
In agreement with Figure 27, combining the PTAP- mutation with the LD4 mutation (lane 3 of Figure 
30) did not worsen the CA-SP1 processing defect of the PTAP- mutant. The lower panel of the blot in 
Figure 30 shows that the effect of combining the mutation on virus release is also not additive, as 
similar amounts of Gag are present in the supernatant of the PTAP- and LD4/PTAP- mutants. 
 The LD4 processing defect is comparable to that of NC mutation and neither can be 
rescued by ALIX overexpression 
In performing ALIX overexpression experiments (Figure 28 and Figure 30) it was found that 
overexpression of ALIX accelerated CA-SP1 processing. Measuring the ability of ALIX to accelerate 
processing may be another way to determine which sequences in the viral genome are required for its 
function. Accordingly, cells were transfected with proviruses containing mutations in ALIX binding sites 
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(YPXnL- in p6 and the first zinc finger of NC (F16A)), the PTAP motif (serving as a negative control), and 
the LD4 mutant (Figure 31). 
Figure 31 – Requirements for acceleration of CA-SP1 processing by ALIX 
 
A) Western blot of cell lysates following transfection with the indicated proviruses, with or without 
ALIX-HA. B) Quantitation of the fold-change in CA-SP1 processing upon overexpression of ALIX. The 
graph shows the mean values from 3 independent experiments. Error bars represent standard 
deviation. C) Quantitation of the efficiency of CA-SP1 processing relative to WT. The graph shows the 
mean values from 3 independent experiments. Error bars represent standard deviation. 
ALIX overexpression increased the efficiency of CA-SP1 processing by two-fold in the wild type virus 
and the PTAP- mutant (Figure 31B). However, mutation of either NC or the YPXnL motif prevented ALIX 
from accelerating processing, as did mutation of SL1. 
In the absence of ALIX overexpression, the PTAP- and YPXnL- mutations resulted in the most severe CA-
SP1 processing defects, whereas the LD4 mutant possessed a much milder CA-SP1 processing defect 
of comparable intensity to the F16A NC mutant (Figure 31C). 
 Compensatory mutations require intact late domains and TSG101 and ALIX to restore 
CA-SP1 processing 
Compensatory mutations emerging from SL1 mutant cultures (Liang et al., 2000, 1998) rescue 
defective virus replication (Figure 19) and restore CA-SP1 processing (Figure 18). The data shown above 
suggest that SL1 may interact with the ESCRT pathway. It was of interest therefore to investigate if the 
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compensatory mutations cooperate with the ESCRT pathway by evaluating their ability to accelerate 
processing in the presence of mutated late domain motifs (Figure 32). 
Figure 32 – Late domain-dependence of compensatory mutations 
 
A)  Western blot of cell lysates following transfection with the indicated proviruses. B) Quantitation of 
the fold-change in CA-SP1 processing upon introduction of compensatory mutations. The graph shows 
the mean values from 3 independent experiments. Error bars represent standard deviation.  
Unlike in the wild type virus where acceleration of CA-SP1 processing was observed, the compensatory 
mutations were unable to correct the processing defects observed in the single or double late domain 
mutants (Figure 32). 
As the PTAP and YPXnL motifs interact with TSG101 and ALIX respectively, siRNA transfections were 
performed to knock down these proteins in the presence or absence of compensatory mutations 
(Figure 33B & C). To test knockdown efficiency cells were transfected with the various siRNAs and 
Western blotting was performed with anti-ALIX and anti-TSG101 antibodies (Figure 33A). 
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Figure 33 – ESCRT-dependence of compensatory mutations 
 
A) Western blot of cell lysates following transfection with the indicated proviruses and siRNAs. B) 
Quantitation was performed as in Figure 32. The graph shows the mean values from 3 independent 
experiments. Error bars represent standard deviation. 
Consistent with the results in Figure 32, knockdown of TSG101 and/or ALIX resulted in a failure to 
accelerate processing. Differences were observed in the intensity of Gag bands following different 
siRNA treatments. Knockdown of TSG101 potently inhibits virus release resulting in intracellular 
accumulation of Gag (Garrus et al., 2001), whilst knockdown of ALIX has been previously observed to 
result in lower levels of intracellular Gag likely due to reduced cell viability (Martin-Serrano et al., 
2003).  
The compensatory mutations were also tested for their ability to rescue the release of the late domain 
mutants, in addition to the wild type and LD4 mutant (Figure 34). 
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Figure 34 – Effect of compensatory mutations on virus release 
 
A) Western blot of cell lysates and purified virions following transfection with the indicated proviruses. 
B) Quantitation of the release of wild type and LD4 mutant virion, with and without compensatory 
mutations. Densitometry was performed on all Gag bands from virion and lysate Westerns. The graph 
shows the mean values from 6 independent experiments. Error bars represent standard deviation. 
Consistent with failure to accelerate processing, the compensatory mutations did not rescue release 
of late domain mutant viruses. They did however partially rescue the release of the LD4 mutant (Figure 
34), and surprisingly they also increased release of wild type virus. 
4.4. Discussion  
 SL1 mutants have a late domain mutant-like phenotype 
As CA-SP1 processing defects were observed in SL1 mutants (Figure 15), the effect of SL1 mutation on 
virus release was investigated. There was approximately a 4-fold reduction in the release ratio of the 
LD4 mutant compared to wild type (Figure 25). This effect was not due to particle instability (Figure 
26). It was hypothesised that the late domain mutant-like phenotype caused by SL1 mutation may be 
due to the disruption of the ESCRT pathway. 
To investigate this, a mutant provirus containing both the LD4 mutation and the PTAP- mutation was 
created. Combining the mutations did not produce an additive effect on CA-SP1 processing (Figure 27), 
suggesting that they do indeed act through a shared mechanism to delay processing.  
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 SL1 is involved in efficient ALIX function 
One plausible mechanism by which SL1 might be involved in the ESCRT pathway is through interactions 
with the positively charged interfaces in NC and the Bro1 domain of ALIX. RNA has been shown to be 
capable of mediating the ALIX-NC interaction in vitro (Sette et al., 2012) although the relevance of an 
RNA-mediated interaction in vivo is not known. 
To explore this an ALIX rescue assay was performed. The rationale behind this experiment was that if 
SL1 is required for ALIX to function, ALIX would be less able to rescue release of a mutant containing 
an SL1 mutation. 
The data show that release of both mutants could be increased upon expression of ALIX-HA, but the 
LD4/PTAP- mutant was rescued with an average efficiency of 60% relative to the PTAP- mutant (Figure 
30). However, this rescue was not completely blocked suggesting that an intact SL1 is not essential for 
ALIX function, but that it is required for efficient function. 
This contrasts with data showing that mutation of the NC zinc fingers severely reduces the ability of 
ALIX to rescue release (Popov et al., 2008) most likely by blocking the lipid-mediated interaction 
hypothesised to occur between NC and ALIX for recruitment of ESCRT-III to the budding neck (Figure 
24) (Sette et al., 2016). As the NC domain of the LD4 mutant is not disrupted, this would presumably 
not affect the lipid-mediated interaction, explaining the discrepancy between the NC and SL1 data. 
However, the observation that SL1 mutation does impair rescue suggests that RNA may be important 
for the interaction between NC and ALIX at the late stage of virus release. 
 SL1 mutation produces a similar phenotype to NC mutation 
Mutation of NC also results in an accumulation of CA-SP1 and reduced virus release (Dorfman et al., 
1993). SL1 is one of two stem-loops important for packaging, so the observation that mutation of either 
cis- and trans- acting packaging signals results in similar phenotypes suggests that the defects observed 
may be caused by disruption of the interaction between NC and psi. 
To compare the effects of various mutations on the severity of the CA-SP1 processing defect, NC 
mutant F16A as well as the LD4, PTAP- and YPXnL- p6 mutants were assessed. The F16A mutation is in 
the first zinc finger motif and reduces gRNA binding (Dorfman et al., 1993) but has no effect on non-
specific RNA binding (Cimarelli et al., 2000). The LD4 mutation causes a milder CA-SP1 processing 
defect than classic late domain mutations, resembling the defect causes by the F16A mutant (Figure 
31). The Bro1 domain of ALIX interacts with NC through its zinc fingers (Popov et al., 2008), and as the 
residue substituted in the F16A mutant is within zinc finger 1 and is critical for its function (Dorfman 
et al., 1993) it is tempting to speculate that the defect in CA-SP1 processing caused by the F16A 
mutation is also due to disruption of this interaction. A possible explanation for the milder phenotype 
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of the LD4 and F16A mutants is that both contain a wild type p6 domain, which is critical for recruiting 
ESCRT components for virus release. 
 Motifs required for ALIX to accelerate CA-SP1 processing 
Overexpression of ALIX accelerated CA-SP1 processing (Figure 31), possibly due to enhanced 
recruitment of ESCRT-III (Morita et al., 2011). ALIX was overexpressed in different contexts and the 
effect on processing observed to determine which motifs are required for its function. 
On average, ALIX overexpression caused a 2-fold increase in CA-SP1 processing in the wild type and 
PTAP- mutant (Figure 31). This was not observed in the YPXnL- mutant. The F16A mutation in NC also 
blocked acceleration of processing, suggesting that specific binding of gRNA to NC is required for 
efficient ALIX function. Likewise, acceleration was also blocked in the LD4 mutant, supporting the 
finding that the LD4 mutation reduced ALIX’s ability to rescue release (Figure 30).  
 ALIX and TSG101 are required for rescue of late domain mutant-like phenotype by 
compensatory mutations 
It was hypothesised that if SL1 mutation disrupts ESCRT function, then the MP2 and MNC 
compensatory mutations which restore Gag processing and infectivity to SL1 mutants might act 
through a mechanism involving ESCRT. The compensatory mutations were introduced into late domain 
mutants to see if they were capable of correcting the defective Gag processing associated with these 
mutants. 
Interestingly, the compensatory mutations failed to enhance CA-SP1 processing when the PTAP and 
YPXnL motifs were mutated individually or in combination (Figure 32) or when the motifs’ binding 
partners TSG101 and ALIX were knocked down (Figure 33). They also failed to rescue the release of 
late domain mutants, but they increased release of both the wild type and LD4 mutant viruses (Figure 
34). This suggests that binding of ALIX and TSG101 to the p6 domain of Gag is required for the 
compensatory mutations to be able to correct the defective Gag processing and budding caused by 
SL1 mutation.  
The apparent requirement for ALIX and TSG101 to rescue SL1 mutants may be due to compensatory 
mutations restoring an interaction with these proteins which is lost upon SL1 mutation. It is known 
that the MNC mutation enhances packaging efficiency (Liang et al., 2000, 1998; Shen et al., 2000) and 
the MP2 mutation enhances packaging specificity (Roy et al., 2006; Russell et al., 2003), so restoration 
of gRNA binding may restore ESCRT binding to NC. 
As ALIX can bind to NC in an RNA-dependent manner (Chamontin et al., 2015; Popov et al., 2008; Sette 
et al., 2012) the compensatory mutations may indirectly restore the interaction between these 
proteins enabling increased recruitment of ESCRT-III and restored Gag processing and virus release. 
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These data provide further evidence of a link between the packaging signal in the 5’UTR and the p6 
domain of Gag, as they show that mutations in SL1 are rescued by the evolution of mutations which 
act through a mechanism requiring the p6 domain and its host cell protein binding partners. 
It is intriguing that compensatory mutations which disrupt wild type Gag processing by accelerating it 
have no effect on virus infectivity (Figure 19). Interference with the coordinated process of Gag 
processing is usually detrimental to infectivity (Li et al., 2003; Nowicka-Sans et al., 2016; Wiegers et al., 
1998). Data from a recent study show that delaying budding causes critical virion components such as 
RT and IN to escape the virion before the budding neck closes (Bendjennat and Saffarian, 2016). If the 
rate of processing alone was accelerated, the result might be the same. However, if increased 
processing is matched by increased budding, the two processes would be in equilibrium enabling the 
virus to remain fully infectious as shown in Figure 19. 
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5. Effect of gRNA and 5’UTR expression in trans on Gag processing 
and virus release 
5.1. Introduction 
The data presented in the previous chapters suggest that correct binding of NC to SL1 is required for 
efficient ESCRT recruitment, stimulating virus maturation and release. Expression of Gag in the absence 
of gRNA is sufficient for formation and budding of VLPs from cells (Gheysen et al., 1989). However, 
following cotransfection of labelled Gag and gRNA, 90% of released virions were observed to contain 
gRNA (Chen et al., 2009), indicating that there is a strong preference for release of virions containing 
successfully packaged viral genomes. Coordination of packaging with ESCRT recruitment may serve as 
a quality control mechanism by preferentially releasing gRNA-containing virions, maximising the 
opportunities for productive infection of new host cells whilst avoiding unnecessary activation of the 
immune system by empty virions. 
If a Gag-gRNA interaction is important for ESCRT recruitment, then one might predict that artificially 
increasing the levels of gRNA in the cytoplasm would influence CA-SP1 processing and virus release. In 
support of this, a previous study found that Gag-expressing cells released more VLPs when 
cotransfected with a construct expressing a truncated version of the HIV-1 genome (Ueno et al., 2004). 
However, the effect on Gag processing was not investigated as the Gag construct used lacked PR. 
5.2. Experimental aims 
To investigate the effect of in trans overexpression of gRNA on Gag processing and virus release, cells 
were transfected with proviruses and a construct expressing full length gRNA containing mutations to 
prevent Gag translation. Western blotting was performed to determine if gRNA expressed in trans 
could rescue the CA-SP1 processing defect of the LD4 mutant, and if there was any effect on processing 
and release of wild type virions. The experiment was also performed with constructs expressing the 
5’UTR alone, with or without the packaging signal, to observe if this region is responsible for the effects 
observed when gRNA is expressed in trans. The requirement for ALIX was also tested by including a 







 Overexpression of gRNA accelerates CA-SP1 processing 
To produce a construct which can be transcribed to produce gRNA but without being translated, a 
single mutation was made in the Gag start codon, changing it from AUG to AAG. Following transfection 
and Western blotting with an anti-CA antibody a truncated version of Gag was observed (Figure 35 
lane 2). This was due to the presence of an alternative start codon in Gag (Poon et al., 2002). Therefore, 
a premature stop codon was introduced into the CA domain of Gag. Western blotting confirmed that 
the additional mutation blocked Gag expression (Figure 35 lane 3), so this construct was used to 
express gRNA in trans for subsequent experiments. 
Figure 35 – Expression profiles of wild type Gag and Gag mutants 
 
Western blot of cell lysates following transfection with the indicated proviruses. AAG = single mutant 
containing Gag start codon mutation; AAG/CA = double mutant containing Gag start codon mutation 
and frameshift in CA. 
gRNA was expressed in trans to observe the effects on defective CA-SP1 processing caused by the LD4 
mutation (Figure 36A) and on CA-SP1 processing in the wild type virus (Figure 36B).  
Expression of wild type gRNA in trans with the LD4 mutant led to elevation of CA-SP1 processing (Figure 
36A), but more intriguingly, CA-SP1 processing in the wild type virus was also accelerated (Figure 36B). 
Quantitation revealed that in both the wild type and LD4 mutant the effect of gRNA expression in trans 
on processing was specific to the final step of cleavage (Figure 36C).  
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However, no difference was observed in the amount of virus present in the supernatant for the wild 
type virus (Figure 36D). Virion samples for the LD4 mutant were unavailable, so it wasn’t possible to 
assess the effect of gRNA on release of the LD4 mutant. 
Figure 36 – Effects of in trans gRNA expression on Gag processing and virus release – first 
experiment 
 
Western blot of cell lysates (A, B) following transfection with the indicated proviruses with or without 
overexpression of gRNA. C) Quantitation of the fold change in the efficiency of each step of processing 
upon gRNA overexpression, performed as described in Figure 18. The graph shows the mean values 
from at least 3 independent experiments. Error bars represent standard deviation. D) Quantitation of 
wild type virus release ratios without and with gRNA overexpression. The graph shows the mean values 
from 4 independent experiments. Error bars represent standard deviation. 
The experiment was therefore repeated to determine the effect of overexpression on both WT and 
LD4 virus release, and to compare the virus constructs side by side in the same gels (Figure 37). 
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Figure 37 – Effects of in trans gRNA expression on Gag processing and virus release – second 
experiment 
 
A) Western blot of cell lysates following transfection with the indicated proviruses, with or without 
overexpression of gRNA. B) Quantitation of mean release ratios relative to WT, from three independent 
experiments. Error bars represent standard deviation. 
Upon repeating the experiment, the effect of gRNA on CA-SP1  CA processing was far less 
pronounced, although in Figure 37A above some degree of acceleration is observed for the LD4 
mutant. In agreement with the first experiment, the effect of overexpressing gRNA on WT virus release 
is minimal. However, LD4 mutant release rises from approximately 60% relative to WT, to be on par 
with WT release. This result isn’t statistically significant (p = 0.13) but with further repeats a trend may 
become more apparent (n = 3). 
 Expression of wild type 5’UTR containing the packaging signal in trans is sufficient to 
accelerate CA-SP1 processing 
It has been shown that mutating SL1 is sufficient to delay CA-SP1 processing (Figure 15). An interesting 
question then arose as to whether in trans expression of the 5’UTR alone would be able to reverse the 
Gag cleavage defect caused by the LD4 mutation. To investigate this, constructs expressing the full 
length 5’UTR (pJHIV-1, pJHIV-1 Luc) or truncated 5’UTR lacking stem-loops 1-4 (pJHIV-1 ΔΨ) were 
expressed in trans. pJHIV-1 and pJHIV-1 ΔΨ express the 5’UTR upstream of a truncated influenza NS 
gene, and pJHIV-1 Luc expresses the 5’UTR upstream of luciferase (Figure 38A). First, to confirm 
expression, a range of transfections were performed with increasing amounts of pJHIV-1 Luc, and 
luciferase expression was measured. The signal increased linearly with transfection amount showing 
that production of truncated viral RNA correlates with the amount of construct transfected (Figure 
38B). 
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Figure 38 – 5’UTR constructs and expression of luciferase from pJHIV-1 Luc 
 
A) Cartoon representation of the composition of the 5’UTR constructs. B) Graph showing the effect of 
transfecting increasing amounts of pJHIV-1 Luc construct on the expression of luciferase.  
Having confirmed 5’UTR expression the constructs were expressed alongside the wild type provirus, 
and the effect on Gag processing was assessed by Western blotting (Figure 39). 
Expression of pJHIV-1 Luc or pJHIV-1 in trans was sufficient to accelerate CA-SP1 processing to a similar 
extent to that seen with the gRNA constructs (Figure 39B). However, when stem-loops 1-4 were 
deleted the rate of CA-SP1 processing remained unchanged.  There was no significant difference in the 
amount of virus released under any of the conditions (Figure 39C). 
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Figure 39 – Effects of in trans 5’UTR expression on Gag processing and virus release 
 
A) Western blot of cell lysates and purified supernatants following transfection with the indicated 
proviruses. B) Quantitation of relative CA-SP1 processing efficiency without and with 5’UTR 
overexpression. The graph shows the mean values from at least 4 independent experiments. Error bars 
represent standard deviation C) Quantitation of relative release ratios without and with 5’UTR 
overexpression. The graph shows the mean values from at least 3 independent experiments. Error bars 
represent standard deviation. 
 Acceleration of CA-SP1 processing by gRNA overexpression requires YPXnL motif 
The acceleration of processing caused by in trans expression of gRNA expressing-constructs containing 
the packaging signal is reminiscent of the effect observed upon overexpression of ALIX (Figure 31). To 
test if this acceleration is ALIX-dependent, the experiment was repeated with the YPXnL- mutant (Figure 
40). 
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Figure 40 – Effect of in trans gRNA expression on Gag processing in a YPXnL- mutant 
 
A) Western blot of cell lysates following transfection with the indicated proviruses with or without gRNA 
overexpression. B) Quantitation of the fold-change in CA-SP1 processing upon overexpression of gRNA. 
The graph shows the mean values from 3 independent experiments. Error bars represent standard 
deviation. 
Intriguingly, the acceleration of processing observed by expressing gRNA in trans Gag was blocked 
when the YPXnL motif was mutated. 
5.4. Discussion 
The experiments described in this chapter were performed to further clarify the role of gRNA in virus 
maturation and release. It was hypothesised that the role of gRNA is to assist in the recruitment of 
ESCRT proteins to ensure the preferential release of gRNA-containing virions. If this is the case, then 
increasing the concentration of gRNA in the cell should influence CA-SP1 processing and virus release. 
Consistent with this, the defect in processing caused by the LD4 mutation could be rescued by 
expression of wild type gRNA in trans (Figure 36A), and virus release also appeared to be rescued 
(Figure 37). These observations may be due to the wild type gRNA out-competing the LD4 mutant gRNA 
for packaging, resulting in the formation of ‘hybrid’ virions which are essentially wild type in 
composition and phenotype. 
Intriguingly, expression of gRNA in trans with a wild type provirus also accelerated processing (Figure 
36), reminiscent of the acceleration observed by overexpression of ALIX (Figure 31) and introduction 
of compensatory mutations into Gag (Figure 18). The packaging signal is responsible for this effect 
since expression of the 5’UTR alone is sufficient, providing stem-loops 1-4 are intact (Figure 39). This 
region of the 5’UTR contains multiple Gag binding sites (Section 1.12) (Kenyon et al., 2015), so it 
93 
appears likely that binding of Gag to gRNA stimulates these phenotypes. Acceleration was also 
dependent on an intact YPXnL binding motif (Figure 40). 
Despite enhanced processing, there was no effect on wild type virus release (Figure 36B & C, Figure 
37, and Figure 39A). After these experiments had been performed two highly relevant papers were 
published by Becker et al and Dilley et al (Becker and Sherer, 2017; Dilley et al., 2017). They 
investigated the effects of altering gRNA subcellular localisation (Becker and Sherer, 2017) and 
abundance (Dilley et al., 2017) on formation and release of Gag complexes. In both studies 
experiments were performed where non-translatable gRNA was provided in trans. Becker et al co-
expressed codon-optimised Gag-GFP, derived from a Gag expressing construct lacking PR, and an MS2-
labelled gRNA construct containing a Gag start codon mutation. There was no significant difference in 
virus release when gRNA was expressed in trans, but the subcellular localisation of Gag changed. Dilley 
et al expressed a gRNA construct containing a frameshift in Gag and a mixture of CeFP-labelled and 
unlabelled helper construct. The helper construct expressed all genes except for Env and contained a 
mutated packaging signal to prevent in cis encapsidation. When gRNA, or a mini construct containing 
just the 5’UTR, was expressed in trans, there was a 2.5-fold increase in virus release. This effect was 
dependent on the presence of the packaging signal and the effect size was inversely proportional to 
the concentration of Gag, suggesting that the role of gRNA in assembly and release is more important 
at lower, physiologically relevant, Gag concentrations.  
The authors hypothesised that gRNA acts as a nucleation point for particle assembly. If this is correct, 
the possibility that some of the enhanced CA-SP1 processing observed in these experiments was due 
to enhanced nucleation of assembly cannot be excluded, although no significant increases in virus 
release were observed (Figure 36 and Figure 39), in agreement with Becker et al (Becker and Sherer, 
2017). However, the finding that the YPXnL motif was required for this phenomenon (Figure 40) 
combined with data from the previous chapter showing that acceleration of CA-SP1 processing by 
compensatory mutations was late domain-dependent (Figure 32 and Figure 33) suggests that gRNA 
binding to Gag per se is not sufficient to accelerate processing, but that ALIX and potentially other 
ESCRT factors are involved. 
The reason for the discrepancy in virus release is unclear, but the experimental conditions varied a 
great deal between those experiments and the ones performed here. Dilley et al noted that the effect 
of gRNA expression on release was lessened at higher concentrations of Gag, so differences in Gag 
concentration, due to different transfection protocols or promoter activities, may be one explanation. 
In this study and the Becker et al study 1:1 and 3:1 ratios of gRNA:Gag were used, whereas the ratio 
used by Dilley et al is not stated. Perhaps a much higher concentration of gRNA is required to see a 
significant effect on virus release. 
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When the experiment in Figure 36 was repeated, the CA-SP1  CA cleavage acceleration effect was 
far less apparent. The reason for this is unclear, but it is difficult to imagine that the accelerated 
processing upon gRNA overexpression observed in Figure 36 is artefactual, as the trend is clear in that 
blot and others, such as the blot in Figure 39, produced at the time.  
Noting the above caveat, these results suggest that gRNA regulates CA-SP1 processing in a psi- and 
ALIX- dependent manner, supporting the hypothesis that the NC domain of Gag recruits ALIX in a psi-






The experiments described in this thesis were designed to further explore the link between genome 
dimerisation and Gag processing in HIV-1, with a focus on the effect of mutations in the packaging 
signal region of the 5’UTR. Previous work by others has shown that delaying or inhibiting Gag 
processing hinders maturation of the gRNA dimer (Darlix et al., 1990; Muriaux et al., 1996), however 
less is known about the reverse process – the effect (if any) of genome dimerisation in influencing the 
rate of Gag processing. Work in HIV-2 showed that mutation of a critical GGAG motif hindered 
dimerisation and also delayed a step of Gag processing, resulting in the formation of virions with 
abnormal morphology (L’Hernault et al., 2007), and in HIV-1 it was shown that gross mutation of SL1 
also affects both processes (Liang et al., 1999a), but that work was performed using substantial 
deletions of SL1 that likely have a major effect on the tertiary structure of the region surrounding SL1. 
6.2. Investigating the link between the packaging signal and regulation of Gag 
processing (Chapters 3 and 4) 
Using more targeted mutation of SL1, I found an example of a mutation (Stem B) that disturbed 
genome dimerisation whilst leaving the rate of the various steps of Gag processing unaffected. This 
suggests that efficient gRNA dimerisation is not required for efficient Gag processing, in contrast with 
the findings in HIV-2. Gag processing was studied by Western blotting at fixed time points post-
transfection. Results were reproducible, but an effort was made to complement this with pulse-chase 
metabolic labelling to study processing over time. This was challenging due to a high level of non-
specific background caused by inefficient immunoprecipitation, but the results seem to support those 
obtained using Western blots (see Appendix C). 
The previous work in HIV-2 and HIV-1 highlighted the ability of replicating viruses to compensate for 
disabling packaging signal mutations, enabling restoration of Gag processing and (in the case of HIV-2) 
dimerisation. Using molecular cloning I introduced compensatory mutations previously shown to 
rescue the Gag processing defects of large SL1 mutants (Liang et al., 1999a) into the SL1 mutants tested 
in this study. Not only did these compensatory mutations correct defective CA-SP1 processing the Loop 
B and LD4 mutants, but they also accelerated processing in the case of the wild type, DIS and Stem B 
mutants. The acceleration was specific to the final stage of Gag processing, when CA-SP1 is cleaved 
into CA and SP1, an event that triggers the dramatic structural change in virions whereby the immature 
spherical core becomes a mature conical one (Wiegers et al., 1998). Taken together these novel 
findings suggest that particular components of SL1 play an important role in coordinating Gag 
processing. Currently much more is known about the effect of SL1 on genome dimerisation, but these 
results shed some light on its effects on Gag processing. 
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CA-SP1 processing defects are a hallmark of ‘late domain’ mutants (‘late’ in this context referring to 
the late stage of the virus replication cycle that the mutations disrupt). The late domain (also known 
as p6) is responsible for recruitment of ESCRT components ALIX and TSG101, enabling the virus to 
hijack this host process to enable it to bud from the cell. It was therefore of interest to determine if 
the mutations in SL1 affect virus release and the recruitment of ESCRT components. This was found to 
be the case, with the previously studied LD4 mutation causing an approximately four-fold reduction in 
the amount of virus released into the supernatant. To exclude the possibility that this was caused by 
excessive degradation of virions rather than reduced release, a stability assay was conducted. Although 
no statistically significant difference in stability was observed, there was an indication that stability 
may play a role, although it is unlikely that this is the sole reason for the reduced virus release. 
In attempting to formulate a hypothesis to explain the link between mutations in the packaging signal 
and the hijacking of host ESCRT machinery, I came across papers that showed the ESCRT protein ALIX 
binds to NC (the region of Gag that binds the packaging signal) (Popov et al., 2008), and that it does so 
in an RNA-dependent manner (Sette et al., 2012). A rescue experiment was performed in which ALIX 
was overexpressed in the context of the PTAP- mutant control, which rescues release, and a mutant 
combining this mutation with the LD4 SL1 mutation. The results showed that PTAP-/LD4 was rescued 
with 50% the efficiency of PTAP-. Interestingly, the LD4 mutation acted similarly to late domain and NC 
mutations in that it also blocked the acceleration of CA-SP1 caused by ALIX overexpression. 
To establish a link between these observations and the compensatory mutation findings discussed in 
Chapter 3, the compensatory mutations were tested for their ability to rescue CA-SP1 processing in 
the context of a disabled ESCRT system (using both late domain mutagenesis and siRNA knockdown of 
ALIX and TSG101). These experiments revealed a requirement for TSG01 and ALIX and their interaction 
with Gag for the compensatory mutations to act in this way. 
Results from Chapter 3 and Chapter 4 provide the first evidence, to my knowledge, that the packaging 
signal of HIV-1 interacts with the host ESCRT pathway, and that disturbing the packaging signal through 
mutagenesis affects recruitment of ALIX, potentially causing the aberrant Gag processing previously 
observed by others and confirmed here but hereto unexplained. These results do not confirm that the 
disruption of ESCRT recruitment is responsible for the disturbed Gag processing, but they show a 
correlations, and the reductions in CA-SP1 processing efficiency and virus release are likely to be due 
to altered ESCRT binding, as these defects are hallmarks of interference with ESCRT recruitment (Fisher 
et al., 2007; Garrus et al., 2001; Huang et al., 1995; Meng et al., 2015; Morita et al., 2011) 
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6.3. Proposed model explaining the link between the packaging signal and effects on 
Gag processing and virus release 
The results discussed above suggests that the function of ALIX is directly affected by mutation of SL1. 
The model from Sette et al for the role of ALIX in virus assembly proposes that a subset of Gag 
molecules switch binding preference from an NC-RNA interaction to an NC-lipid one to enable co-
anchoring with the Bro1 domain of ALIX via a lipid intermediate in the budding neck (Figure 24).  
The finding that RNA can act as a bridge between the two molecules in vitro (Sette et al., 2012) is not 
accounted for in this model. It is also not known what would determine which subset of the 2400 Gag 
molecules (Carlson et al., 2008) in the virion make the switch from RNA binding to membrane binding. 
If RNA acts as a bridge to recruit the Bro1 domain of ALIX to NC in vivo, it could be gRNA or any spliced 
viral or cellular RNA as NC possesses specific and non-specific RNA binding capability. However, the 
finding that SL1 mutation results in a phenotype consistent with reduced ESCRT recruitment in Chapter 
3, and that ALIX function is disrupted by SL1 mutation in Chapter 4 suggests that gRNA is involved in 
ALIX recruitment during viral assembly. 
Each virion contains only two copies of gRNA, compared to 2400 Gag molecules. This stoichiometry 
means that only a few NC domains would be bound to the packaging signal region in the 5’UTR. An 
attractive hypothesis would be that ALIX is recruited to the subset of NC domains that are bound to 
this region. gRNA binding to NC may maintain the zinc fingers in a configuration preferentially 
recognised by Bro1. The RNA bridge would then be traded for a lipid one causing ALIX to localise to the 
budding neck. ALIX could then recruit ESCRT-III to sever the budding neck and trigger virion maturation 
(Figure 41).  
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Figure 41 – Model for role of gRNA in virus maturation and release 
 
ALIX initially anchors onto the p6 domain of Gag in the immature virion. Packaging of gRNA results in 
the formation of a specific contact between the NC domain of Gag and structures such SL1 in the 5’UTR. 
This conformation is recognised by the Bro1 domain of ALIX enabling a second contact to be made. 
Migration of the Gag molecule to the budding neck results in replacement of the gRNA bridge for a lipid 
one. ESCRT-III proteins are then recruited by ALIX, triggering virion maturation and release. 
This model accounts for the observations made in the experiments performed in this study and others. 
Mutation of SL1 or NC reduces the formation of Bro1-NC complexes mediated by gRNA (and lipids in 
the case of NC mutation). This reduces migration of ALIX to the budding neck and subsequent ESCRT-
III recruitment required for virus maturation and release. Overexpression of ALIX increases the 
formation of gRNA-mediated Bro1-NC complexes, reversing these phenotypes.  
An additional role for gRNA in the less well understood NC-TSG101 interaction cannot be excluded. It 
is possible that the LD4 mutation interferes with both the ALIX and TSG101 interactions with NC, as 
both ALIX and TSG101 recruit ESCRT-III (Garrus et al., 2001; Kim et al., 2005) and have been shown to 
bind to NC in vitro in the presence of RNA (Chamontin et al., 2015; Sette et al., 2012). 
6.4. Investigating the effect of varying cellular gRNA levels (Chapter 5) 
The experiments described in Chapter 5 were motivated by a desire to better understand the apparent 
requirement for coordination to occur between gRNA packaging and virus release. Work in the past 
decade has highlighted the degree of success with which HIV-1 packages its genome – over 90% of 
virions in one study contained gRNA (Chen et al., 2009). One hypothesis arising from this observation 
is that successful gRNA packaging is a checkpoint in the virus release process, ensuring preferential 
release of virions that have successfully packaged gRNA and are thus capable of replicating. This would 
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prevent the release of VLPs derived from multimerisation of Gag independently of gRNA, which would 
only serve to attract the attention of the immune system and would not result in productive infection. 
Based on the results in Chapters 3 and 4 it seemed plausible that regulation of release could work by  
ESCRT recruitment (in particular ALIX) being gRNA-dependent. The first experiments in Chapter 5 
assessed the effect of overexpressing gRNA or a construct containing the 5’UTR only, on Gag processing 
and virus release.  
Initial experiments suggested that overexpression of gRNA specifically accelerates the CA-SP1 step of 
Gag processing (analogous to the effect of the compensatory mutations investigated in Chapter 4), in 
both wild type and an LD4 mutant virus. To clarify the effect on virus release the experiment was 
repeated. Although the result was not statistically significant, there was an indication that 
overexpressing gRNA may contribute to restoring the defect in virus release caused by the LD4 
mutation.  
The next set of experiments looked at the effect of overexpressing the 5’UTR in the context of a non-
viral RNA, to confirm that this is the region responsible for the effects on processing and release. This 
indeed turned out to be the case, with both constructs containing a complete packaging signal 
accelerating processing, and the one lacking the packaging signal failing to do so. In agreement with 
the gRNA overexpression results, WT virus release was not changed. 
Considering the proposed model presented in Figure 41, gRNA overexpression may be increasing the 
opportunity for interaction between NC and ALIX, accelerating ESCRT recruitment and therefore Gag 
processing and virus release. For the final experiment performed in Chapter 5, gRNA was 
overexpressed in the wild type virus as before, and in the YPXnL- mutant, which lacks the primary ALIX 
binding site. Intriguingly, this mutation appeared to prevent the gRNA-mediated acceleration of 
processing, further adding weight to the argument that acceleration of processing depends on the 
interplay between ALIX and gRNA. 
6.5. Future experiments 
The results presented here show correlations, and suggest causations, between various events in the 
late stages of HIV-1 assembly, but more conclusive evidence remains elusive. A number of different 
experimental techniques were attempted during the project, but these were either unsuccessful or 
not reproducible. In others’ hands these may help to make the findings here more robust. 
Perhaps the most obvious next step would be to demonstrate that the physical interaction between 
Gag and ALIX is dependent on SL1. I attempted to do this using electrophoretic mobility shift assay 
experiments, but these were hampered by a lack of sensitivity. The rationale was to incubate purified 
Gag and purified ALIX in vitro in the presence of either WT SL1 or SL1 containing mutations such as the 
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Loop B and LD4 mutations described in this report. I would then separate these samples using 
electrophoresis and observe the effect, if any, of the mutation in SL1 on the mobility of Gag and ALIX. 
Whilst I was able to observe specific bands, the low intensity made it difficult to determine if the 
mutation was resulting in a different phenotype. These experiments were attempted using non-
radiolabelled probes, so using a radiolabelled assay should help to improve sensitivity. Encouragingly, 
work by other members of the lab has produced some positive preliminary results, which suggest that 
mutation of SL1 does indeed hinder the interaction between Gag and ALIX.  
Another approach would be to use immunofluorescence or fluorescence microscopy to study the 
interaction in cells. Again, preliminary work was conducted using immunofluorescence, and whilst Gag 
was readily observed in cells, ALIX was difficult to label so it was decided not to pursue this line of 
work. If set up correctly, this system could be used to look at co-localisation of Gag and ALIX in cells 
expressing either WT or SL1-mutant virus, and also the effect of any differences in co-localisation on 
the timing and extent of virus budding. By using fluorescently-labelled proteins, fluorescence 
microscopy could be performed, although this introduces the risk of the fusion protein having different 
biological function to its natural counterpart.  
A less direct but equally interesting study could look at the recruitment of ESCRT proteins into wild 
type and SL1-mutant virions, This could be done using mass spectrometry, for example. It would be of 
interest to measure the levels of ALIX, TSG101 and other ESCRT proteins incorporated into WT and 
SL1-mutant virions.  
Given the parallels between the effects of the compensatory mutations and MI resistance mutations, 
it would be interesting to test whether the compensatory mutations provide any resistance against 
MIs and vice versa. 
A study by Ogawa et al (Ogawa et al., 2015) found a novel interaction between the SP1 protein (also 
known as p2; produced by the key Gag processing step discussed in this thesis – the proteolytic 
cleavage of CA-SP1 into CA and SP1) and mitochondrial protein important for ATP synthesis. They 
found reduced intracellular ATP production in MT-4 cells and MDMs in cells infected with HIV-1 lacking 
functional SP1, and that this in turn had negative effect on reverse transcription. I performed some 
preliminary experiments attempting to measure the levels of ATP and the effect on reverse 
transcription in cells following infection with WT and SL1 mutant viruses, but the experiments were 
difficult to reproduce.  
6.6. Importance of this work 
The hypotheses discussed in this thesis represent a new way of looking at the role played by the 5’UTR 
in the late stages of HIV-1 particle assembly and release, and the results, although not always 
conclusive, tend to support these hypotheses and help to frame future research questions. While much 
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has been known about the effect of Gag processing on HIV-1 dimer formation and maturation, little is 
known about the reverse side of the coin – the effect of dimerisation on Gag processing and 
subsequent virus release. As we continue to grapple for a HIV cure, increased understanding of its 
molecular mechanisms provides us with new drug targets. RNA structures such as SL1 are amongst the 
most highly conserved regions of the virus genome, which, in a virus with a great capacity to evolve 
resistance, makes them desirable drug targets (Le Grice, 2015). Preclinical research into the activity of 
RNA aptamers directed against the 5’UTR highlights the potential of this approach (Sánchez-Luque et 
al., 2014). By showing that SL1 is involved in processes other than packaging, the desirability of 
targeting this region of the genome is increased, as disruption of multiple key processes in virus 





Appendix A: Buffer and solution recipes 
Table 10 – buffers and solutions used 
Solution Recipe 
dNTP mix 10mM dATP, 10mM dCTP, 10mM dGTP, 10mM dTTP (all Promega) 
ELISA coating antibody 
solution 
10 µg/ml anti-p24 antibody (Aalto Bio Reagents), 0.1M NaHCO3 
ELISA secondary antibody 
solution 
2% (w/v) milk powder, 79.5% (v/v) 1X TBS, 20% (v/v) sheep serum, 
0.5% 1XTBS-10% Tween, 1/16000 (v/v) alkaline phosphatase-
conjugated anti-p24 antibody (Aalto Bio Reagents) 
Gel drying solution 30% (v/v) methanol, 5% (v/v) glycerol 
Gel fixing solution 40% (v/v) methanol, 10% (v/v) acetic acid 
High stringency wash 
buffer 
15 mM NaCl, 1.5 mM trisodium citrate, 0.1% (w/v) SDS 
Laemmli buffer (2X) 20% (v/v) glycerol, 0.1% (w/v) bromophenol blue, 100 mM 2-
mercaptoethanol, 2% (w/v) SDS, 125 mM Tris-HCl pH 6.8 
Low stringency wash 
buffer 
300 mM NaCl, 30 mM trisodium citrate, 0.1% (w/v) SDS 
LB agar 1% (w/v) tryptone, 1% (w/v) NaCl, 0.5% (w/v) yeast extract, 1.5% 
(w/v) agar 
LB medium 1% (w/v) tryptone, 1% (w/v) NaCl, 0.5% (w/v) yeast extract 
Proteinase K extraction 
buffer 
50 mM Tris-HCl pH 7.5, 100 mM NaCl, 10 mM EDTA, 1% (w/v) SDS, 
100 µg/ml yeast tRNA (Sigma-Aldrich) and 100 µg/ml proteinase K 
solution (Thermo Fisher) 
Radioimmunoprecipitation 
assay (RIPA) buffer  
1% (v/v) Triton X-100, 1% (w/v) sodium deoxycholate, 0.1% (w/v) 
SDS, 100 mM NaCl, 50 mM Tris-HCl pH 7.5 
Saline-sodium citrate (SSC) 
buffer (20X) 





12-15% (v/v) ProtoGel acrylamide mix (National Diagnostics), 375 




89 mM tris, 89 mM boric acid, 2 mM EDTA 
Tris-buffered saline (TBS) 50 mM Tris-HCl pH 7.5, 150 mM NaCl 
Western blot running 
buffer 
25 mM tris, 250 mM glycine, 0.1% (w/v) SDS 
Western blot transfer 
buffer 




Appendix B: Comparison of transfection reagents 
Four transfection reagents were tested for their transfection efficiency in 293T cells by transfecting a 
plasmid expressing eGFP into 293T cells (Figure 42). 
Figure 42 – Comparison of transfection reagent efficiency 
 
Transit-LT1, Fugene HD (Promega), jetPRIME (Polyplus-transfection) and Lipofectamine 2000 (Thermo 
Fisher) were compared by following the manufacturers’ recommended protocols to transfect 200 ng 
plasmid DNA per well of an 80% confluent 24-well plate. Two independent transfections were 
performed. 48 hours post-transfection the supernatants were discarded, and the cells were analysed 
under a fluorescence microscope 
Transit-LT1 and Fugene HD were comparable in terms of their transfection efficiency, whereas 
jetPRIME and Lipofectamine 2000 performed poorly. Since Transit-LT1 appeared to be marginally 
superior to Fugene HD this transfection reagent was used for transfections in the study. 
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Appendix C: Pulse-chase assessment of Gag processing 
Figure 43 – Pulse-chase experimental setup 
 
The medium on wild type and mutant provirus-transfected cells was replaced with medium containing 
radiolabelled methionine and cysteine for one hour. This was then removed, and cells were harvested 
at regular intervals, before immunoprecipitating Gag and its processing products. Processing products 
were separated by SDS-PAGE before exposure to film.  
Due to high levels of background from other radiolabelled proteins it was not possible to perform 
quantitation of the full-length Gag and MA-CA-SP1 bands. Examples of gels showing the CA-SP1 and 
CA bands for each mutant following 20, 40 and 60-minute chases are shown in Figure 44A, with 
quantitation of the average CA/CA-SP1 ratios over time for each mutant in Figure 44B. The quality of 
the blots is poor due to faint bands so interpretation of the quantified plots must be performed with 
caution, however by inspecting the blots it appears that processing in the DIS mutant is no different to 
wild type, whilst processing in the Loop B and LD4 mutants is delayed especially at the 60-minute time 
point. The bands in the Stem B blot are extremely faint but appear to exhibit wild type-like processing. 
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Figure 44 – Pulse-chase analysis of CA-SP1 processing in cells 
 
A) Representative gels showing the processing of CA-SP1 over time. It was not possible to run all 
mutants on the same gel so 3 independent gels using different mutants are shown. B) The graphs show 
the mean ratio of CA/CA-SP1 at each time point for each mutant, overlaid onto the wild type graph. At 
least 2 independent experiments were performed for the wild type, DIS, Stem B and Loop B viruses, and 
1 experiment was performed for the LD4 mutant. Error bars represent range.  
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Appendix D: Phenotypic properties of SL1 mutants 
Table 11 – phenotypes of SL1 mutants 
Mutant name Infectivity (% 
WT) (Cell type) 
Dimerisation (% 
WT) (Cell type) 
Packaging (% WT) 
(Cell type) 
Reference 




- < 20% (SW480) (Kim et al., 1994) 
Δ243-277 0.1% (SupT1) - 100% (COS7) 
 
20% (SupT1) 
(Paillart et al., 
1996) 
Δ248-270 0.1% (SupT1) - 100% (COS7) 
 
20% (SupT1) 
(Paillart et al., 
1996) 
ΔSL1 < 10% (HOS) - 19% (293T) (Clever and 
Parslow, 1997) 














- 50% (Jurkat-tat) (Harrison et al., 
1998) 
LD3/Δ241-256 < 1% (MT-2) 53% (COS7) 20% (COS7) 
 
30% (COS7) 
(Liang et al., 
1998; Shen et al., 
2000) 




- - (Liang et al., 
1999a) 











50% (COS7) 65% (COS7) (Russell et al., 
2003) 




100% (but more 
diffuse dimers) 
(293T) 
50% (293T) (Hill et al., 2003) 




100% (but more 
diffuse dimers) 
(293T) 
50% (293T) (Hill et al., 2003) 
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100% (SupT1) 50% (SupT1) (Berkhout, 1996) 
G-loop < 10% (HOS) - 83% (293T) (Clever and 
Parslow, 1997) 
GCGCUC < 10% (HOS) - 42% (293T) (Clever and 
Parslow, 1997) 
KL-  < 25% (C8166) Reduced but not 
abolished (C8166) 
100% (C8166) (Haddrick et al., 
1996) 
S257-259 1% (SupT1) - 100% (COS7) 
 
50% (SupT1) 
(Paillart et al., 
1996) 
S255-263 10% (SupT1) - 100% (COS7) 
 
50% (SupT1) 
(Paillart et al., 
1996) 
ACS- < 1% (MT-4) not quantified but 
described as less 
dimeric (COS7) 
24% (COS7) (Laughrea et al., 
1997) 
GGCG2 < 5% (MT-4) 59% (COS7) 60% (COS7) 
 
78% (COS7) 
(Laughrea et al., 
1999; Shen et al., 
2000) 
GGCC - 97% (COS7) - (Shen et al., 
2000) 
ΔLoop - 50% (COS7) 90% (COS7) (Russell et al., 
2003) 
ΔDIS - 100% (293T) - (Song et al., 
2007) 
C258G2 - 100% (293T) - (Song et al., 
2007) 
Stem mutants     
dS.1 < 10% (HOS) - 11% (293T) (Clever and 
Parslow, 1997) 
mS.1 < 50% (HOS) - 42% (293T) (Clever and 
Parslow, 1997) 
S1 - - 80% (HeLa) (McBride and 
Panganiban, 
1996) 











- 60% (Jurkat-tat) (Harrison et al., 
1998) 
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A13 100% (Jurkat-tat) - 100% (Jurkat-tat) (Harrison et al., 
1998) 
Δ243-247 < 0.1% (MT-4) 56% (COS7) 60% (COS7) (Laughrea et al., 
1999; Shen et al., 
2000) 
Δ248-256 < 0.1% (MT-4) 53% (COS7) 70% (COS7) (Laughrea et al., 
1999; Shen et al., 
2000) 
Δ243-2463 < 0.1% (COS-7) 59% (COS7) 25% (COS7) (Shen et al., 
2001) 
Δ274-277 < 0.1% (COS-7) 59% (COS7) 40% (COS7) (Shen et al., 
2001) 
Loop mutants     
ΔB.1 < 10% (HOS) - 14% (293T) (Clever and 
Parslow, 1997) 
mB.1 < 10% (HOS) - 18% (293T) (Clever and 
Parslow, 1997) 
Δ271-2734 < 1% (COS-7) 59% (COS7) 44% (COS7) (Shen et al., 
2001) 
Δ247 < 5% (COS-7) 59% (COS7) 65% (COS7) (Shen et al., 
2001) 
Numbers in superscript format indicate mutants that are equivalent to the LD4 (1), DIS (2), Stem B (3) 
and Loop B (4) mutants used in this study. Mutant names that include nucleotide positions use the 
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